Are cannabinoids an effective treatment for chronic non-cancer pain? — Allende-Salazar RF, Rada G (2017) · DOI 10.5867/medwave.2017.6972 · meta analise · The use of cannabinoids has been proposed as an analgesic for different painful conditions, especially for chronic pain refractory to usual treatment. However, its real efficacy and safety remains controversial. We sought to determine whether cannabinoids are an effective treatme · es

Cannabis-Based Products for Chronic Pain : An Updated Systematic Review. — Chou R, Fu R, Ahmed AY, Morasco BJ (2026) · DOI 10.7326/annals-25-03152 · revisao sistematica · nabilone moderadamente reduz dor ~1.59 pontos vs dronabinol · en

Health-related quality of life in patients receiving medicinal cannabis: systematic review and meta-analysis of primary research findings 2015-2025. — Tait MA, Acret L, Costa DSJ, Campbell R, White K, Rutherford C (2026) · DOI 10.1007/s11136-026-04170-7 · meta analise · pequenas melhorias na qualidade de vida relacionada à saúde (d=0.30, p=0.03) em RCTs · en

Cannabinoids for Medical Use: A Systematic Review and Meta-analysis — Whiting PF et al. (2015), JAMA · DOI 10.1001/jama.2015.6358 · meta analise · OR resposta à dor ≈1,41 (IC95% 0,99–2,00) · en

Cannabis-based medicines for chronic neuropathic pain in adults. — Ateş G, Welsch P, Klose P, Phillips T, Lambers B, Häuser W et al. (2026) · DOI 10.1002/14651858.cd012182.pub3 · revisao sistematica · Rationale Estimates of the population prevalence of chronic pain with neuropathic components range from 6% to 10%. Current pharmacological treatments for neuropathic pain help only a minority. New treatments are needed. Cannabis is increasingly promoted in the media as a treatmen · en

Cannabinoids, cannabis, and cannabis-based medicines for pain management: an overview of systematic reviews. — Moore RA, Fisher E, Finn DP, Finnerup NB, Gilron I, Haroutounian S et al. (2021) · DOI 10.1097/j.pain.0000000000001941 · revisao sistematica · Abstract Cannabinoids, cannabis, and cannabis-based medicines (CBM) are increasingly used to manage pain, with limited understanding of their efficacy and safety. We assessed methodological quality, scope, and results of systematic reviews of randomised controlled trials · en

General risks of harm with cannabinoids, cannabis, and cannabis-based medicine possibly relevant to patients receiving these for pain management: an overview of systematic reviews. — Mohiuddin M, Blyth FM, Degenhardt L, Di Forti M, Eccleston C, Haroutounian S et al. (2021) · DOI 10.1097/j.pain.0000000000002000 · revisao sistematica · evidências variáveis de associações entre exposição à cannabis e danos psiquiátricos e psicossociais · en

International Association for the Study of Pain Presidential Task Force on Cannabis and Cannabinoid Analgesia: research agenda on the use of cannabinoids, cannabis, and cannabis-based medicines for pain management. — Haroutounian S, Arendt-Nielsen L, Belton J, Blyth FM, Degenhardt L, Di Forti M et al. (2021) · DOI 10.1097/j.pain.0000000000002266 · revisao sistematica · Abstract The President of the International Association for the Study of Pain established a task force on cannabis and cannabinoid analgesia to systematically examine the evidence on (1) analgesic pharmacology of cannabinoids and preclinical evidence on their efficacy in · en

Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials. — Fisher E, Moore RA, Fogarty AE, Finn DP, Finnerup NB, Gilron I et al. (2021) · DOI 10.1097/j.pain.0000000000001929 · revisao sistematica · Abstract Cannabinoids, cannabis, and cannabis-based medicines (CBMs) are increasingly used to manage pain, with limited understanding of their efficacy and safety. We summarised efficacy and adverse events (AEs) of these types of drugs for treating pain using randomised c · en

Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of nabiximols in cancer pain — Johnson JR et al. (2010), Journal of Pain and Symptom Management · DOI 10.1016/j.jpainsymman.2009.06.008 · ensaio clinico rct · Redução significativa da dor vs placebo · en

Cannabis-based extract for managing pain in dogs with osteoarthritis: efficacy and safety assessment. — Griebeler NM, Cremonese RP, Fakih Correa YR, Pereira PRM, Rial AF, Leite E et al. (2025) · DOI 10.3389/fphar.2025.1539704 · ensaio clinico rct · reduz HCPI em 2.4 pontos vs placebo · en

Randomized and Blind Evaluation of the Efficacy of a Full-Spectrum Oral <i>Cannabis sativa</i> Oil Extract, Standardized Based on CBD-A, CBD and THC-A, THC in Canines with Chronic Osteoarthritis. — Benjamin ET, Maria Teresa SE, Alexander NS, Stephanie SA, Martín SC, Sylvia AB (2026) · DOI 10.3390/ani16060900 · ensaio clinico rct · reduz CBPI em 39.6% vs placebo · en

Investigating the effects of cannabinoids for the reduction of inflammation and sickle cell disease pain (CRISP); A protocol for a randomized double-blind placebo-controlled study. — Bellis J, Monk L, Jhawar R, Pollock G, Liu A, Jacobs-McFarlane C et al. (2026) · DOI 10.1371/journal.pone.0340917 · ensaio clinico rct · Sickle Cell Disease (SCD) is a hemoglobinopathy affecting millions of people globally. Pain, both acute and chronic, affects over half of those living with SCD, but treatment of chronic pain is an ongoing challenge. While opioid treatments are widely used for chronic pain, it's e · en

Real-Time and Long-Term Effects of Medical Marijuana on Older Adults: Protocol for a Prospective Cohort Study. — Robinson KR, Seeger SD, Nave L, Mejia M, Vander Meulen M, Rashid A et al. (2026) · DOI 10.2196/78900 · coorte · Background Older adults represent the fastest-growing group of medical marijuana (MM) users in the United States, with chronic pain being the most common reason for use. Despite this trend, scientific evidence remains limited regarding the short- and long-term effects of MM on cr · en

Baseline Factors Associated with Intention to Initiate Medical Cannabis among Older Adults with Chronic Pain in a Prospective Cohort. — LaMontagne LG, Fillingim RB, Lopez-Quintero C, Mickle AM, Patel S, Brownstein M et al. (2026) · DOI 10.1159/000552277 · coorte · cada unidade de diminuição na qualidade do sono aumenta em 69% as chances de intenção de iniciar MC · en

The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research — National Academies of Sciences, Engineering, and Medicine (NASEM) (2017), National Academies Press · DOI 10.17226/24625 · documento de politica · Evidência conclusiva para dor crônica · en

[Therapeutic potential of Cannabis sativa]. — Avello L M, Pastene N E, Fernández R P, Córdova M P (2017) · DOI 10.4067/s0034-98872017000300010 · revisao narrativa · pode ser usado para manejo da dor crônica · es

Industrial and Therapeutic Applications of Hemp: A Review. — Chiririwa H (2026) · DOI 10.3390/molecules31101699 · revisao narrativa · Hemp ( Cannabis sativa L.) is a multipurpose crop with significant industrial and therapeutic potential. This article reviews the various uses of hemp in production, building, food, cosmetics and medicine, focusing on its economic, environmental and health benefits. Industrially, · en

Delta-9-tetrahydrocannabinol and Cannabidiol for Pain: Preclinical and Clinical Models. — Harris HM, Moore CF, Jenkins BW, Bedillion MF, Weerts EM, Arout CA (2026) · DOI 10.1007/7854_2025_604 · revisao narrativa · Cannabinoids are increasingly being used to manage pain resulting from a variety of conditions. Both preclinical animal models and human studies have played a crucial role in advancing our knowledge of cannabinoids, their involvement in pain mechanisms, and their potential utilit · en

Preoperative cannabinoid exposure and postoperative pain: A narrative review. — King DD, Temmermand R, Greenwood JE (2026) · DOI 10.1016/j.jclinane.2025.112097 · revisao narrativa · associado a maior dor pós-operatória e maior uso de opioides em alguns contextos cirúrgicos · en

Navigating dose-effect complexities and challenges in cannabinoid therapy for aging-related neurobiological changes. — Tudorancea IM, Filipiuc LE, Vieru DS, Dobre CE, Tamba BI (2026) · DOI 10.3389/fphar.2026.1794928 · revisao narrativa · THC exhibits a dual, dose-dependent profile; low doses may be neuroprotective while high doses are neurodisruptive. · en

Therapeutic use of cannabinoids in age-related pain: Current evidence and clinical perspectives. — Pulone S, Moulton C, Nucera S, Ilari S, Muscoli C, Tasciotti E (2026) · DOI 10.1016/j.phrs.2026.108130 · revisao narrativa · Pain is a frequently reported long lasting symptom among older adults, often associated with age-related conditions such as osteoarthritis, neuropathies, and musculoskeletal degeneration. In a normal inflammatory condition, the release of pro-inflammatory mediators and the concom · en

Insights Into Cannabis and Cannabinoids: Chemical Properties, Legal Perspectives, and Therapeutic Applications. — Vihal S, Singh V, Rana R, Kaur SD (2026) · DOI 10.1002/cbdv.202503030 · revisao narrativa · Cannabis sativa L. has been used for thousands of years in various cultural, medical, and industrial settings. This review brings together evidence from historical records, plant chemical studies, clinical trials, and laws to explain the chemical properties, healing potential, an · en

Endocannabinoid system modulation in acute, chronic, and neuropathic pain: reviewing experimental models, clinical evidence, and nanotechnology delivery. — Elgohary R, Baraka SM (2026) · DOI 10.1007/s11011-026-01862-4 · revisao narrativa · Chronic pain is highly prevalent and inadequately managed by current therapeutic strategies, which present significant limitations such as the development of tolerance, dependence, and cognitive impairment. Therefore, searching for new pain management strategies is an ultimate go · en

Minor Cannabinoid Use Among Medical Cannabis Patients. — Cuttler C, Boehnke KF, Doucette ML, Wilson-Poe AR, Kruger DJ (2025) · DOI 10.1080/02791072.2025.2607725 · outro · The legalization of cannabis in the United States (US) has increased the availability of a variety of novel cannabinoids such as cannabigerol (CBG) and cannabinol (CBN), delta-8 tetrahydrocannabinol (delta-8 THC) and THC-O acetate ester (THC-O), yet little is understood about the · en

Assessing the Efficacy of Cannabinoid Compositions for Treating 3 Classes of Chronic Pain: A Real-World Evidence Study. — Kruger DJ, Dautrich T, Hall B, Keeling K, Provost K, Boehnke KF (2026) · DOI 10.1016/j.clinthera.2026.04.018 · outro · Purpose Cannabis has been determined to be effective at treating chronic pain, although research on the effects of specific cannabinoids, especially for different mechanisms of chronic pain, is limited. This study examined therapeutic efficacy for combinations of intoxica · en

Reliability of a self-reported questionnaire assessing the use of cannabis products to treat chronic pain — Kröger E, Dionne CE, Bérété ZC, Amiri M, Lacasse A, Zongo A (2025), Research Square · DOI 10.21203/rs.3.rs-8050715/v1 · outro · Abstract Background : Cannabis-based products are increasingly used worldwide for chronic pain. However, there is a lack of reliable instruments assessing cannabis exposure. Objective : To develop a questionnaire measuring the use of cannabis to manage chronic pain and asse · en

Pharmacogenetic association study of cannabis use in chronic pain. — Beauchesne W, Turcotte J, Mercier P, Lavoie F, Tessier L, Gagnon AL et al. (2026) · DOI 10.1186/s42238-026-00408-w · ensaio clinico · associação entre variantes genéticas e eventos adversos psicóticos · en

Distinct contributions of mu opioid and CB2 cannabinoid receptors to neuroimmune and behavioral responses. — Kibret B, Onaivi ES, Sharma V (2026) · DOI 10.3389/adar.2026.16646 · outro · Marijuana (cannabis) and cannabinoids are getting global medical and recreational approvals in this era of the opioid epidemic. Both opiates and cannabis are often co-abused, and their use increases the risk of opioid and cannabis use disorders (OUDs and CUDs), and dependency. Op · en

Case Report: Oral and topical chronic administration of THC-rich and CBD-rich cannabis oil as palliative care in a rescued horse with open wound, sarcoid and chronic pain. — Zamith Cunha R, Kuhn EH, Medeiros JLL, Medeiros GC, Amazonas E (2026) · DOI 10.3389/fvets.2026.1794084 · relato caso · melhora na dor e mobilidade com uso de cannabis · en

Reliability of a Self-Reported Questionnaire Assessing the Use of Cannabis Products to Treat Chronic Pain. — Kröger E, Dionne CE, Bérété ZC, Amiri M, Lacasse A, Zongo A (2026) · DOI 10.1016/j.jopan.2026.06.014 · outro · Purpose To develop a questionnaire measuring the use of cannabis to manage chronic pain and assess its reliability. Design A questionnaire was developed based on a review of the literature and input from an expert panel. A longitudinal survey was conducted to asses · en

Cannabinoids for spasticity in patients with multiple sclerosis: A systematic review and meta-analysis. — Azadvari M, Pourshams M, Guitynavard F, Emami-Razavi SZ, Taftian-Banadkouki E, Ghajarzade M et al. (2024) · DOI 10.1177/20552173241282379 · meta analise · reduz espasticidade em pacientes com esclerose múltipla (SMD -1.41) · en

Efficacy of Sativex® on pain, spasticity, and disability in patients with multiple sclerosis: A systematic review and meta-analysis. — Nucera S, Ilari S, Caminiti R, Mazza V, Proietti S, Pulone S et al. (2026) · DOI 10.1016/j.phrs.2026.108250 · meta analise · reduz intensidade da dor (SMC: -0.88) e severidade da espasticidade (SMC: -1.29) · en

Cannabinoids in Chronic Pain Management: A Review of the History, Efficacy, Applications, and Risks. — Johnson BW, Strand NH, Raynak JC, Jara C, Habtegiorgis K, Hand BA et al. (2025) · DOI 10.3390/biomedicines13030530 · revisao sistematica · moderada eficácia em dor neuropática e fibromialgia · en

Cannabinoids in Motor Control: From Receptor Distribution to Motor Disorders. — Faganeli D, Lipnik-Stangelj M (2026) · DOI 10.3390/biomedicines14040844 · revisao sistematica · Cannabinoid receptors occupy strategic control nodes within motor circuitry, making them potential targets for modulating different motor manifestations. They are positioned both within basal ganglia circuits that regulate movement and within spinal circuits that control skeletal · en

Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits. — Hoch E, Volkow ND, Friemel CM, Lorenzetti V, Freeman TP, Hall W (2025) · DOI 10.1007/s00406-024-01880-2 · revisao sistematica · produz pequenos a modestos benefícios em condições como dor crônica e espasticidade muscular · en

Therapeutic Drug Monitoring of Cannabinoids: Therapeutic Reference Ranges for Delta-9-tetrahydrocannabinol in Medical Cannabis, Nabiximols, Dronabinol and Nabilone. — Amann F, Hefner G, Cremer-Schaeffer P, Gründer G, Häuser W, Hart XM et al. (2026) · DOI 10.1055/a-2853-4984 · revisao sistematica · 15-30 ng/mL delta-9-tetrahydrocannabinol para redução da dor em neuropatia periférica diabética · en

Efficacy and safety of cannabinoids in the treatment of spasticity in multiple sclerosis: A systematic review of randomized clinical trials. — Hamm-Buiar L, Gorski D, Kagueiama MH, Wiens A (2026) · DOI 10.1002/bcp.70719 · revisao sistematica · Aims This work aimed to evaluate the efficacy and safety of cannabinoids for the treatment of MS-related spasticity. Methods Systematic searches were conducted in PubMed, EMBASE, and LILACS on 2 December 2025. Randomized controlled trials evaluating natural or synthetic cannabino · en

Nabiximols in Multiple Sclerosis: Beyond Spasticity-An Exploratory Systematic Review and Meta-Analysis of Symptomatic Outcomes. — Kleiner D, Horváth IL, Mátis D, Nagy R, Gergő D, Lugosi K et al. (2026) · DOI 10.3390/medsci14030346 · revisao sistematica · Background/Objectives: Nabiximols, a standardized extract of Cannabis sativa , has been approved as an add-on therapy for patients with moderate to severe spasticity associated with multiple sclerosis (MS). Moreover, current Italian treatment algorithms suggest that cannabis-base · en

Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS): multicentre randomised placebo-controlled trial — Zajicek J et al. (2003), The Lancet · DOI 10.1016/S0140-6736(03)14738-1 · ensaio clinico rct · Melhora subjetiva de espasticidade/dor · en

[Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids]. — Oreja-Guevara C (2012) · DOI 10.33588/rn.5507.2012362 · ensaio clinico rct · reduz espasticidade em pacientes refratários a outras terapias · es

<i>ABCB1</i>GENE POLYMORPHISMS ARE ASSOCIATED WITH CLINICAL RESPONSE TO NABIXIMOLS IN PATIENTS WITH MULTIPLE SCLEROSIS-RELATED SPASTICITY — Gemma A, Mauri M, Banfi P, Versino M, Zollo A, Boneschi FM et al. (2025), medRxiv · DOI 10.1101/2025.06.20.25329925 · coorte · TT homozygotes have odds ratios of 20.5 and 30.9 for response to NBX · en

UK Medical Cannabis Registry: An Updated Analysis of Cannabis-Based Medicinal Products for Multiple Sclerosis. — Shah Y, Erridge S, Clarke E, McLachlan K, Coomber R, Rucker J et al. (2025) · DOI 10.1159/000549178 · caso controle · melhora na qualidade de vida relacionada à saúde · en

The Health Effects of Cannabis and Cannabinoids (NASEM 2017), capítulo espasticidade — NASEM (2017), National Academies Press · DOI 10.17226/24625 · documento de politica · Evidência substancial (sintomas de espasticidade auto-relatados) · en

[Cannabinoid drugs for neurological diseases: what is behind?]. — Fernández-Ruiz J (2012) · DOI 10.33588/rn.5410.2011689 · revisao narrativa · In recent years progress has been made in the development of pharmaceuticals based on the plant Cannabis sativa or on synthetic molecules with a similar action. Some of these pharmaceuticals, such as the mouth spray Sativex, have recently been approved for the treatment of spasti · es

Disease-Modifying Symptomatic Treatment (DMST) Potential of Cannabinoids in Patients with Multiple Sclerosis. — Bruno A, Annovazzi P, Clerico M, Cocco E, Conte A, Marfia GA et al. (2025) · DOI 10.2174/011570159x329058240820070701 · revisao narrativa · nabiximols é uma estratégia eficaz para o tratamento da espasticidade em MS · en

Under the Influence: Cognitive Effects of Medical Marijuana on Developing Minds. — Vuong M, Parkhill K (2025) · DOI 10.5863/jppt-25-01209 · revisao narrativa · Cannabis is a highly discussed topic in medicine today. From therapeutic applications in conditions such as chronic pain, multiple sclerosis, epilepsy, chemotherapy-induced nausea and vomiting, and inflammatory bowel disease to the growing prevalence of recreational use, cannabis · en

[Clinical immunomodulatory effects of cannabinoids in autoimmune diseases in internal medicine : A literature review]. — Lopez JG (2026) · DOI 10.1016/j.revmed.2026.06.013 · revisao narrativa · Cannabis has been used for nearly five millennia for its medicinal properties. The endocannabinoid system and the pharmacology of the main phytocannabinoids (Δ9-tetrahydrocannabinol, cannabidiol) were characterized between the 1970s and 1990s. Two types of cannabinoid receptors h · fr

Therapeutic Use of Medical Cannabis Beyond Pain Management in Physical Medicine and Rehabilitation. — Cameron A, Fraix MP, Agrawal DK (2026) · DOI 10.26502/aimr.0246 · revisao narrativa · Medical cannabis has emerged as a rapidly evolving therapeutic modality with expanding clinical interest beyond its traditional role in pain management. Particularly relevant to Physical Medicine and Rehabilitation (PM&R), where the focus extends beyond symptom control to functio · en

Cannabidiol in Neurology: Current Insights and Translational Perspectives. — Białoń M, Kędziora M, Starowicz K (2026) · DOI 10.3390/ph19020330 · revisao narrativa · Cannabidiol (CBD) is one of the most studied compounds of Cannabis sativa and has attracted significant interest due to its therapeutic and beneficial properties, which have been confirmed in numerous preclinical and clinical studies over the last few years. A great advantage of · en

Cannabinoids in Chronic Pain: Clinical Outcomes, Adverse Effects and Legal Challenges. — Sic A, George C, Gonzalez DF, Tseriotis VS, Knezevic NN (2025) · DOI 10.3390/neurolint17090141 · revisao narrativa · Cannabinoids have gained increasing attention as potential therapeutic agents in chronic pain management. Their mechanisms of action, mediated through CB1 and CB2 receptors, provide a pharmacological alternative to conventional analgesics. The evidence is strongest for neuropathi · en

Cannabinoid Therapies in Less-Common Disorders: Clinical Evidence and Formulation Strategies. — Afonso S, Gonçalves J, Brinca AT, Rosendo LM, Rosado T, Duarte AP et al. (2026) · DOI 10.3390/diseases14020083 · revisao narrativa · Background/Objectives: Cannabinoids are increasingly recognised for their therapeutic potential beyond well-established indications such as chronic pain, multiple sclerosis, and specific epileptic syndromes. Recent advances have highlighted their possible role in less-common or o · en

[Delta-9-tetrahydrocannabinol-cannabidiol in the treatment of spasticity in chronic spinal cord injury: a clinical experience]. — Grao-Castellote C, Torralba-Collados F, Gonzalez LM, Giner-Pascual M (2017) · DOI 10.33588/rn.6507.2017118 · ensaio clinico · melhora significativa em três escalas de avaliação · es

[News about therapeutic use of Cannabis and endocannabinoid system]. — Duran M, Laporte JR, Capellà D (2004) · DOI 10.1016/s0025-7753(04)74251-7 · outro · Growing basic research in recent years led to the discovery of the endocannabinoid system with a central role in neurobiology. New evidence suggests a therapeutic potential of cannabinoids in cancer chemotherapy-induced nausea and vomiting as well as in pain, spasticity and other · es

[Assessment of the effectiveness and safety of Sativex® in compassionate use]. — Cimas-Hernando I, Pato-Pato A, Lorenzo-González JR, Rodríguez-Constenla I (2015) · DOI 10.33588/rn.6005.2014461 · outro · reduz consumo de medicamentos concomitantes ~34.2% e melhora na escala de espasticidade ~65.6% · es

Correction: Enhancing the endocannabinoid system to treat residual disease in relapse-free multiple sclerosis. — Annovazzi P, Clerico M, Cocco E, Conte A, Marfia GA, Salvetti M et al. (2026) · DOI 10.3389/fneur.2026.1829952 · outro · [This corrects the article DOI: 10.3389/fneur.2026.1747131.]. · en

Abcb1 Gene Polymorphisms Are Associated With Clinical Response to Nabiximols in Patients With Multiple Sclerosis-related Spasticity — Gemma A, Mauri M, Banfi P, Versino M, Zollo A, Boneschi FM et al. (2025), Research Square · DOI 10.21203/rs.3.rs-7008522/v1 · outro · TT homozygotes have odds ratios of 20.5 and 30.9 for response to NBX · en

A matter of formulation: Efficacy and tolerability of nabiximols and cannabis decoction for the treatment of multiple sclerosis-related spasticity. — Sartori A, Favero A, Rossi L, Lotto M, Colla S, Dinoto A et al. (2026) · DOI 10.1016/j.msard.2026.107428 · outro · Background Spasticity is one of the most disabling symptoms in multiple sclerosis (MS) and is often inadequately controlled by standard treatments. Nabiximols is an approved cannabinoid therapy for MS-related spasticity, while cannabis decoctions may offer alternative efficacy an · en

Enhancing the endocannabinoid system to treat residual disease in relapse-free multiple sclerosis. — Annovazzi P, Clerico M, Cocco E, Conte A, Marfia GA, Salvetti M et al. (2026) · DOI 10.3389/fneur.2026.1747131 · outro · The recent introduction of High-Efficacy Therapies (HETs) in clinical practice has drastically reduced the frequency of acute inflammatory episodes and relapses, in patients with Multiple Sclerosis (MS), gradually shifting the interest of clinicians toward preventing disease prog · en

Nabiximols improves sleep architecture in multiple sclerosis: A prospective polysomnographic study. — Fortunato F, Saraceno A, Barone S, Sturniolo M, Bruno PA, Martino I et al. (2026) · DOI 10.1016/j.neurot.2026.e00840 · ensaio clinico · We aim to evaluate sleep disruption in people with multiple sclerosis (MS) compared to an age- and gender-matched control cohort using patient-reported outcome measures and formal polysomnography (PSG) scoring, and testing the effect of Nabiximols on these measures in people with · en

Cannabinoids Treatment for Agitation in Alzheimer's Disease: A Systematic Review and Meta-Analysis With Bayesian and Sequential Trial Analyses. — da Silva AMP, de Siqueira Lima DV Jr, Figueiroa Souza R, Lopes VHP, Januario Campos Cardoso L, Ornelas Pinto EL et al. (2026) · DOI 10.1016/j.jagp.2026.05.016 · meta analise · reduz sintomas neuropsiquiátricos e agitação em comparação ao placebo (SMD -0.31 a -0.40) · en

Therapeutic Potential for Cannabidiol on Alzheimer's Disease-Related Neuroinflammation: A Systematic Review and Meta-Analysis. — Wu S, Rajiah T, Ali AB (2025) · DOI 10.3390/ijms262411963 · meta analise · reduz marcadores de neuroinflamação em modelos pré-clínicos · en

Cannabinoids, the Blood-Brain Barrier, and Neurodegeneration: Mechanisms, Dysregulation, and Therapeutic Perspectives. — Ben-Shabat S, Yarmolinsky L, Sharon N, Zeadnaa-Aldda T, Dayan S, Khalfin B et al. (2026) · DOI 10.3390/biom16020225 · revisao sistematica · Neurodegenerative diseases are a large and complex group of neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, and so on, which adversely affect the physical and mental health of millions of people globally. Unfor · en

A Comprehensive Exploration of the Multifaceted Neuroprotective Role of Cannabinoids in Alzheimer's Disease across a Decade of Research. — Tyrakis P, Agridi C, Kourti M (2024) · DOI 10.3390/ijms25168630 · revisao sistematica · cannabinoides mostram promessa em melhorar memória e cognição · en

Exploring the diversity of cannabis cannabinoid and non-cannabinoid compounds and their roles in Alzheimer's disease: A review. — Doumar H, Mostafi HE, Elhessni A, Ebn Touhami M, Mesfioui A (2025) · DOI 10.1016/j.ibneur.2024.12.011 · revisao sistematica · Cannabis sativa is recognized for its chemical diversity and therapeutic potential, particularly in addressing neurodegenerative diseases such as Alzheimer's disease (AD). Given the complexity of AD, where single-target therapies often prove inadequate, a multi-target approach ut · en

Identifying a combination of biomarkers to predict treatment response to nabilone for agitation in Alzheimer's disease - an exploratory &lt;i&gt;post hoc&lt;/i&gt; analysis. — Wang HJ, Ruthirakuhan M, Andreazza AC, Beroncal EL, Black SE, Gallagher D et al. (2026) · DOI 10.1080/17582024.2025.2587549 · ensaio clinico rct · nabilone reduz agitação em Alzheimer com diferença média de CMAI de -20.6 vs placebo · en

A Randomized Controlled Trial of the Safety and Efficacy of Dronabinol for Agitation in Alzheimer's Disease. — Rosenberg PB, Amjad H, Burhanullah H, Nowrangi M, Vandrey R, Pierre MJ et al. (2026) · DOI 10.1016/j.jagp.2025.10.011 · ensaio clinico rct · dronabinol diminui a agitação em comparação ao placebo · en

NTI164, a novel medicinal cannabis extract, improves core symptoms of autism spectrum disorder: Results from a double-blind, randomised, controlled trial (The Harmony study). — Keating BA, Ogru Y, Isikgel E, Sharma K, El-Sukkari D, Fahey MC (2026) · DOI 10.1016/j.neurot.2026.e01033 · ensaio clinico rct · melhora sintomas centrais do transtorno do espectro autista em comparação ao placebo · en

Sativex (nabiximols) for the treatment of Agitation &amp; Aggression in Alzheimer's dementia in UK nursing homes: a randomised, double-blind, placebo-controlled feasibility trial. — Albertyn CP, Guu TW, Chu P, Creese B, Young A, Velayudhan L et al. (2025) · DOI 10.1093/ageing/afaf149 · ensaio clinico rct · Background Alzheimer's Disease (ad) patients often experience clinically significant agitation, leading to distress, increased healthcare costs and earlier institutionalisation. Current treatments have limited efficacy and significant side effects. Cannabinoid-based therapies, su · en

Cannabinoids for Alzheimer's disease: A promising trial, although not yet ready for the prescription pad. — Dos Santos Silva J (2026) · DOI 10.1177/13872877261452183 · ensaio clinico rct · modesto aumento cognitivo no Mini-Mental State Examination · en

A randomised, double-blind, placebo-controlled crossover trial on cannabinoid-based medication for behavioural disorders in old patients with severe dementia: the study results. — Bianchi F, Broers B, Desmeules JA, Langlois A, Wampfler J, Curtin F et al. (2026) · DOI 10.1093/ageing/afag239 · ensaio clinico rct · reduz uso de medicamentos psicotrópicos conforme necessário · en

Assessment of clinical factors that predict response to nabilone for agitation in Alzheimer's disease: A post hoc analysis of a randomized placebo-controlled trial. — Feldman OJ, Herrmann N, Ruthirakuhan M, Gallagher D, L G Verhoeff NP, Kiss A et al. (2026) · DOI 10.1016/j.inpsyc.2026.100183 · ensaio clinico rct · 82% responder rate in top tertile vs 40% in lowest tertile · en

A randomized clinical trial of low-dose cannabis extract in Alzheimer's disease. — Cury RM, da Silva T, Cezar-Dos-Santos F, Fakih YRC, Narvaez KAR, Gouvea MC et al. (2025) · DOI 10.1177/13872877251389608 · ensaio clinico rct · aumento do escore total do Mini-Mental State Exam em comparação ao placebo · en

Cannabis use, cognitive function and dementia risk in older adults: observational and genetic analyses. — Ishrat S, Levey DF, Gelernter J, Ebmeier KP, Topiwala A (2026) · DOI 10.1136/bmjment-2025-302290 · coorte · cannabis use não está ligado a declínio cognitivo ou risco de demência · en

Demographic features, health status, and behavioral changes associated with cannabidiol use in the Dog Aging Project. — Conrow KD, Haney RS, Malek-Ahmadi MH, Albright JD, Kaplan BLF, Snyder-Mackler N et al. (2025) · DOI 10.3389/fvets.2025.1666663 · coorte · declínio na intensidade de comportamentos agressivos com uso consistente de CBD · en

Clinical and Public Health Challenge of Handling Synthetic Cathinone and Cannabinoid Abuse in Pediatric Care: A Narrative Review. — Ricci V, Maina G (2025) · DOI 10.3390/pediatric17010019 · revisao narrativa · exposição a canabinoides sintéticos resulta em efeitos tóxicos imprevisíveis e graves · en

Exploring cannabinoid modulation on autophagy mechanisms in Alzheimer's disease: a review. — Ntsapi C, Weyers M, Chinheya R, Jim T, Matsabisa M (2025) · DOI 10.3389/fphar.2025.1748368 · revisao narrativa · Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the accumulation of toxic protein aggregates in the brain, leading to brain cell death and cognitive impairment. Central to AD pathogenesis is the autophagy pathway, a crucial cellular self-digestion proces · en

Medicinal cannabis extracts are neuroprotective against Aβ_1-42-mediated toxicity in vitro. — Marsh DT, Shibuta M, Kato R, Smid SD (2024) · DOI 10.1111/bcpt.14078 · ensaio clinico · significativa neuroproteção contra toxicidade induzida por Aβ 1-42 · en

A Combination of Low-Dose Δ&lt;sup&gt;9&lt;/sup&gt;-THC and Celecoxib as a Therapeutic Strategy for Alzheimer's Disease. — Zhang J, Zhu D, Hu M, Pan M, Chen C (2025) · DOI 10.14336/ad.2025.1206 · pre clinico · reduz Aβ e tau patologia e melhora função cognitiva · en

Optimized Extraction Method for Neutral Cannabinoids Quantification Using UHPLC-HRMS/MS. — Meirelles JV, Estevam DCD, Dos Santos VF, Pereira HMG, Saint Pierre TD, Veiga-Junior VF et al. (2025) · DOI 10.3390/biom15020246 · outro · The Cannabis market is experiencing steady global growth. Cannabis herbal extracts (CHE) are interesting and sought-after products for many clinical conditions. The medical potential of these formulations is mainly attributed to neutral cannabinoids, such as cannabidiol (CBD), te · en

Combining cannabidiol and delta-9-tetrahydrocannabinol at a 50:3 ratio - a new therapeutic strategy for APP&lt;sub&gt;Swe&lt;/sub&gt;/PS1ΔE9 transgenic mice? — Coles M, Rosa Porto R, Chesworth R, Steiner-Lim GZ, Karl T (2026) · DOI 10.1016/j.neurobiolaging.2026.04.003 · pre clinico · melhora a localização inicial da zona de recompensa em APP/PS1 · en

Magnetic nanoparticles anchored with zeolites: An alternative material for dispersive magnetic solid-phase extraction for cannabinoids from urine samples. — Raspini E Silva L, Campos CEM, Marchioni C (2026) · DOI 10.1016/j.jchromb.2026.125029 · outro · This study presents the development and validation of an analytical method using a magnetic sorption phase anchored with zeolites for cannabinoid extraction from urine samples of patients suspected of Cannabis sativa intoxication. High-performance liquid chromatography coupled wi · en

[Who gives a positive cannabis in paediatric emergencies?]. — Velasco Arnaiz E, Trenchs Sainz de la Maza V, Curcoy Barcenilla AI, Velasco Rodríguez J, Matalí Costa JL, Luaces Cubells C (2010) · DOI 10.1016/j.anpedi.2010.01.015 · outro · Introduction and aim Cannabis is the most frequently consumed illicit substance in Spain. Adolescence is the period when most people come into contact with this drug. The aim of this study is to evaluate the characteristics of patients who have recently consumed cannabis and who · es

Effects of cannabidiol on anxiety- and depressive-like behaviors and cognition: a systematic review and meta-analysis of preclinical studies. — Jantsch J, Wickert F, Fraga GF, de Fraga LS, Durán-Carabali LE, Guedes RP (2026) · DOI 10.1038/s41380-026-03733-x · meta analise · Background Cannabidiol (CBD) has emerged as a promising neuroprotective compound, with potential benefits for cognitive and emotional behaviors. However, the consistency of its effects across preclinical models remains uncertain. Methods We conducted a systematic review and meta- · en

Synergistic Neuroimmune Modulation by Cannabidiol and Probiotics for Therapeutic Advancement in CNS Disorders: A Systematic Review. — Baghel Chauhan S, Jaitawat DPS, Jain C, Singh I (2026) · DOI 10.2174/0118715273411035251111055748 · revisao sistematica · melhora na comunicação gut-brain e potencial terapêutico para ansiedade e depressão · en

Functional neuroimaging of Cannabidiol in stress and anxiety: a systematic review. — Rutledge O, Goyette RB, Wang KL, Park MS, Gabrieli JDE (2026) · DOI 10.3389/fnimg.2026.1860919 · revisao sistematica · Cannabidiol (CBD) is a non-intoxicating phytocannabinoid primarily derived from hemp ( cannabis sativa L.) that has been investigated for its potential anxiolytic effects. Prior functional neuroimaging studies suggest that CBD may affect brain regions associated with stress and a · en

Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients — Bergamaschi MM, Crippa JAS et al. (2011), Neuropsychopharmacology · DOI 10.1038/npp.2011.6 · ensaio clinico rct · Redução significativa de ansiedade/cognição vs placebo · en

Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial — Chagas MHN, Zuardi AW, Crippa JAS et al. (2014), Journal of Psychopharmacology · DOI 10.1177/0269881114550355 · ensaio clinico rct · Melhora de qualidade de vida (PDQ-39) · en

Cannabidiol in Anorexia Nervosa: A Double-Blind Randomized Placebo Controlled Pilot Study to Test Safety, Pharmacokinetics, and Symptom Change. — Sahota N, Grelotti DJ, Nguyen T, Kaye WH, Swindle S, Suhandynata R et al. (2026) · DOI 10.1002/eat.70034 · ensaio clinico rct · aumento do IMC em favor do CBD (F=3.039, p=0.046) · en

Acute behavioural effects of low-dose cannabidiol: A randomised crossover trial in healthy volunteers. — Chester LA, Hebert FO, Lachance-Touchette P, Mahroug A, Abboud A, McCrea TP et al. (2026) · DOI 10.1177/02698811261464527 · ensaio clinico rct · Background Cannabidiol (CBD) is widely consumed in low-dose products. However, evidence for its psychotropic effects at non-clinical doses is sparse and inconsistent. Aims To characterise the acute behavioural effects of low-dose synthetic CBD in healthy volunteers. We hypothesis · en

Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report — Crippa JAS, Derenusson GN, Ferrari TB, et al. (2011), Journal of Psychopharmacology · DOI 10.1177/0269881110379283 · ensaio clinico rct · Redução subjetiva de ansiedade + modulação de fluxo cerebral · en

Insights into public use and attitudes of cannabidiol (CBD) in England, Wales and Northern Ireland: secondary analysis of an official statistic consumer survey, Food and You 2. — Armstrong B, Ogunmayin L, Bhamra SK (2026) · DOI 10.1136/bmjph-2025-003924 · transversal · Introduction Cannabidiol (CBD) is a naturally occurring phytocannabinoid found in Cannabis plants. CBD is used for skin care, pain, anxiety and insomnia. There is a growing range of CBD products and formulations on the market, which have been driven by the increased demand for CB · en

Cannabinoid receptor-mediated modulation of the gut-brain axis under chronic stress: Neuroinflammatory mechanisms, microbial metabolites, and sexual dimorphism. — Metello Neves LB, Domingues S D Jr, Baldessarini BL, Laino P, Lima BC (2026) · DOI 10.1016/j.pnpbp.2026.111860 · revisao narrativa · Chronic stress disrupts the gut-brain axis (GBA) through coordinated dysfunction of the intestinal barrier and of the vascular interfaces that protect the brain, fostering a neuroinflammatory state implicated in mood disorders, neuropsychiatric conditions, and chronic pain. This · en

Cannabidiol in Digital Fatigue: Neuroadaptive Mechanisms and Therapeutic Perspectives on Chronic Screen Exposure. — Kalra Y, Chauhan SB, Singh I, Jain C (2026) · DOI 10.2174/0118715273430387260121093126 · revisao narrativa · potencial para tratar a fadiga digital · en

Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age — Campos AC, Fogaça MV, Sonego AB, Guimarães FS (2016), Frontiers in Immunology / Pharmacological Research · DOI 10.1016/j.phrs.2016.01.033 · revisao narrativa · Efeitos ansiolíticos/antidepressivos e neuroprotetores · en

Cannabidiol and Cancer Survivors: Utilization and Experiences. — Salz T, Mishra Meza A, Chino F, Furberg H, Raghunathan NJ, Jinna S et al. (2026) · DOI 10.1177/10966218261448666 · outro · Background The benefits and harms of cannabidiol (CBD), a cannabis constituent with minimal psychoactive effects, are unknown in cancer populations. Objective We sought to describe CBD experiences among people currently or recently treated for cancer (survivors). Design We conduc · en

Cannabidiol Use in Inflammatory Bowel Disease: Insights From a Gastroenterology Outpatient Population. — Fatakhova K, Khan MJ, Perera R, Perera S, Glazebnik B, Donnelly L et al. (2026) · DOI 10.1002/jgh3.70402 · outro · 87.5% dos usuários perceberam benefício · en

Investigating Cannabidiol's Effectiveness to Mitigate the Adverse Consequences of Exposure to Neonatal Procedural Pain. — Timmerman B, Honeycutt JA, Skully J, Patel D, Khan W, Neagu A et al. (2026) · DOI 10.1002/dev.70125 · ensaio clinico · diminui contagem de USV em machos comparado ao tratamento com veículo · en

Place preference in a female adolescent rat model of neuropathic pain: The effects of cannabidiol and oxycodone on cerebellum cell density. — Li CN, Warren S, Vlassopoulos E, Sgro M, Harris S, Henderson LA et al. (2026) · DOI 10.1007/s00213-026-07056-1 · ensaio clinico · preferência por cannabidiol e oxycodone · en

Cannabidiol in the Anterior Insular Cortex Attenuates Chronic Neuropathic Pain and Comorbid Anxiety- and Depression-Like Behaviors: Involvement of CB1 and 5-HT1A Receptor Signaling — Acunha RM, Domingues BRR, Barros N, Medeiros P, Hallak JEC, Coimbra NC et al. (2026), Research Square · DOI 10.21203/rs.3.rs-9226782/v1 · pre clinico · reduz alodinia mecânica e comportamentos de ansiedade e depressão de forma dose-dependente · en

Prenatal Cannabidiol and Δ9-Tetrahydrocannabinol exposure lead to sex-specific disruptions in risk assessment and behavioral switching via divergent rewiring of the adult mPFC — Cáceres-Rodríguez A, Iezzi D, Lassalle O, Dudek AE, Wang S, Chavis P et al. (2026), bioRxiv · DOI 10.64898/2026.06.27.734813 · outro · aumento de comportamento repetitivo em ambos os sexos · en

Chronic CBD treatment differentially modulates neurobehavioral outcomes and endocannabinoid signaling in an aged HIV-1 Tat transgenic mouse model. — Yadav-Samudrala BJ, Johnson ML, Ale A, Jiang KX, Lee WWY, Nguyen A et al. (2026) · DOI 10.1371/journal.pone.0353267 · ensaio clinico · melhora a memória de reconhecimento em fêmeas Tat(+) com CBD · en

Prenatal Cannabidiol and THC Exposure Induce Sex-Specific Executive Dysfunction via Divergent Pathological Rewiring of the Adult Medial Prefrontal Cortex — Manzoni O, Cáceres-Rodríguez A, Iezzi D, Lassalle O, Wang S, Chavis P (2026), Research Square · DOI 10.21203/rs.3.rs-9428628/v1 · ensaio clinico · impaired risk appraisal em fêmeas expostas ao CBD · en

The cannabidiol (CBD): Tetrahydrocanabinol (THC) concentration ratio is critical for neuroprotection and recovery following traumatic brain injury. — Friedman LK, Zeman RJ, Peng H (2026) · DOI 10.1016/j.expneurol.2026.115756 · outro · CBD 10:1 e THC 20:1 oferecem a maior proteção contra lesões pós-TBI · en

Cannabidiol in the anterior insular cortex attenuates chronic neuropathic pain and comorbid anxiety- and depression-like behaviors: involvement of CB&lt;sub&gt;1&lt;/sub&gt; and 5-HT&lt;sub&gt;1A&lt;/sub&gt; receptor signaling. — Acunha RM, Domingues BRR, Barros N, Medeiros P, Hallak JEC, Coimbra NC et al. (2026) · DOI 10.1007/s00213-026-07116-6 · outro · Background Chronic neuropathic pain (NP) is frequently accompanied by anxiety- and depression‑like symptoms, reflecting maladaptive interactions between nociceptive and affective brain networks. The anterior insular cortex (AIC) integrates sensory and emotional dimensions of pain · en

Cannabis for Tic Control: A Systematic Review and Meta-Analysis of Its Efficacy in Tourette Syndrome Management — Mann DGS, Gadelmawla DAF, Dway DA, Fayaz FH, Kebede DEA, Varadharaj NK et al. (2024), Preprints.org · DOI 10.20944/preprints202409.1392.v1 · meta analise · reduz a gravidade dos tiques · en

Cannabis and cannabinoids for the treatment of mental and substance use disorders and symptoms: A systematic review and meta-analysis of experimental and observational studies. — Bharat C, Huang X, Campbell G, Tisdale C, Glasgow S, Nielsen S et al. (2026) · DOI 10.1016/j.psychres.2026.117380 · meta analise · reduz sintomas de ansiedade (SMD=-0.40) e PTSD (SMD=-2.60) em RCTs · en

Efficacy of cannabis-based medicine in the treatment of Tourette syndrome: a systematic review and meta-analysis. — Serag I, Elsakka MM, Moawad MHED, Ali HT, Sarhan K, Shayeb S et al. (2024) · DOI 10.1007/s00228-024-03710-9 · meta analise · Background Tourette syndrome (TS) is a neurodevelopmental disorder characterized by motor and phonic tics. It is a condition that affects between 0.3% and 0.7% of children, and its pathophysiology remains largely elusive. TS is associated with structural and functional alteration · en

Cannabis for tic control: a systematic review and meta-analysis of its efficacy in Tourette syndrome management. — Mann GS, Gadelmawla AF, Dway A, Fayaz FH, Kebede EA, Varadharaj NK et al. (2026) · DOI 10.1016/j.neuroscience.2026.05.044 · meta analise · reduz YGTSS em média 13.29 pontos e PUTS em média 4.09 pontos · en

Cannabinoids for Medical Purposes in Children: A Living Systematic Review. — Chhabra M, Paul A, Abulannaz O, Lê ML, Mansell H, Finkelstein Y et al. (2025) · DOI 10.1111/apa.70140 · revisao sistematica · reduz frequência de crises entre 30% e 50% · en

Effects of Different Cannabinoid Formulations on Anxiety-Related Disorders, and Tourette Syndrome: A Systematic Review and Meta-Analysis. — Raminelli AO, Simei JLQ, Guimarães FS, Zuardi A, Hallak JEC, Crippa JA et al. (2025) · DOI 10.1177/25785125251378242 · meta analise · moderado efeito significativo com SMD: -0.61 · en

Arrhythmias and cannabis use: A comprehensive overview. — Paulraj S, Upreti P, Tamirisa K, Batnyam U (2025) · DOI 10.1016/j.hroo.2024.10.020 · revisao sistematica · associação significativa entre uso de cannabis e arritmias · en

Efficacy of cannabinoids in neurodevelopmental and neuropsychiatric disorders among children and adolescents: a systematic review. — Rice LJ, Cannon L, Dadlani N, Cheung MMY, Einfeld SL, Efron D et al. (2024) · DOI 10.1007/s00787-023-02169-w · revisao sistematica · evidência limitada e de baixa qualidade para a eficácia de CBP · en

The safety and efficacy of cannabinoids for the treatment of mental health and substance use disorders: protocol for a systematic review and meta-analysis. — Wilson J, Langcake A, Bryant Z, Freeman TP, Leung J, Chan GCK et al. (2025) · DOI 10.1186/s13643-024-02657-3 · revisao sistematica · There has been a global increase in the use of cannabinoids as a treatment for mental health (MH) and substance use disorders (SUD). In 2016, an Australian government-funded review found that although medicinal cannabinoids accounted for a small reduction in MH symptoms, the resu · en

The Use of Compounds Derived from <i>Cannabis sativa</i> in the Treatment of Epilepsy, Painful Conditions, and Neuropsychiatric and Neurodegenerative Disorders. — Stasiłowicz-Krzemień A, Nogalska W, Maszewska Z, Maleszka M, Dobroń M, Szary A et al. (2024) · DOI 10.3390/ijms25115749 · revisao sistematica · Neurological disorders present a wide range of symptoms and challenges in diagnosis and treatment. Cannabis sativa , with its diverse chemical composition, offers potential therapeutic benefits due to its anticonvulsive, analgesic, anti-inflammatory, and neuroprotective propertie · en

The Effect of Nabiximols on Driving Ability in Adults with Chronic Tic Disorders: Results of a Substudy Analysis of the Double-Blind, Randomized, Placebo-Controlled CANNA-TICS Trial. — Müller-Vahl KR, Pisarenko A, Ringlstetter R, Cimpianu CL, Fremer C, Weidinger E et al. (2024) · DOI 10.1089/can.2023.0114 · ensaio clinico rct · aumento na aptidão para dirigir de 55.8% para 71.8% com nabiximols · en

A Double-Blind, Randomized, Controlled Crossover Trial of Cannabis in Adults with Tourette Syndrome. — Abi-Jaoude E, Bhikram T, Parveen F, Levenbach J, Lafreniere-Roula M, Sandor P (2023) · DOI 10.1089/can.2022.0091 · ensaio clinico rct · significativo efeito de THC 10% no PUTS, SUDS e CGI-I vs placebo · en

A Pilot Randomized Placebo-Controlled Crossover Trial of Medicinal Cannabis in Adolescents with Tourette Syndrome. — Efron D, Taylor K, Chan E, Payne JM, Prakash C, Lee KJ et al. (2025) · DOI 10.1089/can.2024.0188 · ensaio clinico rct · três participantes melhoraram muito com MC vs um com placebo · en

Tetrahydrocannabinol and Cannabidiol in Tourette Syndrome. — Mosley PE, Webb L, Suraev A, Hingston L, Turnbull T, Foster K et al. (2023) · DOI 10.1056/evidoa2300012 · ensaio clinico rct · reduz escore total de tiques em 8.9 vs 2.5 no grupo placebo · en

Medical cannabis utilization in children - a study based on a nationwide cohort. — Treves N, Yakirevich-Amir N, Allegaert K, van den Anker JN, Kohn E, Berlin M et al. (2025) · DOI 10.3389/fphar.2025.1646560 · coorte · ajuste na terapia de cannabis é necessário devido à alta taxa de descontinuação · en

Adverse events associated with medical cannabis reported within a centralized call center. — Illamola SM, Lyu X, Luciana M, Dahmer S, Lehfeldt P, Dikmen S et al. (2026) · DOI 10.3389/fphar.2026.1792520 · coorte · AEs often clinically meaningful and led to treatment discontinuation · en

Licensed Medical Cannabis Use in Gilles de la Tourette Syndrome: A Retrospective Long-term Follow-Up. — Anis S, Zalomek C, Korczyn AD, Lassman S, Rosenberg A, Gurevich T (2024) · DOI 10.1089/can.2022.0281 · coorte · sujeitos relatam melhora no controle dos sintomas · en

Therapeutic use of medical Cannabis in neurological diseases: a clinical update. — Hidding U, Mainka T, Buhmann C (2024) · DOI 10.1007/s00702-023-02719-1 · revisao narrativa · The use of medical Cannabis has increased in recent years due to changing legal circumstances in many countries. Approval exists only for a few neurological conditions such as rare forms of epilepsy or spasticity in multiple sclerosis. Beyond that, however, medical Cannabis is us · en

Editorial: Are we too high on medicinal cannabis in child psychiatry? Examining the evidence in Tourette syndrome. — Hardeman LS, Farhat LC, Koenig J, Bloch MH (2025) · DOI 10.1111/jcpp.70075 · revisao narrativa · There has been renewed interest in elucidating the role of the endocannabinoid system on both brain development and psychological phenomena across the lifespan. In parallel to these efforts, the use of cannabis-related drugs for the treatment of psychiatric disorders in the commu · en

The Use of Cannabis-Based Medicine in Selected Neurological Disorders. — Szejko N, Saramak K, Müller-Vahl KR (2026) · DOI 10.1007/7854_2024_564 · revisao narrativa · melhora tics e comorbidades psiquiátricas em síndrome de Tourette · en

Cannabis-based medicine in treatment of patients with Gilles de la Tourette syndrome. — Szejko N, Saramak K, Lombroso A, Müller-Vahl K (2022) · DOI 10.5603/pjnns.a2021.0081 · revisao narrativa · Introduction Gilles de la Tourette syndrome (GTS) is a childhood onset disorder characterised by the presence of motor and vocal tics. The guidelines of both the American Academy of Neurology (AAN) as well as the European Society for the Study of Tourette Syndrome (ESSTS) recomme · en

Medical cannabis in Israel: a comprehensive review of trends and regulations, 2011-2025. — Aviram J (2025) · DOI 10.1186/s42238-025-00344-1 · revisao narrativa · BACKGROUND: Since its initial approval in 1992, medical cannabis (MC) in Israel has undergone extensive regulatory and structural transformation. This study aims to present the most comprehensive retrospective analysis to date of the evolving MC policy framework in Israel and its · en

Cannabinoids in the Treatment of Selected Mental Illnesses: Practical Approach and Overview of the Literature. — Müller-Vahl KR (2024) · DOI 10.1055/a-2256-0098 · revisao narrativa · cannabinoides podem melhorar sintomas em transtornos mentais · en

Long-term use of cannabis-based medicines in two children with Tourette syndrome: a case report. — Woerner LK, Szejko N, Fremer C, Schmitt S, Müller Vahl KR (2025) · DOI 10.3389/fpsyt.2025.1647969 · relato caso · resulta em melhora clínica dos sintomas · en

Case Report: Effect of medicinal cannabis on fitness to drive in a patient with Tourette Syndrome and ADHD. — Streetz CM, Szejko N, Pisarenko A, Fremer C, Teske J, Brunnauer A et al. (2025) · DOI 10.3389/fpsyt.2025.1595649 · relato caso · considerado apto para dirigir mesmo com altas doses de cannabis · en

Investigating medical cannabis for adolescents with Tourette syndrome: tread carefully. — Abi-Jaoude E (2026) · DOI 10.1192/bjo.2025.10959 · outro · The emerging evidence for cannabis in the management of tics in Tourette syndrome has come almost exclusively from studies in adult patients. We now have two published feasibility studies of cannabis for adolescents with Tourette syndrome. Although both readily recruited adolesce · en

Medicinal cannabis for tics in adolescents with Tourette syndrome. — Eapen V, Lin PI, Taylor K, Chan E, Chay P, Cranswick N et al. (2025) · DOI 10.1192/bjo.2025.35 · ensaio clinico · melhora tics e questões emocionais/comportamentais com P = 0.003 · en

Medicinal cannabis plant extract (NTI164) modifies epigenetic, ribosomal, and immune pathways in paediatric acute-onset neuropsychiatric syndrome. — Keating BA, Han VX, Nishida H, Aryamanesh N, Marshall LL, Gloss BS et al. (2026) · DOI 10.1016/j.neurot.2025.e00828 · ensaio clinico · diminui CGI-S de 4.8 para 3.3 (p = 0.002) · en

Corrigendum to "The use of cannabidiol as adjunctive therapy in adult patients with drug-resistant epilepsy: a systematic review and meta-analysis". — — (2025) · DOI 10.1177/17562864251400528 · meta analise · [This corrects the article DOI: 10.1177/17562864251313914.]. · en

Adjunctive Cannabidiol for Drug-Resistant Epilepsy: A Systematic Review and Meta-Analysis of Randomized Trials Across Syndromes, Formulations, and Dose Ranges. — Pratama R, Muhaimin M, Khairinisa MA, Chaerunisaa AY (2026) · DOI 10.2147/tcrm.s601774 · meta analise · Background Cannabidiol (CBD) has emerged as a promising adjunctive therapy for drug-resistant epilepsy, yet clinical findings remain heterogeneous across trials. This meta-analysis aimed to evaluate the efficacy, safety, and formulation-dependent performance of CBD in pat · en

A systematic review of highly purified cannabidiol in developmental and epileptic encephalopathies and complex treatment-resistant epilepsies: Changes in seizure frequency and adverse events. — Coppola A, Moore-Ramdin L, Navetta M, Samanta D (2026) · DOI 10.1016/j.eplepsyres.2026.107731 · revisao sistematica · estabelece eficácia na redução de crises · en

[Advances and guidance in the treatment of drug-resistant epilepsy: a review by the Andalusian Epilepsy Society of the new drugs cenobamate, fenfluramine and cannabidiol]. — Arenas-Cabrera C, Cabezudo-García P, Calvo-Medina R, Galeano-Bilbao B, Martínez-Agredano P, Ruiz-Giménez J et al. (2024) · DOI 10.33588/rn.7906.2024086 · revisao sistematica · This review, conducted by the Andalusian Epilepsy Society, provides an update on recent advances in the treatment of drug-resistant epilepsy, focusing on three new anti-seizure drugs: cenobamate, fenfluramine and cannabidiol. These emerging drugs offer new therapeutic alternative · es

A systematic review of highly purified cannabidiol in developmental and epileptic encephalopathies and complex treatment-resistant epilepsies: Nonseizure outcomes. — Samanta D, Moore-Ramdin L, Navetta M, Coppola A (2026) · DOI 10.1016/j.eplepsyres.2026.107873 · revisao sistematica · Objective A plant-derived, highly purified cannabidiol (CBD) oral solution (Epidiolex® [US]/Epidyolex® [EU]) is approved for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC). Improvements in · en

Cannabidiol and epilepsy: therapeutic, mechanistic and clinical significance. — Gupta N, Maan P, Shrivastava J, Ansari MHR (2026) · DOI 10.1016/j.seizure.2026.06.014 · revisao sistematica · apoia eficácia do CBD em epilepsias refratárias · en

Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome — Thiele EA et al. (2018), The Lancet · DOI 10.1016/S0140-6736(18)30136-3 · ensaio clinico rct · Redução mediana de drop seizures 43,9% vs 21,8% placebo · en

Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome — Devinsky O et al. (2017), New England Journal of Medicine · DOI 10.1056/NEJMoa1611618 · ensaio clinico rct · Crises convulsivas: −38,9% (CBD) vs −13,3% (placebo) · en

Chronic administration of cannabidiol to healthy volunteers and epileptic patients — Cunha JM, Carlini EA et al. (1980), Pharmacology · DOI 10.1159/000137430 · ensaio clinico rct · Redução de crises em 7/8 pacientes tratados · en

New therapeutic approach in Dravet syndrome and Lennox-Gastaut syndrome with cannabidiol. — Villanueva V, Carreño-Martínez M, Gil Nagel-Rein A, López-González FJ (2021) · DOI 10.33588/rn.72s01.2021017 · ensaio clinico rct · reduz convulsões em pacientes com DS e LGS · es

Effectiveness and tolerability of cannabidiol in paediatric epilepsy: a one-year multisite prospective study. — Halman A, Freeman JL, Fahey M, Chenhall R, Perkins D (2026) · DOI 10.1016/j.yebeh.2026.111095 · coorte · Epilepsy affects ∼50 million people worldwide, with drug-resistant forms occurring in over a third of cases and resulting in major health and quality-of-life burdens. Cannabidiol, a non-psychoactive cannabis compound, shows promise in paediatric epilepsy, but evidence remains lim · en

[Real-life study with pharmaceutical cannabidiol in refractory epilepsy] — Di Giuseppe LA, Appendino JI, García MDC, Alvarez KE, Buela G, Burgos MA et al. (2025) · DOI 10.31053/1853.0605.v82.n1.45350 · coorte · 44% reduziram frequência de crises · es

Highly Purified Cannabidiol Treatment Outcomes in Pediatric Patients with Highly Refractory Epilepsy at a Tertiary Center. — Kang K, Grewal R, Boelman C, Connolly MB, Huh L, Datta A (2026) · DOI 10.1017/cjn.2026.10554 · coorte · 22% dos pacientes alcançou redução de crises ≥50% · en

[Cannabinoids in neurology--Brazilian Academy of Neurology]. — Brucki SM, Frota NA, Schestatsky P, Souza AH, Carvalho VN, Manreza ML et al. (2015) · DOI 10.1590/0004-282x20150041 · revisao narrativa · The use of cannabidiol in some neurological conditions was allowed by Conselho Regional de Medicina de São Paulo and by Agência Nacional de Vigilância Sanitária (ANVISA). Specialists on behalf of Academia Brasileira de Neurologia prepared a critical statement about use of cannabi · pt

Cannabidiol in Developmental Epilepsy: Organoid-Guided Precision Medicine Across Critical Neurodevelopmental Windows. — Joo J, Yang WS, Koh HJ (2026) · DOI 10.3390/ijms27062899 · revisao narrativa · apoia intervenções com CBD para epilepsias de início na infância · en

[Cannabidiol: its use in refractory epilepsies]. — Pesantez-Rios G, Armijos-Acurio L, Jimbo-Sotomayor R, Pascual-Pascual SI, Pesantez-Cuesta G (2017) · DOI 10.33588/rn.6504.2016573 · observacional · reduz frequência de crises em 40% dos pacientes · es

[Judicialization of cannabidiol-based products in Brazil: an analysis from 2019 to 2022]. — Portela R, Mota DM, Ferreira PJG, Lula MD, Reis BB, Oliveira HN et al. (2023) · DOI 10.1590/0102-311xpt024723 · outro · aumento de 3.0 vezes na chance de opinião favorável para pacientes do Nordeste · pt

[Characterization of the problem of the therapeutic use of Cannabis Oil in Córdoba, Argentina]. — Manzo PG, Martín S, Uema S, Charles G, Montero Bruni F, Núñez Montoya S et al. (2022) · DOI 10.31053/1853.0605.v79.n2.30922 · outro · 84% perceberam como eficaz (moderado a altamente eficaz) · es

&lt;i&gt;STXBP1&lt;/i&gt; Encephalopathy: Cannabidiol as a Treatment Option and Expansion of the Genotype-Phenotype Spectrum - Case Reports. — Ngoh A, Wei H, Yeo TH, Krishnappa J, Ling S, Tan EC et al. (2026) · DOI 10.1159/000550657 · relato caso · CBD pode ser benéfico para indivíduos severamente afetados com crises e distúrbios de movimento · en

A temporary spike: Investigating Lennox-Gastaut syndrome incidence in the US following FDA approval of cannabidiol. — Marcinski Nascimento KJ, Li Y, Lin BY, Dixon-Salazar T, Perry MS, Xu KY et al. (2026) · DOI 10.1002/epd2.70168 · outro · aumento temporário de diagnósticos de LGS ~30% de 2018 a 2019 · en

Co-Creation of the EpiCom Clinical Trial: Bringing the Tuberous Sclerosis Complex Patient Community, Healthcare Professionals, and the Pharmaceutical Industry Together. — Moore-Ramdin L, van Eeghen A, Stevens J, Takhar P, Meitzler S, Fladrowski C et al. (2026) · DOI 10.1007/s40271-026-00830-5 · ensaio clinico · Background Tuberous sclerosis complex (TSC)-associated neuropsychiatric disorders (TAND) affect most patients with TSC and encompass a range of psychiatric, intellectual, neuropsychological, and behavioral manifestations of the disease. Epilepsy Comorbidities (EpiCom), an ongoing · en

Characterization and Anticonvulsant Effects of a Colombian Cannabis sativa Extract: A Preclinical Study in Murine Models of Epilepsy — smith adt (2026), Research Square · DOI 10.21203/rs.3.rs-8935396/v1 · pre clinico · protege completamente contra crises no modelo 6 Hz · en

Highly purified cannabidiol (CBD) in CDKL5 deficiency disorder (CDD): Open-label prospective study. — Perulli M, De Gioia A, Ruggiero F, Ascione F, Porto C, Musto E et al. (2026) · DOI 10.1002/epi4.70213 · ensaio clinico · reduz frequência de crises >50% em 8/9 pacientes aos 3 meses · en

Real-world effectiveness of highly purified cannabidiol in epilepsy associated with 15q11.2-q13.1 duplication and deletion syndromes: A multicenter study. — Cerulli Irelli E, Mazzeo A, Perulli M, Ramantani G, Battaglia D, Bagnasco I et al. (2026) · DOI 10.1002/epi4.70241 · outro · This multicenter retrospective study evaluated the effectiveness and safety of highly purified cannabidiol (CBD) in 22 patients with 15q11.2-q13.1 duplication or deletion syndromes (15q-DDS), including 12 with 15q duplication syndrome (dup15q) and 10 with Angelman syndrome (AS). · en

Cannabidiol reduces atypical absence seizures and epileptic spasms in a Gabrb3&lt;sup&gt;+/D120N&lt;/sup&gt; mouse model of Lennox-Gastaut syndrome. — Harman T, Sharman LA, Yip KL, Bedoya-Pérez M, Janve V, Arnold JC (2026) · DOI 10.1002/epi4.70289 · pre clinico · reduz frequência de crises e duração com CBD · en

Cannabidiol attenuates seizure progression and recognition memory deficit induced by hippocampal HCN&lt;sub&gt;1&lt;/sub&gt; knockdown in the kindling model of epilepsy in male rats. — Aliakbari S, Naderi N, Hasanzadeh L, Sayyah M, Ilkhanizadeh-Qomi M, Cheng Y et al. (2026) · DOI 10.1016/j.neuropharm.2026.111114 · pre clinico · Epilepsy is a neurological disorder characterized by excessive neuronal firing, frequently originating in the hippocampus. Hyperpolarization-activated cyclic nucleotide-gated channel-1 (HCN 1 ) regulates neuronal excitability and resting membrane potential, yet its role · en

Cannabidiol inhibits phenytoin clearance and can result in clinical changes: Two cases. — Blond BN, Cardoza C, Mattson RH (2026) · DOI 10.1016/j.seizure.2026.02.019 · relato caso · Purpose Cannabidiol has well described drug interactions including inhibition of clobazam metabolism. Phenytoin is known to induce metabolism of cannabidiol. Cannabidiol inhibition of phenytoin metabolism is predicted but not well described. Methods We present the cases of two in · en

Preliminary Prospective Study of Pharmaceutical-Grade Cannabidiol for Seizure Frequency, Anxiety, and Comorbid Symptoms in Pediatric Epilepsy: Associations With Circulating Endocannabinoids and Lipid Biomarkers. — Hopkins S, Weber A, MacDougall J, Evanski J, Marusak HA, Luat A (2026) · DOI 10.1177/08830738261439213 · ensaio clinico · 73% dos cuidadores relataram melhorias em ansiedade e frequência de crises · en

Behavioral, electrophysiological, and epigenetic characterization of acute cannabinoid treatment during pilocarpine-induced status epilepticus in mice — Gatica RI, Noches V, Gonzalez M, Henny P, Andrés ME (2026), Research Square · DOI 10.21203/rs.3.rs-9569465/v1 · outro · Abstract There is growing interest in using cannabis and its active ingredients for epilepsy treatment. The main components of cannabis are cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC), with some formulations of CBD approved for treating epilepsies refractory to tradition · en

Cannabidiol in Epilepsy: Restoring Locomotion and Seizure Control. — Ogbu JI, Mendes Rosa T, Nakao de Aguiar AS, Borges LL, Perjesi P, Napolitano HB et al. (2026) · DOI 10.2174/0118715273398370251129105507 · outro · Epilepsy remains a global challenge, with about one-third of affected patients being resistant to treatment. Seizures and motor abnormalities characterized by movement difficulties are common in epilepsy, highlighting the need for treatments that can both improve motor outcomes a · en

Subchronic Cannabidiol (CBD) Treatment During the Silent Period Fails to Prevent the Increased Seizure Susceptibility Following Lithium Pilocarpine-Induced Status Epilepticus — Taborda C, Fernandez F, Jara A, Borda N, Moscovicz F, Yauri-Huaman Y et al. (2026), Preprints.org · DOI 10.20944/preprints202606.2067.v1 · ensaio clinico · In recent years, cannabidiol (CBD) has been used as an adjunct therapy to anti-seizure medications for the control of seizures in patients with drug-resistant epilepsies. In addition to its anticonvulsant effect, CBD also well-defined anti-inflammatory properties. Since neuroinfl · en

The prevalence of cannabidiol (CBD) use in North America and Europe: A meta-analysis. — Weidberg S, Iza-Fernández C, Alemán-Moussa L, Krotter A, González-Roz A (2026) · DOI 10.1111/add.70360 · meta analise · cannabidiol use mais prevalente na América do Norte em comparação com a Europa · en

Cannabis therapy in rheumatological diseases: A systematic review. — de Carvalho JF, Ribeiro MFLDS, Skare T (2024) · DOI 10.14744/nci.2023.43669 · revisao sistematica · importante redução na dor em 12 dos 13 estudos sobre fibromialgia · en

Medical Cannabis: A Review from the American Society of Pain and Neuroscience. — Strand N, D'Souza RS, Karri J, Kalia H, Weisbein J, Kassa BJ et al. (2023) · DOI 10.2147/jpr.s425862 · revisao sistematica · Cannabinoids have recently gained a renewed interest due to their potential applicability to various medical conditions, specifically the management of chronic pain conditions. Unlike many other medications, medical cannabis is not associated with serious adverse events, and no o · en

Medical Cannabis in the United States: Comparing 2017 and 2024 State Qualifying Conditions to the 2017 National Academies of Sciences Report. — Stains EL, Kennalley AL, Tian M, Boehnke KF, Kraus CK, Piper BJ (2025) · DOI 10.1016/j.mayocpiqo.2025.100590 · revisao sistematica · apenas 8.3% dos QCs em 2024 tinham evidência substancial · en

Evidence synthesis of medical cannabis research: current challenges and opportunities. — Senator B, Pardal M, Vandam L (2025) · DOI 10.1007/s00406-024-01893-x · revisao sistematica · As a wide group of medicines, the effectiveness and safety of 'medical cannabis' products is likely to vary in relation to product-specific dimensions such as potency, dosage, route of administration, and cannabinoid composition. Systematic reviews can perform a crucial role in a · en

Cannabis for the Treatment of Fibromyalgia: A Systematic Review. — Strand NH, Maloney J, Kraus M, Wie C, Turkiewicz M, Gomez DA et al. (2023) · DOI 10.3390/biomedicines11061621 · revisao sistematica · reduz dor a curto prazo em pacientes com fibromialgia · en

Therapeutic potential of cannabinoids in neurological conditions: a systematic review of clinical trials. — Hakami AY, Alshehri FS (2025) · DOI 10.3389/fphar.2025.1521792 · revisao sistematica · promissores resultados em manejo de sintomas para condições como Esclerose Múltipla e Fibromialgia · en

The Efficacy and Safety of Use of Cannabis and Cannabinoid Products for Pain Relief in Orthopaedic Conditions and Trauma. — Shah D, Murhekar S, Ward M, Sagane S, Pahwani A (2025) · DOI 10.7759/cureus.87208 · revisao sistematica · evidência mínima de eficácia em comparação com placebo ou sem tratamento · en

A Scoping Systematic Review of Cannabis Use in Endometriosis. — McLaren K, Erridge S, Sodergren MH (2026) · DOI 10.1111/ajo.70081 · revisao sistematica · cannabis ajudou a reduzir dor associada à endometriose · en

Effectiveness and safety of cannabis-based products for medical use in patients with fibromyalgia syndrome: A systematic review. — Lopera V, Restrepo JC, Amariles P (2024) · DOI 10.1016/j.rcsop.2024.100524 · revisao sistematica · importante melhoria em dor, qualidade de vida e hábitos de sono · en

Cannabis-Based Medicines for Nociplastic Pain: A Scoping Review of Efficacy, Safety, and Patient Outcomes. — Miguel-Seno H, Reis-Pina P (2026) · DOI 10.1080/15360288.2026.2704788 · revisao sistematica · modest benefits em fibromialgia e dor musculoesquelética crônica · en

Evaluation of the use of different forms of medical cannabis in the treatment of fibromyalgia: a systematic review. — Duarte GO, Feitosa MHR, Bringel FA, Prado SMB (2026) · DOI 10.1016/j.ero.2026.01.016 · revisao sistematica · Objectives To systematically review, based on randomised controlled trials (RCTs), some forms of medical cannabis (nabilone, tetrahydrocannabinol-rich oil, and Bediol) in the treatment of fibromyalgia syndrome (FMS). Methods According to the Preferred Reporting Items for Systemat · en

Cannabinoids for Anxiety and Sleep Disturbances: A Scoping Review. — Perez JG, LaMontagne LG, Garcia GA, Vaddiparti K, Gupta PS, Churba BZ et al. (2025) · DOI 10.1159/000548890 · revisao sistematica · cannabinoides, especialmente CBD, podem melhorar sintomas de ansiedade e distúrbios do sono · en

Oral Medicinal Cannabis Does Not Alter Plasma Levels of Endocannabinoid-Related &lt;i&gt;N&lt;/i&gt;-Acylethanolamines in Fibromyalgia Patients: Findings from a Randomized Placebo-Controlled Trial. — Kurlyandchik I, Van Crugten J, Lauche R, Tiralongo E, Schloss J (2026) · DOI 10.1177/25785125261469541 · ensaio clinico rct · não altera níveis plasmáticos de NAEs · en

Comparison of two carbohydrate-based biostimulant complexes for their ability to enhance &lt;i&gt;Cannabis sativa&lt;/i&gt; flower yield and quality. — Wise K, Simovich T, Alengaden R, Gill H, Zandberg A, Selby-Pham J (2026) · DOI 10.3389/fpls.2026.1842299 · ensaio clinico rct · BC2 aumentou o rendimento em 2.22 vezes vs controle · en

The impact of tetrahydrocannabinol on central pain modulation in chronic pain: a randomized clinical comparative study of offset analgesia and conditioned pain modulation in fibromyalgia. — Agbaria Y, Preger R, Aloush V, Ablin JN, Sharon H, Jacob G (2025) · DOI 10.1186/s42238-025-00348-x · ensaio clinico rct · reduz dor espontânea no McGill comparado ao placebo (P=0.02) · en

Feasibility, Safety and Preliminary Efficacy of 1:1 THC:CBD Cannabis Oil for Fibromyalgia Symptoms: Results From a Randomised, Double-Blind, Placebo-Controlled Pilot Trial. — Kurlyandchik I, Tiralongo E, Lauche R, Tracey G, Ng J, Schloss J (2026) · DOI 10.1155/prm/7311235 · ensaio clinico rct · 40% dos tratados com cannabis tiveram melhora clinicamente significativa no FIQR vs 10% com placebo · en

Cannabidiol to reduce persistent post-surgical pain following total knee arthroplasty: protocol for a multi-centre, randomized, controlled pilot trial. — Busse JW, Flood B, Madden K, Ashoorion V, Olaonipekun E, Atrey A et al. (2026) · DOI 10.1186/s40814-026-01822-w · ensaio clinico rct · Background Total knee arthroplasty (TKA) is commonly performed to reduce pain and improve functional limitations associated with late-stage osteoarthritis. However, 1 in 4 patients experience persistent post-surgical pain (PPSP); a complaint that is associated with higher peri-op · en

Phase II randomized controlled trial comparing traditional Thai cannabis-based medicine with lorazepam for insomnia treatment. — Kamoltham T, Chokchaisiri S, Yongram C, Sripan P, Im-Iam S, Sanasit P et al. (2026) · DOI 10.1186/s42238-026-00415-x · ensaio clinico rct · não inferior a lorazepam com diferença média de -1.34 no PSQI · en

UK Medical Cannabis Registry: a case series analysing clinical outcomes of medicinal cannabis therapy for fibromyalgia. — Varadpande M, Erridge S, Aggarwal A, Clarke E, McLachlan K, Coomber R et al. (2026) · DOI 10.1007/s10067-025-07846-6 · caso controle · melhora em dor, ansiedade, sono e qualidade de vida · en

Neurologists' perspectives of cannabis-based medicines: results from an all-Ireland survey. — Savio M, Kearney H, Downer EJ (2025) · DOI 10.1007/s11845-025-03880-0 · transversal · Background Advancements continue to be made in the development of medicines containing components of the Cannabis sativa L. plant. Consultants can prescribe specific cannabis-based products for a restricted set of indications in Ireland, with neurologists being at the forefront o · en

Cannabinoid products for pain management: recommendations from the São Paulo State Society of Anesthesiology. — de Barros GAM, Pos AM, Sousa ÂM, Pereira CL, Nobre CDA, Palmeira CCA et al. (2024) · DOI 10.1016/j.bjane.2024.844513 · revisao narrativa · cannabinoid products podem servir como adjuntos na gestão da dor · en

The Regulatory Environment Surrounding Cannabis Medicines in the EU, the USA, and Australia. — Jardim C, Delgado-Charro MB (2025) · DOI 10.3390/pharmaceutics17050635 · revisao narrativa · Background/Objectives : Recent evidence supporting the medicinal use of cannabis has brought significant regulatory changes regarding its legal status, cultivation, and use. Several countries have adopted regulatory strategies enabling access to cannabis-based medicinal products; · en

Evaluating the pharmacokinetics, efficacy and safety of low-dose cannabidiol. — Warren WG, Osborn M, Yates A, O'Sullivan SE (2026) · DOI 10.1002/bcp.70691 · revisao narrativa · muito pouca evidência de efeito biológico ou valor terapêutico · en

An Overview of the Potential for Pharmacokinetic Interactions Between Drugs and Cannabis Products in Humans. — Caicedo DA, Pérez-Mañá C, Farré M, Papaseit E (2025) · DOI 10.3390/pharmaceutics17030319 · revisao narrativa · Cannabis is the most commonly used illicit substance worldwide. Recent years have seen an increase in cannabis consumption, and with new approvals and therapeutic indications, there are challenges in minimizing the risks and interactions between cannabis-based products, cannabis · en

Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review. — Christo PJ, Vortsman E, Gharibo C, LeQuang JAK, Pergolizzi JV (2025) · DOI 10.7759/cureus.81577 · revisao narrativa · Chronic pain is prevalent and challenging to treat. Cannabinoids, in particular cannabidiol (CBD), have been evaluated as analgesics without the issues of tolerance or dependence. Side effects tend to be mild and infrequent. These products have multiple routes of administration a · en

Role of the Endocannabinoid System in Fibromyalgia. — García-Domínguez M (2025) · DOI 10.3390/cimb47040230 · revisao narrativa · Fibromyalgia is a chronic disease marked by extensive musculoskeletal pain, persistent fatigue, and cognitive impairments. Despite its high prevalence, the underlying pathological mechanisms of fibromyalgia are still not fully elucidated. Emerging research has identified the endo · en

Cannabinoids in immune system-related diseases: From bench to clinic. — Zhang W, Chen B, Cao Y, Lei W, Zhao H, Yang Y et al. (2026) · DOI 10.1097/cm9.0000000000003818 · revisao narrativa · Abstract As a psychoactive drug, marijuana is used for recreational purposes. Given its addictive nature and the serious damage it causes to both individual health and social stability, marijuana has been banned in most countries worldwide. In recent years, with the continuous im · en

Cannabidiol Use and Perceptions of Effectiveness in Women With Chronic Pelvic Pain. — Till SR, Whitmore G, As-Sanie S, Matallana L, Boehnke KF (2025) · DOI 10.1016/j.jogc.2025.102839 · outro · 80.9% relataram melhora da dor com uso de CBD · en

How to ESCAPE from Pain? An Observational Study on Improving Pain and Quality of Life with the Cannamedical&lt;sup&gt;®&lt;/sup&gt; Hybrid Cannabis Extract. — Wagner Y, Samel I, Probst K, Schollenberger L, Ruckes C, Nadstawek J et al. (2025) · DOI 10.1007/s12325-025-03262-z · observacional · reduz intensidade da dor de 5.46 a 3.37 na população geral e de 5.92 a 2.37 na subpopulação canábis-naiiva · en

Self-reported use of cannabidiol as a substitute or adjunct for approved medications. — Austin EAC, Berghammer L, Ellis SE, Appolon G, Brooks J, Rice NM et al. (2026) · DOI 10.3389/fpubh.2026.1720348 · outro · 32.0% dos usuários de CBD usaram como substituto ou adjunto para medicamentos · en

Efficiency and safety of cannabinoid medical use: an analysis of discussions and observed trends on Instagram. — Litvinova O, Baral B, Wochele-Thoma T, Matin M, Tzvetkov NT, Adamska O et al. (2024) · DOI 10.3389/fpubh.2024.1494018 · outro · Background Cannabis and its derivatives show encouraging therapeutic effects in the treatment of various diseases. However, further studies are needed to better assess their efficacy and safety. A promising base for research in the field of medicine and additional pharmacovigilan · en

Navigating the Grey Zone: The Impact of Legislative Frameworks in North America and Europe on Adolescent Cannabis Use-A Systematic Review. — Jablonska B, Negura L (2024) · DOI 10.3390/bs14060484 · revisao sistematica · variações na prevalência de uso de cannabis entre adolescentes após mudanças legislativas · en

Exploring the Influence of Recreational Cannabis Legalization on Women's Perceptions and Experiences with Perinatal Cannabis Use: A Qualitative Meta-synthesis. — Maturino K, Morton J, Weston K, Anbari A (2026) · DOI 10.1007/s10995-026-04228-5 · meta analise · OBJECTIVE: We aimed to explore how women living in places with legalized recreational cannabis perceive perinatal cannabis use, and how legalization potentially impacts their experiences. METHODS: Between September 2024 and December 2025, we searched databases including PubMed, C · en

Expected population prevalence following decriminalization of recreational use of cannabis in Sweden. — Andersson F, Ramstedt M, Thiesmeier R, Magnusson C, Orsini N, Galanti MR (2026) · DOI 10.1186/s42238-026-00405-z · meta analise · aumento imediato no uso de cannabis após descriminalização · en

Evaluating the association between cannabis decriminalization and legalization and cannabis arrests and related disparities: A Systematic review. — McCarthy SDS, Gaudreault A, Xiao J, Fischer B, Hall W, Lee K et al. (2025) · DOI 10.1016/j.drugpo.2025.104705 · revisao sistematica · reduz ofensas relacionadas à cannabis entre 13.5% e 78.0% após descriminalização · en

The Persistence of Stigma and Other Challenges Experienced by Medical Cannabis Users: A Thematic Synthesis of Qualitative Studies. — Breuning M, Nie J, Schlesinger M, Smith L, Lavie-Ajayi M, Babinski S et al. (2026) · DOI 10.1159/000551584 · revisao sistematica · Background The legislation, practices, and guidance shaping patient and professional access to medical cannabis (MC) for managing chronic pain and other conditions vary widely across jurisdictions. Despite promising evidence of effectiveness, challenges persist for those trying t · en

Adult-use cannabis legalization in the united states: a scoping review of outcome monitoring recommendations. — Liu Y, Suleiman AO, Iverson MG, Wiser A, Cunningham SD, O'Grady MA (2025) · DOI 10.1186/s12889-025-25720-7 · revisao sistematica · Background Legalization of adult-use cannabis continues to expand across the United States. However, little is known about recommendations for monitoring its public health impacts. This scoping review will identify the scope and size of the literature on cannabis outcome monitori · en

Associations Between Evolving Cannabis Policies and Cannabis-Related School Discipline Among Secondary School Students in Massachusetts, 2005-2019. — English F, Laws HB, Yi Y, Martínez AD, Bertone-Johnson E, Whitehill JM (2026) · DOI 10.1016/j.amepre.2025.108129 · coorte · aumento de incidentes disciplinares relacionados à cannabis em 34% durante a descriminalização · en

Associations between recreational cannabis legalization and cannabis use disorder treatment outcomes in California, 2010-2021. — Bass B, Padwa H, Khurana D, Urada D (2025) · DOI 10.1186/s42238-025-00323-6 · coorte · reduz probabilidade de retenção em tratamento em 90 dias · en

Driving under the influence of alcohol and cannabis: Associations with substance use and behavioral health characteristics. — Choi NG, Marti CN (2025) · DOI 10.1080/15389588.2025.2587850 · coorte · Objectives Driving under the influence of alcohol (DUIA) and cannabis (DUIC) continues to increase. Given the increased number of states with cannabis legalization in recent years, updates on driving under the influence (DUI) prevalence and risk factors are needed to inform targe · en

Changes in and correlates of cannabis-involved substance use treatment admissions age 50 and older, 2000-2021. — Choi NG, Marti CN, Choi BY (2025) · DOI 10.3389/fpubh.2025.1592551 · coorte · aumento nas admissões de tratamento envolvendo cannabis entre adultos mais velhos · en

A budding problem: Marijuana use in pediatric trauma patients before and after legalization. — Davis RT, Galvin RM, Oag K, Vitale L, Hudson-Bradford C, Rosen RD et al. (2026) · DOI 10.1097/ta.0000000000004979 · coorte · THC positivity aumentou de 19.5% para 34.4% entre pacientes analisados · en

A 2025 Nationwide Cross-Sectional Survey on Public Attitudes Toward the Legalization and Depenalization of Recreational Cannabis in Poland. — Silczuk A, Jankowski M, Mularczyk-Tomczewska P, Olearczyk A, Baran T, Wrześniewska-Wal I et al. (2026) · DOI 10.12659/msm.951939 · transversal · 29.6% apoiam legalização total, 39.6% favorecem depenalização · en

Factors associated with different cannabis supply methods: results from the French 2017 ESCAPAD and Health Barometer surveys. — Wallez S, Eren F, Lahaie E, Spilka S, Rezag Bara SF, Bayle G et al. (2026) · DOI 10.1186/s42238-025-00372-x · transversal · Background Cannabis supply methods vary depending on the country, legislation, availability, and population characteristics. In many countries, cannabis consumption remains illegal and poses a major public health concern. Therefore, it is essential to study the factors associated · en

State funding for cannabis research: an analysis of funding mechanisms and levels. — Balla A, Boyle RG, Dempsey C (2025) · DOI 10.1186/s42238-025-00264-0 · revisao narrativa · Background This paper examines cannabis research funding across U.S. states that have legalized cannabis for medical or adult (non-medical) use. It specifically looks at state legislative efforts to fund cannabis research, and the amount and mechanisms used for funding distributi · en

Marijuana policy and tribal communities in the United States. — Pedersen DE (2025) · DOI 10.1057/s41271-025-00572-y · revisao narrativa · In the United States (US), the policy landscape surrounding marijuana is complex, multijurisdictional, and often messy, if not contradictory-particularly for tribal communities. Currently, tribes may choose to criminalize or legalize marijuana but may be located within a state or · en

The Impact of Adult Cannabis Use Legalization in California: A Qualitative Review of Subject Matter Expert Opinions on Proposition 64. — Ageze D, Dell'Acqua R, Marcotte TD, Baird S, Garcia J, Rybar J et al. (2025) · DOI 10.26828/cannabis/2025/000291 · revisao narrativa · Objective California legalized adult cannabis use in 2016 with the passing of Proposition 64: The Adult Use Marijuana Act (Prop 64). This qualitative study aimed to explore the impact of legalization on various stakeholders and institutions within California, especially as it rel · en

Cannabis Policy and Consumption: Taking into account Substitution Effects. — Wilds KM, Riddell JR (2024) · DOI 10.1080/10826084.2023.2262012 · outro · apoia aumento da prevalência de uso de cannabis · en

Recreational cannabis legalization and immigration enforcement: a state-level analysis of arrests and deportations in the United States, 2009-2020. — Bruzelius E, Martins SS (2024) · DOI 10.1186/s12889-024-18334-y · outro · imigração enforcement foi menor em estados com RCL · en

Public health orientation of Cannabis and alcohol regulators: An analysis of state-level variation in the United States. — Carr CJ, Reuter P, Midgette G (2025) · DOI 10.1016/j.drugpo.2025.105060 · outro · Objectives To provide an analysis of state-level variation in how alcohol and adult-use cannabis regulatory agencies articulate their involvement in, and pursuit of, public health goals. Methods An important slogan in state-level campaigns to legalize adult-use cannabis was to re · en

Impact of cannabis legalization on drug possession offences among people who experience incarceration in Ontario, Canada. — Butler A, Croxford R, Owusu-Bempah A, Akbari H, Kouyoumdjian F (2026) · DOI 10.1016/j.drugpo.2026.105305 · outro · reduz ofensas de posse imediatamente · en

Do Recreational Cannabis Laws Narrow the Black/White Gap in Marijuana Arrests? Evidence from Staggered Difference-in-Differences — Patel P (2026), Research Square · DOI 10.21203/rs.3.rs-10296532/v1 · ensaio clinico · reduz a razão de prisões por posse de maconha entre negros e brancos em cerca de 29 a 32% · en

Cannabis Social Equity Initiatives Across 5 US States Case Studies of Colorado, Washington, Massachusetts, Connecticut, and Missouri. — Speer M, Chakraborty R, Yang YT, LoParco CR, Berg CJ (2025) · DOI 10.1097/phh.0000000000002191 · outro · Context Given the historic cannabis-related injustices in the US, several states that have legalized nonmedical cannabis also launched social equity (SE) initiatives involving criminal justice reform, equitable entrepreneurship assistance, and community reinvestment programs. Obj · en

Global cannabis cultivation as a gendered activity: Findings from the 2020 International Cannabis Cultivation Questionnaire. — Meisel JS, Brummer JE, Søgaard TF, Potter GR, Grigg J, Jauffret-Roustide M (2025) · DOI 10.1016/j.drugpo.2025.105039 · outro · aumento da participação feminina na produção de cannabis em contextos legais · en

The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a systematic review and meta-analysis. — Wilson J, Dobson O, Langcake A, Mishra P, Bryant Z, Leung J et al. (2026) · DOI 10.1016/s2215-0366(26)00015-5 · meta analise · Background Mental disorders and substance use disorders (SUDs) are among the leading reasons for which the medical use of cannabinoids has been approved, but their efficacy and safety in treating these conditions is yet to be established. We conducted a systematic review and meta · en

Behavioral pharmacology of isolated cannabidiol in animal models of autism spectrum disorder: a systematic review. — Vasconcelos IKM, da Silva Pitombeira MH, Fontenele DR, Vasconcelos QDJS, Aragão GF (2026) · DOI 10.1007/s00213-026-07149-x · revisao sistematica · melhora em comportamentos repetitivos e interação social com CBD · en

Randomised Controlled Trial Evidence on Medicinal Cannabis for Treatment of Mental Health and Substance Use Disorders: A Scoping Review. — Cooling S, Bonomo YA, Castle D, Hallinan CM (2026) · DOI 10.1007/s40261-025-01501-3 · revisao sistematica · Background With shifting perceptions about the therapeutic potential of cannabis and evolving regulatory frameworks, global prescribing of medicinal cannabis is increasing. While some emerging evidence supports its use for conditions like multiple sclerosis and epilepsy, its effi · en

Therapeutic Use of Cannabis Derivatives and Their Analogs for Autism Spectrum Disorder: A Systematic Review. — Riera R, de Toledo IP, Farinasso CM, Pacheco RL, Silva RB, Colpani V et al. (2025) · DOI 10.1002/jcph.70068 · revisao sistematica · cannabis pode melhorar sintomas de avaliação global · en

Cannabinoid-based interventions for behavioral outcomes in children and adolescents with autism spectrum disorder: A systematic review of safety and effectiveness. — Vasconcelos QDJS, de Freitas RF, Freitas MC, de Andrade IP, Brandão CB, Nascimento CE et al. (2026) · DOI 10.1016/j.pnpbp.2026.111697 · revisao sistematica · Background Autism spectrum disorder (ASD) lacks effective options for core symptoms. Cannabinoids, especially cannabidiol (CBD) and combined CBD:Δ9-tetrahydrocannabinol (THC) formulations, are of interest, but clinical evidence is heterogeneous. Purpose To evaluate the effectiven · en

Efficacy and Safety of Cannabinoid-Based Products in Children and Adolescents with Autism Spectrum Disorder, Fragile X Syndrome and Rett Syndrome: A Systematic Review. — Boeri S, Bosisio L, Prato G, Martinez Popple M, De Grandis E, Striano P et al. (2026) · DOI 10.1177/10445463261462382 · revisao sistematica · Introduction Neurodevelopmental disorders (NDDs), including Autism Spectrum Disorder (ASD), Fragile X syndrome (FXS), and Rett Syndrome (RTT), share impairments in cognitive and behavioral functioning and may involve an altered excitatory/inhibitory balance modulated by the endoc · en

Potential of cannabinoids as treatments for autism spectrum disorders — Nezgovorova V, Ferretti CJ, Taylor BP, et al. (2021), Journal of Psychiatric Research · DOI 10.1016/j.jpsychires.2020.11.023 · revisao sistematica · Sinais positivos, mas faltam ensaios controlados robustos · en

Cannabidiol (CBD) Treatment for Severe Problem Behaviors in Autistic Boys: A Randomized Clinical Trial. — Trauner D, Umlauf A, Grelotti DJ, Fitzgerald R, Hannawi A, Marcotte TD et al. (2025) · DOI 10.1007/s10803-025-06884-y · ensaio clinico rct · não encontramos CBD claramente eficaz na redução de comportamentos problemáticos · en

Cannabidiol Modulates Right Fronto-Parietal Connectivity in Autistic Children: A Secondary EEG Analysis from a Randomised Placebo-Controlled Crossover Trial — Parrella N, Hill AT, Enticott PG, Downey LA, Catchlove S, Ford TC (2025), medRxiv · DOI 10.1101/2025.09.09.25335467 · ensaio clinico rct · p FDR .60 · en

Cannabidiol blood metabolite levels after cannabidiol treatment are associated with broadband EEG changes and improvements in visuomotor and non-verbal cognitive abilities in boys with autism requiring higher levels of support. — Cazares C, Hutton A, Paez G, Trauner D, Voytek B (2026) · DOI 10.1038/s41398-026-03815-y · ensaio clinico rct · associação positiva entre níveis de metabolitos de CBD e melhorias em habilidades cognitivas e comportamentais · en

Effects of Cannabidiol on Social Relating, Anxiety, and Parental Stress in Autistic Children: A Randomized Controlled Crossover Trial. — Parrella NF, Hill AT, Enticott PG, Botha T, Catchlove S, Downey L et al. (2026) · DOI 10.1002/aur.70159 · ensaio clinico rct · reduz ansiedade no DBC-2 ~3.20 vs placebo · en

Brief Report: Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems—A Retrospective Feasibility Study — Aran A, Cassuto H, Lubotzky A, Wattad N, Hazan E (2019), Journal of Autism and Developmental Disorders · DOI 10.1007/s10803-018-3808-2 · coorte · Melhora comportamental/qualidade de vida relatada pelos cuidadores · en

Cannabinoid treatment impacts adaptive behavior in autism patients and caregivers' mental health: A prospective real-life cohort study. — Guimarães KÁ, Jorge LP, Resende ALO, da Silva Junior EA, Kummer AME, da Silva Lessa Júnior W et al. (2025) · DOI 10.1016/bs.pbr.2025.08.014 · coorte · reduz comportamento maladaptativo e sintomas de saúde mental em cuidadores · en

UK Medical Cannabis Registry: A Clinical Outcomes Analysis for Autism Spectrum Disorder. — Aggarwal A, Erridge S, Varadpande M, Clarke E, McLachlan K, Coomber R et al. (2026) · DOI 10.1002/npr2.70146 · caso controle · melhorias em HRQoL, ansiedade e sono · en

Cannabidiol at the crossroads: panacea, placebo, or problem? — Bidwell LC, Vandrey R (2026) · DOI 10.1038/s41386-026-02415-0 · revisao narrativa · Cannabidiol (CBD) is widely perceived as a safe and effective treatment for a growing list of health indications and use for general wellness. Evidence for its safety and efficacy comes from a variety of sources, including preclinical studies, clinical trials, and observational s · en

Purified cannabidiol leads to improvement of severe treatment-resistant behavioral symptoms in children with autism spectrum disorder. — Fortini PS, Toibaro JJ, Caraballo RH (2025) · DOI 10.1016/j.pbb.2025.173971 · outro · 90% dos pacientes apresentaram melhora em pelo menos um sintoma após início do CBD · en

Evaluating the impact of cannabis oil for autistic children with and without concomitant medications: Insights from an open-label study. — Treves N, Dagan A, Kohn E, Hazan A, Berkovitch M, Abu-Kishk I et al. (2026) · DOI 10.1177/02698811251332841 · ensaio clinico · sem diferenças significativas em eficácia entre monoterapia e terapia adjuvante · en

Cannabidiol-Induced Recovery of Social Behaviour in Mouse Models of Syndromic Autism — Parkhill M, Baglot SL, Lewis V, Rodrigue B, Gantois I, Siddiqui N et al. (2025), Research Square · DOI 10.21203/rs.3.rs-6683632/v2 · ensaio clinico · restaurou comportamentos sociais a níveis de controle após administração de CBD · en

Cannabis Oil Protects Against Valproic Acid-Induced Autism Spectrum Disorder by Reducing Oxidative Stress. — Ali F, Shehzad A, Shahzad R, Khan S, Rashan L, Taha M (2025) · DOI 10.1002/dneu.22969 · pre clinico · CBD oil treatment significantly improved behavioral abnormalities and lowered oxidative stress · en

Comparative Analysis of Cannabidiol and Risperidone on Behavioral and Neurochemical Outcomes, and Neurodevelopment Markers in a Zebrafish Model of Embryonic Exposure to Sodium Valproate. — Costa KCM, Brigante TAV, Lirio PHC, Fernandes GG, Scarante FF, Scomparin DS et al. (2025) · DOI 10.1002/aur.70151 · pre clinico · CBD efetivamente reverteu comportamentos ASD-like e reduziu peroxidação lipídica · en

Nose-to-Brain Administration of Cannabidiol-Loaded Polymeric Micelles Improves the Core Behavioral Symptoms of Autism Spectrum Disorder — Awad R, Aga-Mizrachi S, Maoz I, Simchi L, Avital A, Sosnik A (2025), bioRxiv · DOI 10.1101/2025.11.05.686695 · outro · melhora os sintomas centrais do ASD · en

Long-term follow-up of children with autism spectrum disorder and severe treatment-resistant behavioral symptoms treated with purified cannabidiol. — Fortini PS, Toibaro JJ, Caraballo RH (2026) · DOI 10.1016/j.pbb.2026.174220 · outro · melhora dos sintomas comportamentais em crianças com ASD · en

A Phase-2 Open-Label Trial of Cannabidiol to Treat Core and Associated Symptoms of Autism in Children and Adolescents Without Intellectual Disability. — Lawson J, Robinson L, Conlon GR, Shalev RA, Cervantes PE, Yoncheva Y et al. (2026) · DOI 10.1177/10445463261452514 · ensaio clinico · Objective To evaluate cannabidiol (CBD) in pediatric patients with autism spectrum disorder (ASD), fluent verbal language and an estimated full-scale IQ of 80 or above. Background Preliminary evidence suggests CBD may ameliorate challenges associated with ASD. Whether CBD benefit · en

Knowledge about the health effects of cannabis before and after legalization of 'recreational' cannabis in Canada: findings from the International Cannabis Policy Study, 2018-2024. — Tong W, Hammond D (2026) · DOI 10.1186/s42238-026-00428-6 · revisao sistematica · modestas diferenças no conhecimento sobre efeitos à saúde · en

Cannabis legalization and law enforcement drug seizures: a state-level analysis of cannabis policy effects on cannabis seizures in the United States, 2010-2023. — Fitzgerald ND, Palamar JJ, Cadet K, Rowan E, Bruzelius E, Martins SS (2026) · DOI 10.1016/j.drugpo.2026.105217 · ensaio clinico rct · reduz apreensões de cannabis em estados com RCL ~45% vs MCL-only · en

Relations between depression and cannabis use among college students in evolving state cannabis policy environments. — Bae H, Kerr DCR (2026) · DOI 10.1016/j.drugalcdep.2026.113127 · coorte · depressão foi um fator de risco mais fraco para uso de cannabis em ambientes mais legais · en

Medical cannabis legalization and the use of illicit drugs, alcohol, and tobacco. — Al Hallaj H, Barakat Z (2025) · DOI 10.1186/s42238-025-00324-5 · coorte · legalization associated with an average annual increase of 26.06 tons of MC sales · en

Changing Norms, Changing Risks: Adolescent Cannabis Use Surpasses Tobacco in the United States. — Constantin J, Jayawardhana J (2026) · DOI 10.1016/j.addbeh.2026.108731 · coorte · cannabis-only use aumentou de 3.8% em 2015 para 5.1% em 2023 · en

Cannabis surpasses tobacco among pregnant women: national trends and predictors of use in the U.S., 2015-2023. — Constantin J, Jayawardhana J (2026) · DOI 10.1016/j.addbeh.2026.108740 · coorte · cannabis-only use mais que dobrou e superou o uso de tabaco · en

Reglamento de la Ley General de Salud en materia de control sanitario para el uso medicinal de la Cannabis — Secretaría de Salud (México) (2021), Diario Oficial de la Federación (México) · documento de politica · Regulamento sanitário para uso medicinal · es

Ley 30681 — Uso medicinal y terapéutico del cannabis y sus derivados — Congreso de la República del Perú (2017), El Peruano (Peru) · documento de politica · Uso medicinal e terapêutico autorizado · es

Ley 1787 de 2016 — Uso médico y científico del cannabis — Congreso de Colombia (2016), Diario Oficial (Colombia) · documento de politica · Uso médico e científico regulamentado · es

Ley 27.350 — Investigación médica y científica del uso medicinal de la planta de cannabis — Congreso de la Nación Argentina (2017), Boletín Oficial (Argentina) · documento de politica · Uso medicinal e pesquisa autorizados · es

Ley N° 19.172 — Marihuana y sus derivados: control y regulación del Estado — Parlamento del Uruguay (2013), IMPO (Uruguay) · documento de politica · Regulação estatal de produção, distribuição e venda · es

Lei n.º 30/2000 — Descriminalização do consumo de estupefacientes — Assembleia da República (Portugal) (2000), Diário da República (Portugal) · documento de politica · Posse para uso pessoal deixa de ser crime · pt

Public attitudes and lifetime home cannabis cultivation - a survey after legalization in Germany. — Lehberger M, Kleih AK, Sparke K (2026) · DOI 10.1016/j.drugpo.2025.105121 · transversal · In 2024, Germany became the most populous European country to legalize home cannabis cultivation. This study provides the first empirical evidence on both public support for and engagement in home cultivation in this new regulatory context. Using survey data from a representative · en

Associations between modes of cannabis use and cannabis use disorder: Evidence from the 2022 to 2023 United States National Survey on Drug Use and Health. — Baral A, Dubois C, Kumar L, Devkota J, Vidot DC, Vandrey R et al. (2026) · DOI 10.1111/add.70474 · transversal · Background and aims With expanding cannabis legalization, normalization, and diversifying products and delivery methods in the United States (US), cannabis use disorder (CUD) prevalence is rising. Various modes of cannabis use may influence pharmacokinetics, usage patterns, and h · en

[Regulatory elements on marijuana, for the effective population health protection]. — Santos-Burgoa C (2017) · DOI 10.21149/8503 · revisao narrativa · When discussing the public health approach to the use of marijuana, the complexity of rigorous regulatory interventions for population protection is omitted. Using the experience of governments where these practices already exist, regulation is introduced as an essential public h · es

Cannabis Use Disorder in the Era of Legalization: Implications for Addiction Treatment Systems. — Bahji A (2026) · DOI 10.2147/sar.s581271 · revisao narrativa · Introduction Cannabis legalization has expanded rapidly across high-income jurisdictions, altering patterns of cannabis use, product potency, and commercial markets. Although surveillance systems increasingly quantify cannabis exposure, clinically meaningful harm is more difficul · en

Pediatric Trauma Trends Before and After Recreational Cannabis Legalization in Nevada: A Retrospective Repeated Cross-Sectional Study. — Serr J, Goel V, Sagaribay R, Batra K, Shah AP (2026) · DOI 10.3390/children13050681 · ensaio clinico · incidência de trauma pediátrico estável (21.6 vs. 21.4 por 100.000; IRR = 0.99) · en

Redefining Recovery: The Expanding Cannabis Landscape and Its Implications for the California Sober Approach in Addiction. — Dubois C, Baral A, Durrett R, Kim HS, Danielson EC, Goldstein RS et al. (2026) · DOI 10.1007/s11469-026-01660-0 · outro · An emerging approach called California Sober (CS) has gained attention for promoting abstinence of all intoxicating substances except cannabis and potentially, psychedelics. Cannabis legalization and the expansion of cannabis products have introduced new complexities in addiction · en

Police experiences with cannabis legalization and perceptions of broader drug policy reform. — Silberzahn BE, Schneider KE, Sisson LN, Winiker AK, Weiss M, Pozo BD et al. (2026) · DOI 10.1016/j.drugpo.2026.105356 · outro · Background Sustained attention to the harms and ineffectiveness of punitive drug law enforcement is prompting jurisdictions across the U.S. to explore safer supply and legalization of cannabis and other illicit substances. As reform debates intensify, understanding the experience · en

Early trends in outpatient addiction care for cannabis use disorder following cannabis legalization in Germany: Evidence from National Monitoring Data. — Riemerschmid C, Schwarzkopf L, Hoch E (2026) · DOI 10.1111/add.70539 · outro · declínio nas admissões relacionadas a CUD de 30.0 em 2023 para 25.6 em 2024 (RR=0.85) · en

Cannabis Consumption Before and After Partial Legalization in Germany: Early Trends, Consumption Patterns, and Motives. — Hoch E, Krowartz EM, Hollweck R, Möckl J, Olderbak S (2025) · DOI 10.3238/arztebl.m2025.0161 · outro · aumento na prevalência de uso de cannabis de 8.8% em 2021 para 9.8% em 2024, mas sem significância estatística · en

Harnessing machine learning and multivariate analysis to explore global trends in Cannabis sativa research. — De La Hoz-M J, Montes-Escobar K, Salas-Macias CA (2026) · DOI 10.1186/s42238-026-00397-w · outro · This study employs advanced data science techniques to explore global research trends in Cannabis sativa from 1974 to 2024. This research integrated bibliographic datasets from PubMed, Scopus, and Web of Science. By combining latent Dirichlet allocation (LDA) and HJ-Biplot method · en

Nonmedical cannabis legalization and adolescent inpatient cannabis use disorder, 2008-2020: A quasi-experimental analysis. — Azagba S, Roy B, Ebling T (2026) · DOI 10.1016/j.drugpo.2026.105222 · quasi experimental · não detectou associação estatisticamente significativa com CUD · en

Cannabis legalization and early adolescent expectancies: Findings from the adolescent brain cognitive development study. — Ricklefs C, Santos GM, Brindis CD, Baker FC, Nagata JM (2026) · DOI 10.1016/j.drugalcdep.2026.113138 · ensaio clinico · maior expectativa positiva em relação à cannabis em estados com legalização · en

Patterns and correlates of unlicensed cannabis cultivation in California (USA) following adult-use legalization. — Dillis C, Polson M (2026) · DOI 10.1016/j.drugpo.2026.105412 · outro · reduz cultivo não licenciado em até 660.06 m² por km² com fazendas licenciadas · en

Commentary: Methodological considerations in the interpretation of evidence on cannabis-based medicines for chronic neuropathic pain. — Briques W, Pereira DMR, Aguiar Junior AS (2026) · DOI 10.1186/s42238-026-00448-2 · revisao sistematica · Recent systematic reviews, including a Cochrane review, have concluded that the certainty of evidence supporting the use of cannabis-based medicines for chronic neuropathic pain remains low. While this overall conclusion is reasonable, its interpretation warrants careful scrutiny · en

Charting the therapeutic landscape: a comprehensive evidence map on medical cannabis for health outcomes. — Montagner P, de Salas Quiroga A, Ferreira AS, Duarte da Luz BM, Ruppelt BM, Schlechta Portella CF et al. (2024) · DOI 10.3389/fphar.2024.1494492 · revisao sistematica · 278 de 489 descrições de efeitos de tratamento foram relatadas como 'Positivos' ou 'Potencialmente Positivos' · en

Impact of CBD and hemp oil use on drug test results: a systematic review. — Ovat DY, Bezci E, Balıca K, Kırlı U, Akgur SA (2026) · DOI 10.1007/s00414-026-03790-5 · revisao sistematica · BACKGROUND: Hemp-derived products, especially CBD (cannabidiol) oil and hemp oil, have shown a notable increase of use in recent years. CBD oil is a compound derived from the cannabis plant, whilst hemp oil is a product derived from hemp seeds. Trans-Δ9-tetrahydrocannabinol (THC) · en

Electrophysiological modulation of pain‑related sodium channels by cannabinoids: a systematic review. — Castro SG, Silva SE, Brito JCM, Matavel A (2026) · DOI 10.1186/s42238-026-00436-6 · revisao sistematica · CBD inhibits sodium currents with IC₅₀ values in the low micromolar range (2–3.3 µM) · en

Acute Effects of Cannabis and THC Oils on Cardiovascular Hemodynamics and Muscle Electrical Activity in Healthy Individuals: A Controlled Clinical Crossover Trial Protocol. — Fagundes MLLC, Laurentino EKF, Soares BL, Otto-Yañez M, Nunes EA, Pedrosa MFF et al. (2025) · DOI 10.3390/jcm14217531 · ensaio clinico rct · Background/Objectives: Cannabis sativa (CS) exerts its effects through the endocannabinoid system. Although studies have shown limited evidence regarding the plant's therapeutic efficacy, little is known about the standardization of doses and their corresponding effects. This st · en

RDC nº 660/2022 — Autorização Sanitária de produtos de Cannabis — ANVISA (2022), Agência Nacional de Vigilância Sanitária · documento de politica · Atualiza e consolida a autorização de produtos medicinais · pt

RDC nº 327/2019 — Produtos de Cannabis para fins medicinais — ANVISA (2019), Agência Nacional de Vigilância Sanitária · documento de politica · Autorização sanitária de produtos de Cannabis medicinal · pt

[Therapeutic indications in lawsuits seeking medical Cannabis in Brazil: a cross-sectional study in light of scientific evidence]. — Pinto CDBS, Ferreira TJN, Oliveira CVDS, Esher Â, Hora MFVMPD, Osorio-de-Castro CGS (2026) · DOI 10.1590/0102-311xpt220525 · transversal · apenas cinco diagnósticos têm algum grau de suporte na literatura · pt

Impact of Medical Cannabis on the Quality of Life of Cancer Patients: A Critical Review. — Correa LG, Tucci AM (2026) · DOI 10.1177/27683605251377417 · revisao narrativa · pode melhorar a qualidade de vida em pacientes com câncer · en

Cannabidiol and ∆9-Tetrahydrocannabinol in Endometriosis: A Literature Review on Therapeutic Applications and Mechanisms. — Godoy JR, Castilhos JP, Caruso FB, Hentschke MR (2026) · DOI 10.5935/1518-0557.20250168 · revisao narrativa · Endometriosis is a chronic, inflammatory, and multifactorial disease characterized by the presence of endometrial tissue outside the uterine cavity, often associated with debilitating symptoms. It affects approximately 10% of women of reproductive age and is also related to infer · en

Pharmacological Insights into Cannabidiol for Wound Healing and Bone Regeneration. — Durão LPL, Cunha DM, Pereira MMA, de Avila ED, Maquera-Huacho PM (2026) · DOI 10.1021/acsomega.5c13259 · revisao narrativa · promove cicatrização de feridas e regeneração óssea · en

Exploring Cannabidiol's Role in Regenerative Medicine: Focus on Neural and Skeletal Tissues. — Buchaim RL, Dias LC, de Sousa FGCP, Morais SS, Jacintho AJ, Paulini MR et al. (2025) · DOI 10.3390/biomedicines13102490 · revisao narrativa · apoia regeneração neuronal e óssea · en

Bioactivity and Regenerative Potential of Cannabidiol in Human Dental Pulp Stem Cells: A Scoping Review of In Vitro Studies. — Guimarães LG, de Sousa WV, de Andrade Silva S, Velozo C, Lyra CVV, Rangel LS et al. (2026) · DOI 10.1155/tswj/6756387 · revisao narrativa · melhora a viabilidade, proliferação, migração e diferenciação das hDPSCs · en

Cannabidiol's Antioxidant Properties in Skin Care Products and Legislative Regulations. — Fafaliou M, Papadopoulos A, Pavlou P, Varvaresou A (2025) · DOI 10.3390/plants14223521 · revisao narrativa · exibe propriedades antioxidantes e anti-inflamatórias · en

[The history of the first attempt to produce marijuana-based medicines: Interview with Antônio José Alves]. — Castro Neto AG, Escobar JAC, Lira WL (2020) · DOI 10.1590/1413-81232020256.24612018 · qualitativo · The debate over marijuana regulation has gained strength in recent years, due to its therapeutic potential. Despite this, there is still a lot of prejudice related to the use of medical marijuana. In the mid-1990s, Lafepe proposed to produce a Cannabis sativa-based medicine. This · pt

Assessing patient perceptions of off-label cannabidiol use for insomnia through sentiment analysis. — Pereira GRC, de Brito Mantuan A, Dos Santos Oliveira JC, Fares GES, Dos Santos Santiago Sá VM, de Sousa VP et al. (2025) · DOI 10.1186/s42238-025-00306-7 · outro · Background Recent global policy shifts have greatly expanded access to and the market for medicinal cannabis, broadening its availability for therapeutic use. These changes have led to a notable increase in off-label prescriptions of cannabidiol (CBD) based products, particularly · en

On the human uses of Cannabis sativa: what do Brazilian Congressmen say about the subject? — Guimarães RP, Alves SMC, Delduque MC (2026) · DOI 10.1590/1413-81232026312.17732023 · outro · This article presents results of a research that analyzed the bills in progress in the House of Representatives and Federal Senate, from 2019 to 2022, in order to verify parliamentary intentions about the human use of Cannabis sativa. This was a qualitative, documentary-based res · pt

On activism and knowledge: the experience of cannabis associations in Brazil. — Rodrigues APLDS, Lopes IDS, Mourão VLA (2024) · DOI 10.1590/1413-81232024292.18462022 · outro · The emergence of civil associations in favor of cannabis began in the 2010s. Faced with the inertia of the State, these organizations have acted in the reception, support, information, training, and facilitation of access for patients and their families to the medicine produced f · pt

Correction: Cannabis-based extract for managing pain in dogs with osteoarthritis: efficacy and safety assessment. — Griebeler NM, Penayo Cremonese R, Correa YRF, Pereira PRM, Rial AF, Leite E et al. (2025) · DOI 10.3389/fphar.2025.1758996 · outro · [This corrects the article DOI: 10.3389/fphar.2025.1539704.]. · en

Cannabis use among motorcyclists in Brazil: prevalence and associated factors from a cross-sectional study in two cities. — Bombana HS, Greve JMD, Sinagawa DM, de Oliveira RA, Gonçalves Lopes L, Góes Endo L et al. (2026) · DOI 10.1080/15389588.2026.2681922 · ensaio clinico · 13.1% testaram positivo para pelo menos uma substância psicoativa, com THC detectado em 9.6% · en

Online promotional practices and apparent violations from licensed cannabis retail stores in Canada. — MacDonald-Spracklin R, Waqar A, Islam A, Fischer B, Crépault JF, Thompson K et al. (2026) · DOI 10.1016/j.drugpo.2026.105350 · outro · Background Canada legalized non-medical cannabis in 2018, with marketing and promotion regulated under the Cannabis Act. However, little is known about the promotional practices of licensed cannabis retailers. This study analyzed the online content of Canadian cannabis retailer w · en

Comparison of clinicopathologic findings and urine drug screen results in cannabis-positive and control dogs. — Pereira HCDS, Barbosa WMB, Venceslau MF, Guerra RR, Carvalho LRRA (2025) · DOI 10.3389/fvets.2025.1679400 · ensaio clinico · Introduction Cannabis intoxication is increasingly reported in small animal practice, often resulting from accidental ingestion of human products or unsupervised access to the plant. Although clinical signs are well documented, laboratory alterations remain poorly described. This · en

Cannabinoid Therapy for Refractory Trigeminal Neuropathic Pain: Quantification of Somatosensory Alterations (QualST) by 3D Stereophotogrammetry-Two Case Reports. — Mélo AM, Spadon-Brito LG, Hallak JC, do Nascimento GC, de Oliveira Melchior M, Regalo SCH et al. (2026) · DOI 10.1155/crid/7752444 · relato caso · reduz VAS de 9 a 4 e de 10 a 2 · en

Development and Validation of a Cannabinoid Quantification Method in Oil and Marijuana by UHPLC-MS. — de Almeida JVM, Conceição NS, Pereira AR, Lyrio MVV, Ortiz RS, Dos Santos NA et al. (2025) · DOI 10.1021/acsomega.5c07689 · outro · Cannabis sativa L. is an ancient species that has been cultivated over the years for various applications, including recreational and medicinal use. Nowadays, the demand for its products has grown significantly, leading to an increase in the search for medicinal oils and a rise i · en

Molecular Dynamics and Solvated Interaction Energy Prioritize Cannabidiol and Cannabinol as Variant-Spanning SARS-CoV-2 RBD-ACE2 Interface Blockers. — Kongtaworn N, Sinsulpsiri S, Hanpaibool C, Maitarad P, Mahalapbutr P, Rungrotmongkol T (2026) · DOI 10.3390/molecules31081253 · outro · CBD e CBN atuam como bloqueadores da interface RBD-ACE2 · en

Evaluation of cannabidiol-based products in Brazil: how can current regulations influence their labeling quality? — Gallassi AD, de Oliveira AWC, Mendes NS, Filev R, Nakano EY (2025) · DOI 10.1186/s42238-025-00270-2 · ensaio clinico · N327 produtos mostraram melhor qualidade de rotulagem que N660 · en

Cannabidiol-rich extract suppresses the activation of proinflammatory genes IL-1β and IL-6 in equine mesenchymal stem cells stimulated with lipopolysaccharide. — da Costa Kamura B, de Oliveira Ferreira LV, Chimenes ND, de Oliveira JPM, Rodriguez-Sanchez DN, de Carvalho M et al. (2026) · DOI 10.1007/s11259-026-11105-7 · outro · reduz expressão de IL-1β e IL-6 · en

Regulatory sandboxes as an innovative platform for testing Cannabis edibles in Germany. — Al Hallaj H, Barakat Z (2025) · DOI 10.1186/s42238-025-00263-1 · outro · This paper explores the effectiveness of using Regulatory Sandboxes (RS) to legalize THC edibles in Germany. While RSs have been extensively studied in sectors like Fintech and Healthtech, their application in introducing novel cannabis products or services remains underexplored. · en

Cannabidiol in Sports: A Brazilian Perspective. — Nery T, Nv Andrade JW, Rocha JF, Pinto de Araújo AP, Aguiar AS Jr (2025) · DOI 10.1021/acsptsci.5c00580 · outro · apoia melhor recuperação e alívio da ansiedade · en

Application of liquid chromatography with tandem mass spectrometry detection for the determination of twelve cannabinoids in a feasibility study to produce a pharmacologically active ingredient from seized Cannabis sativa L. (marijuana). — Ortiz RS, Pereira D, de Cassia Mariotti K, de Oliveira Camargo FA (2026) · DOI 10.1016/j.jpba.2026.117665 · outro · The increasing demand for Cannabis-derived medicinal products in Brazil, coupled with the implementation of RDC 1013/2026 (ANVISA), necessitates robust analytical frameworks for pharmacological and forensic purposes. This study is part of the "Paracelsus Project," a feasibility s · en

Challenges for the new regulatory framework of medical Cannabis in Brazil. — Osorio-de-Castro CGS, Esher Â, Oliveira CVDS, Santos-Pinto CDB (2026) · DOI 10.1590/1413-81232026315.04732026 · outro · Until recently, the regulation of medical Cannabis (MC) in Brazil was based on norms that did not comprehensively address its sanitary and regulatory dimensions. In February 2026, the Brazilian Health Regulatory Agency (Anvisa) issued a new set of regulations - Collegiate Board R · pt

Oromucosal Administration of a Cannabidiol-Enriched Cannabis sp. Extract for 2 Weeks Moderately Reduces Cold Hyperalgesia in Rats With Neuropathic Pain. — Campos RMP, Conde L, Aguiar A, Sampaio L, de Melo Reis RA, Pimentel-Coelho PM (2026) · DOI 10.1002/ejp.70307 · ensaio clinico · modestamente reduz hipersensibilidade ao frio · en

Effectiveness and Safety of Cannabis-Based Products for Refractory Epilepsy From Real-World Evidence. — Lula MD, Portela R, Mota DM, Álvares-Teodoro J, Silva ML, Guerra-Júnior AA et al. (2026) · DOI 10.1016/j.clinthera.2026.06.006 · outro · 70.3% relataram redução ≥50% na frequência de crises · en

Effectiveness of THC-containing cannabis for inflammatory bowel disease: a systematic review. — Jugl S, Perez-Vilar S, Galati S, Sandhu SK, Chen HK, Chang SH et al. (2026) · DOI 10.1186/s42238-026-00456-2 · revisao sistematica · melhora em sintomas como inchaço e apetite · en

Cannabidiol in Periodontal Therapy-Is There Hope or Just a Bias? A Systematic Review. — Ștefănescu R, Tero-Vescan A, Vari CE, Sita D, Ősz BE (2026) · DOI 10.3390/biomedicines14051163 · revisao sistematica · reduz perda óssea alveolar e atividade de osteoclastos · en

CBD-Containing Hemp Extracts and Isolated CBD for Acne: A Systematic Review of Anti-Inflammatory Mechanisms, Clinical Signals and Sustainability. — Komane B, Kaye T (2026) · DOI 10.3390/molecules31122017 · revisao sistematica · reduz contagem de lesões e eritema · en

The effects of oral cannabidiol supplementation on blood pressure in adults: a systematic review of randomised controlled trials. — Roberts A, Fountzopoulos S, Desai T (2026) · DOI 10.1186/s42238-026-00463-3 · revisao sistematica · reduz pressão arterial sistólica de forma significativa em comparação ao placebo · en

[Topical Use of Cannabis in Inflammatory Diseases in patients of the IPS Salud Social in Barranquilla, Colombia]. — Calderón J, Parga-Lozano C, Santodomingo N, Gutiérrez P, Lambraño F (2024) · DOI 10.29262/ram.v71i1.1351 · coorte · todos os pacientes mostraram alívio da dor após dois meses de acompanhamento · es

Cannabis use in Patients With Inflammatory Bowel Disease is Associated With Longer Endoscopic Duration and Endoscopic Inflammation. — Loeb L, Hochwald A, Picco MF, Chan JL, Hashash JG, Chadha R et al. (2025) · DOI 10.1093/crocol/otaf034 · caso controle · maior duração endoscópica em usuários de cannabis · en

[Association of cigarette consumption, nicotine derivatives and cannabis with periodontal disease. A review]. — Valenzuela-Torres OY, Zapata-Sifuentes MA, Quispe-Salcedo A (2025) · DOI 10.21142/2523-2754-1303-2025-255 · revisao narrativa · associação entre cannabis e doença periodontal · es

Cannabichromene (CBC): a comprehensive review of biosynthesis, pharmacology, therapeutic potential, and translational perspectives. — Elbouzidi A, Baraich A, Haddou M, El Hachlafi N, Aqlan F, Al-Farga A et al. (2026) · DOI 10.1186/s42238-026-00454-4 · revisao narrativa · Cannabis sativa L. produces a chemically diverse array of over 150 phytocannabinoids, of which cannabichromene (CBC) represents the fourth most abundant constituent in many chemovars, yet remains profoundly underexplored relative to its structural congeners delta-9-tetrahydrocann · en

Cannabidiol in Dietary Supplements: Characteristics, Routes of Administration, Bioavailability, and Research Challenges. — Talar-Śpionek A, Juszczuk-Kubiak E, Roszko M (2026) · DOI 10.3390/molecules31132385 · revisao narrativa · Cannabidiol (CBD) has gained increasing attention as an ingredient in dietary supplements and functional foods due to its potential health-promoting properties. As a major non-psychoactive phytocannabinoid derived from Cannabis sativa L., CBD has been associated with anti-inflamm · en

Cannabidiol and skeletal muscle insulin resistance: translational implications for exercise and rehabilitation medicine. — Todorova G, Gesheva T, Mihaylova A (2026) · DOI 10.4081/ejtm.2026.15541 · revisao narrativa · Insulin Resistance (IR) is a central pathophysiological mechanism underlying obesity, type 2 diabetes mellitus, metabolic syndrome, and metabolic dysfunction-associated steatotic liver disease, with significant implications for skeletal muscle function, exercise capacity, and reh · en

The dual roles of natural cannabidiol in combating oxidative stress and inflammation: A potential intestinal guardian. — Lv B, He J, Zhan S, Jin K, Lei X, Cheng X et al. (2026) · DOI 10.1016/j.redox.2026.104051 · revisao narrativa · promove proteção intestinal através de efeitos antioxidantes e anti-inflamatórios · en

Cannabidiol (CBD) and Colorectal Tumorigenesis: Potential Dual Modulatory Roles via the Serotonergic Pathway. — Liu Z (2025) · DOI 10.3390/curroncol32070375 · revisao narrativa · The 2018 Farm Bill legalized hemp-derived cannabidiol (CBD) products containing less than 0.3% tetrahydrocannabinol (THC) in the United States. This legislative shift catalyzed both public and scientific interest in CBD's potential health benefits. However, the rapid expansion of · en

Therapeutic Potential of Cannabinoid Receptors Type 1 and 2-Novel Insights for Enhancing the Chance of Clinical Success. — Grether U (2025) · DOI 10.3390/ph18091324 · revisao narrativa · This Special Issue of Pharmaceuticals presents eight original articles and three reviews, underscoring the ongoing robust interest in research on cannabinoid receptor type 1 (CB 1 R) and type 2 (CB 2 R) more than 30 years after their discovery [...]. · en

Inflammatory bowel disease patients believe cannabis and cannabidiol oil relieve symptoms. — Lala A, Rodriguez-Palacios A, Cominelli F, Basson AR (2025) · DOI 10.20935/acadmed7773 · outro · mais de 50% dos usuários de cannabis relataram alívio dos sintomas · en

Entourage effects of nonpsychotropic cannabinoids on visceral sensitivity in experimental colitis. — Svendsen K, Bradaia A, Gandini MA, Defaye M, Matisz C, Abdullah NS et al. (2025) · DOI 10.1016/j.jpet.2025.103389 · ensaio clinico · reduz hipersensibilidade visceral com npCBs em doses subterapêuticas · en

Cannabidiol Oil for Feline Gingivostomatitis Complex: A Case Report — Mariga C, Silveira Alves T, dos Santos Ferreira CE, Batista de Sousa M, Wunder Della Flora BG, Dall'Asta BA et al. (2026), Preprints.org · DOI 10.20944/preprints202605.0127.v1 · relato caso · melhora clínica significativa em gato com gingivostomatite · en

Exploration of Possible Effects of Cannabis sativa Seed Oil Applied in Different Doses in Ulcerative Colitis Model — Kavak İ, Şirinyıldız F (2026), Research Square · DOI 10.21203/rs.3.rs-8751706/v1 · pre clinico · Cannabis sativa seed oil effectively ameliorates ulcerative colitis, 3 ml/kg dose shows superior efficacy · en

Monocyte-Derived Macrophages Exhibit Differences in Inflammatory Gene Expression Based on Sex and Cannabis Use Pattern of the Donor: A Post-Hoc Analysis — Avalos B, Searson EG, Walter KC, Mastropietro KF, Ford MK, Funk G et al. (2026), Research Square · DOI 10.21203/rs.3.rs-10658020/v1 · outro · MDMs de mulheres têm 53% mais IL18 e 57% mais TREM2 que homens · en

Delta-9-Tetrahydrocannabinol alleviates doxorubicin-induced weight loss but does not affect dextran sodium sulphate-induced colitis. — Johansen MW, Andersen MCE, Nissen T, Nexoe AB, Ünsal S, Madsen GI et al. (2026) · DOI 10.1186/s42238-026-00386-z · ensaio clinico · reduz perda de peso induzida por doxorubicina · en

Inflammasome formation and interleukin-1β secretion are reduced in peripheral blood monocytes from HIV+ cannabis users. — Finn BM, Sermet S, Crawford RB, Gulick P, Kaminski NE (2026) · DOI 10.1016/j.jpet.2026.104952 · ensaio clinico · reduz secreção de IL-1β em monócitos de HIV+ · en

Orally Administered CBD/CBG Hemp Extract Reduces Severity of Ulcerative Colitis and Pain in a Murine Model. — Godbole SS, Sun D, Coates MD, Himmelberger VJ, Roopchand DE, Raup-Konsavage WM (2025) · DOI 10.3390/jcm14176095 · pre clinico · reduz dano ao epitélio colônico e dor · en

Cannabidiol attenuates atherosclerosis in male ApoE-/- mice with sex-dependent lipidomic and proteomic remodeling. — Cahova M, Ableitner E, Bechyňská K, Kučková Š, Viktorova J, Mikušová V et al. (2026) · DOI 10.1016/j.jlr.2026.101120 · pre clinico · reduz área de placa aórtica em machos · en

Effect of vaporized Cannabidiol (CBD) on neuropathic pain and its potential implication for development of chronic lung inflammation in rats. — Dutta P, Cornejo IJN, Muthaiah VPK, Aalinkeel R, Ignatowski TA, Mahajan SD (2026) · DOI 10.1186/s42238-026-00459-z · ensaio clinico · alivia dor neuropática significativamente · en

A novel enema formulation containing cannabidiol and sodium propionate for ulcerative colitis: preclinical assessment in a murine model. — Naftali T, Prutchi Sagiv S (2026) · DOI 10.1186/s42238-026-00400-4 · pre clinico · aumento de comprimento do cólon em 34.7% vs controle salino · en

Cannabidiol-Dominant &lt;i&gt;Cannabis sativa&lt;/i&gt; L. Inflorescence Extract Ameliorates Atopic Dermatitis by Modulating NLRP3 Inflammasome and JAK1/STAT6 Signaling in DNCB-Induced Mice. — Han JY, Lim DW, Kwon O, Lee YJ, Choi M, Lee B et al. (2026) · DOI 10.3390/nu18142382 · ensaio clinico · reduz infiltração de mastócitos e níveis de IgE no soro · en

Combination of CBD with minor cannabinoid CBDV suppresses CXCR4 via CB2 receptor and alleviates colitis in mice. — Gelfand A, Besser E, Procaccia S, Cohen J, Steinberg M, Kleifeld O et al. (2025) · DOI 10.1016/j.biopha.2025.118768 · ensaio clinico · ameliora a gravidade da doença em modelo murino de colite · en

Special Issue: Therapeutic Potential for Cannabis and Cannabinoids 2.0. — Raup-Konsavage WM (2025) · DOI 10.3390/biomedicines13123056 · outro · While Cannabis sativa L [...]. · en

Chronic oral cannabidiol delays seizure onset and reduces seizure burden in a mouse model of CLN2 disease. — Dearborn JT, Takahashi K, Rensing NR, Wong M, Cooper JD, Sands MS (2026) · DOI 10.1371/journal.pone.0337880 · ensaio clinico · atraso ou eliminação total das crises epilépticas em camundongos com CLN2 · en

Δ&lt;sup&gt;9&lt;/sup&gt;-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) Diminish CD16&lt;sup&gt;+&lt;/sup&gt; Monocyte-Induced Astrocyte Inflammation, while THC Uniquely Inhibits Monocyte Chemotaxis Independent of HIV Status. — Sermet S, Crawford RB, Gulick P, Kaminski NE (2026) · DOI 10.1007/s11481-026-10300-2 · ensaio clinico · THC suppressa migração de monócitos em HIV+ · en

Ubiquitin-proteasome-dependent degradation of HIF-1α by cannabidiol disrupts pro-angiogenic synoviocyte-endothelial crosstalk in rheumatoid arthritis. — Chen J, Li G, Zhao F, Zhang Y, Mu Q, Zhang J et al. (2026) · DOI 10.1016/j.phymed.2026.158661 · ensaio clinico · alivia inflamação articular e angiogênese sinovial em ratos AIA · en

A cannabidiol-sensitive region involved in the allosteric modulation of the α7 nicotinic receptor. — Chrestia JF, Viscarra F, Biggin PC, Bermudez I, Bouzat C (2026) · DOI 10.1073/pnas.2535398123 · outro · inibe atividade do canal α7 · en

Amorphous Solid Dispersion Hydrogel Platform for Transdermal Delivery of Cannabidiol with Therapeutic Potential for Dermatitis. — Chuluunbaatar BA, Jeong Y, Ok J, Song Y, Son JW, Kang JH et al. (2026) · DOI 10.3390/pharmaceutics18060666 · outro · aumenta fechamento de feridas e reduz citocinas inflamatórias · en

Detection and identification of small-molecule cracking products formed on pyrolysis of cannabidiol part 1: C&lt;sub&gt;3&lt;/sub&gt; - C&lt;sub&gt;10&lt;/sub&gt; compounds. — Nichols NA, Dane AJ, Musah RA (2026) · DOI 10.1186/s42238-026-00442-8 · outro · Background Cannabidiol (CBD) is one of over 100 naturally occurring phytocannabinoids in Cannabis. While extensive research has evaluated the effects that CBD and other phytocannabinoids have on consumers, less attention has been directed towards studying the health impacts of th · en

Targeting a Granulocytic–Microbiome Axis Reverses Glioblastoma Progression via Intranasal Cannabidiol — Wang LP, Bhandari B, Naeini SE, Earwood JT, Marshall B, Wakade C et al. (2026), bioRxiv · DOI 10.64898/2026.07.12.737962 · outro · driving dramatic tumor regression · en

Cannabis sativa chemotypes modulate TLR-associated innate immune gene expression and reduce BoAHV-1 replication in bovine cells. — Burucúa MM, Junco M, Quintana S, Plá N, Pérez SE, Colman SL et al. (2026) · DOI 10.1016/j.molimm.2026.08.002 · ensaio clinico · reduz títulos virais em células MDBK infectadas por BoAHV-1 · en

The Therapeutic Potential of Cannabidiol in the Management of Temporomandibular Disorders and Orofacial Pain. — Walczyńska-Dragon K, Kurek-Górecka A, Fiegler-Rudol J, Nitecka-Buchta A, Baron S (2025) · DOI 10.3390/pharmaceutics17030328 · revisao sistematica · alivia dor relacionada ao TMD com efeitos analgésicos e anti-inflamatórios · en

The Effects of an Acute Dose of Cannabidiol on Health and Two-Mile Time Trial Performance-A Pilot Study. — Bell ER, Elias B, Gutierrez SM, Stewart LK (2025) · DOI 10.3390/nu18010029 · ensaio clinico rct · aumenta sentimentos de calma ~21% e relaxamento ~22% vs placebo · en

Vaporized cannabis versus placebo for acute migraine: A randomized, double-blind, placebo-controlled crossover trial. — Schuster NM, Wallace MS, Marcotte TD, Buse DC, Lee E, Liu L et al. (2026) · DOI 10.1111/head.70025 · ensaio clinico rct · THC + CBD foi superior a placebo para alívio da dor (67.2% vs. 46.6%) · en

Influence of Cannabidiol Use on Visual Function and Optical Quality: A Randomized Controlled Trial. — Martino F, Ortiz-Peregrina S, Casares-López M, Granados-Delgado P, Castro-Torres JJ, Anera RG (2025) · DOI 10.1167/tvst.14.10.10 · ensaio clinico rct · não afetou a função visual · en

Potency-related effects of smoked cannabis on simulated driving performance: a randomized, controlled crossover trial. — Brands B, Zaweel A, Wright M, Di Ciano P, Wickens CM, Matheson J et al. (2026) · DOI 10.1038/s41598-026-43045-2 · ensaio clinico rct · aumento da velocidade máxima sob potências média e alta vs placebo · en

Low-dose cannabidiol increases plasma concentrations of amitriptyline: A clinical drug-drug interaction study. — Gorbenko AA, Post TE, Strugala PK, Klaassen ES, Klumpers LE, de Visser SJ et al. (2026) · DOI 10.1002/bcp.70415 · ensaio clinico rct · aumenta AUC de amitriptilina em 13% vs controle · en

Impact of Cannabis Edibles Combined With Alcohol on Driving, Field Sobriety Performance, and Subjective Effects: A Within-Participant Crossover Trial. — Zamarripa CA, Lin S, Klausner M, Rastogi K, Roche DJO, Novak M et al. (2026) · DOI 10.1001/jamanetworkopen.2026.9842 · ensaio clinico rct · todos os grupos ativos, exceto 10 mg THC, impactaram negativamente o desempenho de direção em comparação com placebo · en

Vaporized Cannabis versus Placebo for Acute Migraine: A Randomized Controlled Trial — Schuster NM, Wallace MS, Marcotte TD, Buse DC, Lee E, Liu L et al. (2024), medRxiv · DOI 10.1101/2024.02.16.24302843 · ensaio clinico rct · THC+CBD superior a placebo para alívio da dor ~67.2% vs 46.6% · en

Enhancing cannabinoid bioavailability: a crossover study comparing a novel self-nanoemulsifying drug delivery system and a commercial oil-based formulation. — Hermush V, Mizrahi N, Brodezky T, Ezra R (2025) · DOI 10.1186/s42238-025-00294-8 · ensaio clinico rct · aumenta a biodisponibilidade de canabinoides com Cmax superior e início de ação mais rápido · en

UK Medical Cannabis Registry: A Clinical Outcomes Analysis for Migraine. — Hooper L, Erridge S, Clarke E, McLachlan K, Coomber R, Iqbal A et al. (2026) · DOI 10.1002/brb3.71323 · caso controle · melhora na qualidade de vida relacionada à saúde até 2 anos · en

Over the counter CBD products in Germany: an exploratory survey about consumption patterns and health related effects. — Weissgerber A, Hermanns-Clausen M, Lamy E (2025) · DOI 10.3389/fphar.2025.1571025 · transversal · 89% relataram efeito positivo na saúde · en

Cross-sectional comparison of cannabis use in adults with neuropathic versus non-neuropathic pain. — Laroya CJP, Smith CL, Bindler RJ, McDonell MG, Lewis J, Wilson M (2025) · DOI 10.3389/fpain.2025.1677391 · transversal · uso de cannabis mais frequente em neuropatia (b=5.96, p=0.02) · en

Cannabinoid hyperemesis syndrome: genetic susceptibility to toxic exposure. — Russo EB, Whiteley VL (2024) · DOI 10.3389/ftox.2024.1465728 · revisao narrativa · Cannabinoid hyperemesis syndrome presents as a complex of symptoms and signs encompassing nausea, vomiting, abdominal pain, and hot water bathing behavior, most typically in a heavy cannabis user. Its presentation is frequently associated with hypothalamic-pituitary-adrenal axis · en

Treatment of Migraine With Phytocannabinoids, the Involvement of Endocannabinoids in Migraine, and Potential Mechanisms of Action. — Biringer RG (2025) · DOI 10.1155/prm/7181066 · revisao narrativa · The American Migraine Foundation estimates that over 39 million Americans and over 1 billion people worldwide suffer from some form of migraine. Treatment of migraine generally falls into two categories: treatment of attacks once they have begun, and prophylactic prevention, incl · en

Should CBD be used for migraine? — Luu B, Goldin P, Rice E (2025) · DOI 10.1097/01.jaa.0000000000000234 · revisao narrativa · Abstract In the US, approximately 40 million people, or 12% of the nation's population overall, suffer from migraine. Globally, the prevalence of migraine is estimated at 1.1 billion cases; the condition ranks as the second leading cause of disability-adjusted life years behind c · en

Part 2: Drug Interactions Involving Cannabis Products in Persons Aged 18 and Over: A Summary of Published Case Reports and Analysis of the FDA Adverse Event Reporting System. — Chapin MR, Kane-Gill SL, Li X, Abanyie K, Taneja SB, Egbert S et al. (2025) · DOI 10.1002/prp2.70047 · revisao narrativa · maior proporção de resultados graves com cannabis e substâncias controladas · en

Overlapping pathways of migraine and the endocannabinoid system: Potential therapeutic targets. — Della Pietra A, Russo AF (2026) · DOI 10.1016/j.neurot.2026.e00833 · revisao narrativa · Migraine is a disabling neurovascular disorder with limited therapeutic options, especially for patients unresponsive to current treatments targeting calcitonin gene-related peptide (CGRP) signaling. The endocannabinoid system (ECS) has emerged as a promising alternative for migr · en

Endocannabinoid Modulation in Headache: Mechanisms, Models, and Translational Therapies. — Wen J, Zhang Y (2026) · DOI 10.3390/cells15040331 · revisao narrativa · modulação do sistema endocanabinoide mostra potencial terapêutico em desordens de dor de cabeça · en

Recreational drugs repurposed for medicinal use-cannabis. — Armour M, Sinclair J, Adler H (2025) · DOI 10.1017/s109285292500032x · revisao narrativa · Cannabis has a long history as a medicine and was a part of medical practice until the late 19th century. The discovery of cannabidiol (CBD) and ∆9-tetrahydrocannabinol (THC) in the mid-20th century, and then the various components of the endocannabinoid system (ECS) over the fol · en

Interplay between cannabinoids and the neuroimmune system in migraine. — Zorrilla E, Della Pietra A, Russo AF (2024) · DOI 10.1186/s10194-024-01883-3 · revisao narrativa · reduz degranulação de mastócitos meníngeos · en

Cannabinoid Hyperemesis Syndrome in Adolescents: A Narrative Review. — Pietrantoni C, Margiotta G, Marano G, Mazza M, Proli F, Stella G et al. (2025) · DOI 10.3390/pediatric17040075 · revisao narrativa · Cannabinoid hyperemesis syndrome (CHS) is characterized by a pattern of cyclic vomiting and abdominal pain despite an absence of an organic cause, occurring in regular cannabis users. This syndrome was first described in 2004. Initially considered rare, with the increased use and · en

The Pharmacology of Cannabinoids in Chronic Pain. — Cortez-Resendiz A, Leiter TJ, Riela SM, Graziane NM, Raup-Konsavage WM, Vrana KE (2025) · DOI 10.1159/000543813 · revisao narrativa · cannabis e canabinoides têm efeito analgésico · en

Trends in cannabis adverse reaction reports: A descriptive analysis of spontaneous reporting data submitted to the Canada Vigilance Program since legalization and regulation of cannabis for non-medical purposes in Canada. — Plebon-Huff S, Aziz N, Cavar M, Hassan S, Aoun M, Perwaiz S et al. (2025) · DOI 10.1186/s42238-025-00310-x · outro · Background The cannabis control framework implemented by Canada in October 2018 established a robust post-market surveillance system for cannabis products, adopting tools and practices from the existing pharmacovigilance system for pharmaceuticals and health products. The cannabi · en

Edible cannabis use on simulated driving performance. — Won NY, Bird S, Wrobel J, Brown T, Brooks-Russell A (2025) · DOI 10.1080/15389588.2025.2574271 · ensaio clinico · ocasionais mostraram maior comprometimento que diários · en

The acute and chronic pharmacokinetics and pharmacodynamics of oral cannabidiol with and without low doses of delta-9-tetrahydrocannabinol. — Wolinsky D, Zamarripa CA, Spindle TR, Klausner M, Cone EJ, Winecker RE et al. (2026) · DOI 10.1093/jat/bkaf075 · ensaio clinico · Hemp products [cannabis with ≤0.3% Δ9-tetrahydrocannabinol (Δ9-THC)] are federally legal, but few controlled experiments have explored drug test results, pharmacokinetics, or pharmacodynamics. Healthy adults (n = 60) self-administered 1.5 mL medium-chain triglyceride (MCT) oil co · en

Characterizing Cannabis Use and Perceived Benefit in a Tertiary Headache Center Patient Sample. — Starkey B, Pearlson GD, Bond D, Glaser C, Bhargava A, Grosberg BM et al. (2024) · DOI 10.1212/cpj.0000000000200285 · outro · melhora intensidade ~78.1%, duração ~73.4%, frequência ~62.4% dos episódios de dor de cabeça · en

Full-spectrum cannabis extracts for women with chronic pain syndromes: a real-life retrospective report of multi-symptomatic benefits after treatment with individually tailored dosage schemes. — Soares Silva PM, Medeiros W, Nogueira Borges C, Brasil-Neto JP, Lessa W Jr, Ferreira de Oliveira E Silva R et al. (2025) · DOI 10.3389/fphar.2025.1538518 · outro · todos relataram algum nível de alívio da dor · en

Efficacy of different cannabinoid compounds on migraine-like responses in female rats. — da Luz FMR, Kaup AO, Baggio DF, Costa FHR, Chichorro JG (2025) · DOI 10.1177/03331024251386794 · ensaio clinico · reduz periorbital mechanical allodynia e fotosensibilidade em modelos de enxaqueca · en

Combined effects of cannabidiol and Δ9-tetrahydrocannabinol alleviate migraine-like symptoms in mice. — Zorrilla E, Krivoshein G, Kuburas A, Schenke M, Piña CL, van Heiningen SH et al. (2025) · DOI 10.1177/03331024251314487 · ensaio clinico · mitiga aversão à luz em camundongos · en

Clinical Study to Evaluate Drug Interactions of Cannabidiol with Citalopram and Morphine in Healthy Adults. — Salcedo P, Volpe DA, Chaturbedi A, Shah A, Krishna A, Hyland PL et al. (2026) · DOI 10.1002/cpt.70219 · ensaio clinico · aumenta AUC de citalopram em ~43% vs sem CBD · en

Cannabinoids rescue migraine symptoms caused by central CGRP administration in mice. — Zorrilla E, Duong TL, Piña CL, Russo AF (2025) · DOI 10.1177/03331024251392103 · ensaio clinico · alivia aversão à luz e sintomas de dor induzidos por CGRP · en

Cannabis tolerance reduces symptom relief. — Stith SS, Li X, Brockelman F, Keeling K, Hall B, Vigil JM (2025) · DOI 10.3389/fphar.2025.1496232 · ensaio clinico · 0.5% diminuição na eficácia do alívio dos sintomas por sessão · en

Cannabinoids in peripheral neuropathic pain: Resolving mechanistic mismatch through CB&lt;sub&gt;2&lt;/sub&gt;-oriented phenotype stratification. — Bagher AM (2026) · DOI 10.1016/j.ejphar.2026.179130 · meta analise · modesto e heterogêneo benefício analgésico · en

Cannabidiol as a treatment for cocaine use disorder: a scoping review. — Dos Santos LC, da Cunha VB, Ribeiro JM, Torres LHL, Garcia RCT (2026) · DOI 10.1007/s00210-026-05037-x · revisao sistematica · não demonstra eficácia significativa sobre placebo · en

Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia — Leweke FM et al. (2012), Translational Psychiatry · DOI 10.1038/tp.2012.15 · ensaio clinico rct · Melhora de sintomas psicóticos vs amisulprida, melhor tolerância · en

Adjunctive Cannabidiol in Inpatient Buprenorphine Treatment for Opioid Use Disorder: A Pilot Randomized Trial. — London ED, Dean AC, De La Garza R 2nd, Lachoff H, Mooney LJ, Torrington M et al. (2025) · DOI 10.1097/adm.0000000000001640 · ensaio clinico rct · sem vantagem clara sobre placebo · en

Efficacy and safety of cannabidiol (CBD) on reducing pain and functional impairment associated with exercise-induced muscle injury: a randomized placebo-controlled feasibility trial. — Stauffer JW, Crow JA, Bishop MD, Cook RL, Borsa PA (2026) · DOI 10.1186/s42238-026-00431-x · ensaio clinico rct · BACKGROUND: Exercise and sports-related musculoskeletal injuries often result in pain, and the recovery process can be prolonged and challenging. Many physically-active Americans have begun using cannabidiol (CBD) for pain relief and improved recovery time, and CBD is of particul · en

Comparative Pharmacokinetics and Safety of Cannabidiol in a Powder Formulation, CBtru&lt;sup&gt;®&lt;/sup&gt;, vs an Oil-Based Formulation, Epidyolex&lt;sup&gt;®&lt;/sup&gt;, Under Fasted and Fed Conditions in Healthy Participants: A Randomized Open-Label Cross-Over Phase I Study. — Bendik I, Beck M, Manderna A, Roos FF, Wang J, McCarthy D et al. (2026) · DOI 10.1007/s40263-026-01280-1 · ensaio clinico rct · CBtru ® trended to higher CBD exposure vs Epidyolex ® · en

Safety of Co-Administered Cannabidiol (CBD) and alcohol: a Phase I study. — Wolinsky D, Blaine S, Strickland JC, Peters EN, Harrison A, Weerts EM et al. (2026) · DOI 10.1186/s42238-026-00457-1 · ensaio clinico rct · Background This Phase I randomized controlled trial aimed to assess the safety and tolerability of cannabidiol (CBD) and alcohol co-administration among moderate alcohol consumers in acute laboratory and chronic outpatient settings. Methods Healthy adults ages 21-65 with moderate · en

Safety and Tolerability of Low-Dose Full-Spectrum Cannabidiol in Long-Term Virally Suppressed Adults with HIV: A Randomized Double-Blind Placebo-Controlled Trial — Couton C, Wanneveich M, De Dieuleveult B, Robin C, Ayena K, Harry A et al. (2026), medRxiv · DOI 10.64898/2026.03.21.26348972 · ensaio clinico rct · reduz total bilirubin vs placebo (p=0.046) · en

Safety and Tolerability of Low-Dose Full-Spectrum Cannabidiol in Long-Term Virally Suppressed Adults with HIV: A Randomized Double-Blind Placebo-Controlled Trial. — Couton C, Wanneveich M, De Dieuleveult B, Robin C, Ayena K, Harry A et al. (2026) · DOI 10.1177/25785125261439014 · ensaio clinico rct · reduz total bilirubin vs placebo (p = 0.046) · en

Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer (and elderly cohort) — Bar-Lev Schleider L et al. (2018), European Journal of Internal Medicine · DOI 10.1016/j.ejim.2018.01.019 · coorte · Melhora de dor/qualidade de vida; efeitos adversos leves · en

CARE - A Retrospective, Dual-Cohort, 24-Week Real-World Study from the German Pain e-Registry on the Effectiveness and Safety of CBD-Dominant Oral Cannabis Extracts versus THC/Dronabinol in Older Patients with Chronic Pain. — Überall MA, Müller-Schwefe PCG, Küster MA, Müller-Schwefe GHH (2026) · DOI 10.2147/jpr.s551457 · coorte · CBD-dominant extracts associados a melhores resultados multidimensionais e melhor tolerabilidade que THC/DRO · en

Adjunctive cannabidiol in intractable pediatric epilepsy: A retrospective study on tolerability, efficacy, and safety across genetic and nongenetic etiologies. — Shim Y, Yang DH, Byeon JH, Eun BL (2026) · DOI 10.1097/md.0000000000047425 · coorte · 79.3% alcançou uma redução ≥50% na frequência de crises · en

Real-world efficacy and safety of cannabidiol in developmental and epileptic encephalopathies. — Perulli M, Bianchetti M, Pantalone G, Quintiliani M, Gambardella ML, Picilli M et al. (2025) · DOI 10.1002/epi4.70149 · coorte · 69% alcançou redução de crises ≥50% · en

Cannabidiol (CBD) Critical Review Report — WHO Expert Committee on Drug Dependence (ECDD) (2018), Organização Mundial da Saúde · documento de politica · Sem potencial de abuso; bom perfil de segurança · en

[Psychiatric aspects of commercially available products containing cannabidiol]. — Gahr M (2026) · DOI 10.1007/s00115-026-01998-9 · revisao narrativa · Background Cannabidiol (CBD) has gained sustained public, medical, and scientific attention in recent years. The prevalence of use of commercially available products containing CBD (CPC) is correspondingly high. Objectives Overview of the benefits and risks of CPC, taking into ac · de

Cannabinoids for Neuropathic Pain: A Pharmacological Review of Mechanisms, Clinical Translation, and Future Directions. — Tyagi S, Shrivastava S, Kumar V, Kumar S, Gulia S, Singh U et al. (2026) · DOI 10.2174/0118715249440429260616140926 · revisao narrativa · Introduction Neuropathic pain (NP) continues to be a significant clinical issue because the existing treatment modalities have very low efficacy and tolerability. An increasing body of mechanistic and translational data is identifying the endocannabinoid system (ECS) as a key reg · en

Long-term safety and tolerability of transdermal cannabidiol gel in children and adolescents with Fragile X syndrome (ZYN2-CL-017): an interim analysis of an ongoing open-label extension study. — Berry-Kravis E, Hagerman R, Cohen J, Budimirovic D, Buchanan CB, Silove N et al. (2025) · DOI 10.1186/s11689-025-09657-x · ensaio clinico · Background Dysregulated endocannabinoid signaling is involved in Fragile X syndrome (FXS), suggesting a potential role for the endocannabinoid signaling modulator, cannabidiol, in treatment. ZYN002 is a synthetic cannabidiol that has been uniquely formulated as a gel for transder · en

Exploring the effects of cannabidiol on pain sensitivity using quantitative sensory testing among individuals receiving methadone or buprenorphine for opioid use disorder: an open-label, proof-of-concept study. — Costa GPA, Suh R, Sofuoglu M, De Aquino JP (2026) · DOI 10.1016/j.abrep.2025.100654 · ensaio clinico · indica benefícios potenciais com 400 mg para indivíduos em buprenorfina · en

Early-life exposure to Cannabidiol: Safety assessment of a chronic exposure in Caenorhabditis elegans. — Padilha HA, Reginatto JF, Saleh JD, Jardim NS, Crippa JA, Hallak JEC et al. (2026) · DOI 10.1016/j.taap.2026.117814 · pre clinico · CBD treatment early in life was safe at the lowest concentration · en

Phase 2, open-label INSPIRE trial to assess the tolerability and effectiveness of transdermal cannabidiol gel in children and adolescents with 22q11.2 deletion syndrome (ZYN2-CL-031). — Heussler H, Cohen J, Buchanan CB, Albers DS, Bzdek KG (2026) · DOI 10.1186/s11689-026-09687-z · ensaio clinico · BACKGROUND: 22q11.2 deletion syndrome (22qDS) is a genetic disorder affecting various body systems and associated with behavioral and psychiatric conditions, with no currently approved pharmacological treatments. ZYN002, a transdermal gel containing synthetic cannabidiol, has bee · en

Cannabidiol-hyaluronic acid combination delivered rectally for attenuating abacterial prostatitis symptoms: Single-arm open-label pilot clinical trial. — Student V, Repa V, Vrbkova J, Vacek J (2026) · DOI 10.5507/bp.2026.002 · ensaio clinico · reduz NIH-CPSI em 7.0 pontos (P=0.003) · en

CBD-Containing Topical Formulation for Localized Pain in Fibromyalgia: A 12-Week Pilot Feasibility Study. — Rodríguez-Araya TL, Arias A, Polino L, Ochoa G, Hernández E, Torres X (2026) · DOI 10.1177/25785125261468882 · ensaio clinico · Background Fibromyalgia (FM) is a chronic pain condition characterized by widespread pain, fatigue, and functional impairment. Current pharmacological treatments show limited efficacy and poor tolerability. Cannabidiol (CBD) has demonstrated analgesic and anti-inflammatory proper · en

Cannabidiol synergizes with methotrexate to attenuate rheumatoid arthritis via STAT3/NF-κB signalling-mediated M1 macrophage polarization. — Xu J, Wang Z, Geng Q, Wen C, Jiao Y, Deng T et al. (2026) · DOI 10.1016/j.intimp.2026.116627 · outro · Background Methotrexate (MTX) is the anchor drug for rheumatoid arthritis (RA) treatment, but its clinical application is limited by dose-dependent adverse events, such as hepatotoxicity and gastrointestinal intolerance, and incomplete efficacy in some patients. Cannabidiol (CBD) · en

Safety and Preliminary Clinical Outcomes of a Combined Cannabidiol and Sodium Propionate Enema in Refractory Ulcerative Proctitis: An Open-Label Pilot Study. — Naftali T, Stein A, Kayless H, Prutchi Sagiv S (2026) · DOI 10.1159/000552842 · ensaio clinico · 50% dos pacientes atingiram redução de 3 pontos no escore de Mayo · en

Medical cannabis for treatment of insomnia in adults: A systematic review and meta-analysis. — Begazo K, Laing K, Mineo A, Efre A, Hanson A, Chan J et al. (2026) · DOI 10.1097/jxx.0000000000001289 · meta analise · pode diminuir distúrbios do sono e sonolência diurna, aumentando o tempo total de sono · en

Joint Relations Among Cannabis, Sleep, and Affective Symptomatology: A Scoping Review. — Berey BL, Thomas SA, Sokolovsky AW, Gunn RL, Miller MB (2026) · DOI 10.1007/s40429-026-00735-1 · revisao sistematica · cannabis associado a melhorias no sono em adultos com ansiedade/depressão · en

[Pharmacological and psychosocial interventions for cannabis use disorders]. — Budney AJ, Vandrey RG, Stanger C (2010) · DOI 10.1590/s1516-44462010000500008 · revisao sistematica · intervenções baseadas em comportamentos geram efeitos positivos significativos na abstinência e reduções no uso de cannabis · pt

Cannabis Use Among Caregivers of Older Adults: A Systematic Literature Review. — Jagasia K, Malyan HH, Kim J, Kabakibi M, Moore AA, Nguyen AL (2026) · DOI 10.1177/30495334261426511 · revisao sistematica · cannabis pode ser um mecanismo de enfrentamento para cuidadores com carga emocional · en

Effect of Cannabigerol on Sleep and Quality of Life in Veterans: A Decentralized, Randomized, Placebo-Controlled Trial. — Emerson CR, Webster CE, Daza EJ, Klamer BG, Tummalacherla M (2026) · DOI 10.1159/000549902 · ensaio clinico rct · Introduction This decentralized, randomized, triple-blind, placebo-controlled study evaluated efficacy and safety of oral cannabigerol (CBG) in Veterans with sleep issues. Methods After a 2-week run-in phase, participants received CBG (25 mg daily for 2 weeks, then 50 mg daily fo · en

Cognitive-behavioural therapy for insomnia in adults to decrease cannabis use: study protocol for a randomised controlled trial in a community sample of adults with frequent cannabis use. — Bolling C, Cardoni ME, Conroy DA, Price A, Goldstick JE, Bourgoise M et al. (2026) · DOI 10.1136/bmjopen-2026-116524 · ensaio clinico rct · Introduction Cannabis use is common in the USA and is associated with adverse outcomes across many domains, including sleep difficulties. Targeting insomnia with an evidence-based treatment could improve sleep and reduce frequent cannabis use. This randomised controlled trial (RC · en

Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial. — Suraev A, McGregor IS, McCartney D, Marshall NS, Kao CH, Wassing R et al. (2026) · DOI 10.1111/jsr.70124 · ensaio clinico rct · diminui tempo total de sono em 24.5 min e REM em 33.9 min · en

Integrative therapies for chronic insomnia: A randomized controlled trial of a traditional Thai Herbal Remedy and &lt;i&gt;Cannabis sativa&lt;/i&gt; oil. — Pakdee N, Sribunrieng N, Poowanna R (2026) · DOI 10.1016/j.sleepx.2026.100173 · ensaio clinico rct · melhora na qualidade do sono com Cannabis sativa oil (13.6-3.68) · en

Cannabis to Reduce Chronic Postsurgical Pain Following Total Knee Arthroplasty: A Pilot Randomized Controlled Trial — Busse JW, Flood B, Madden K, Kashir I, Sadeghirad B, Atrey A et al. (2026), Research Square · DOI 10.21203/rs.3.rs-9622221/v1 · ensaio clinico rct · Abstract Background Chronic postsurgical pain (CPSP) after total knee arthroplasty (TKA) affects 20% of patients and is associated with higher peri-operative pain. Cannabis products may be effective for reducing CPSP after TKA. We conducted a pilot trial to determine feasibility · en

Chronic cannabis use and sleep architecture: a cross-sectional analysis of polysomnography outcomes in a sleep-clinic cohort. — Velzeboer R, Wei S, Lai WWK (2026) · DOI 10.1093/sleep/zsaf396 · coorte · aumenta o despertar após o sono em ~21% vs nunca-usuários · en

Canadian real-world evidence: observational 24-week outcomes for health care practitioner authorized cannabis. — Yang B, Diep C, Thaker S, Jackson T, Lakhani A, Landolt C et al. (2026) · DOI 10.1080/24740527.2025.2593253 · coorte · melhora em dor, ansiedade, depressão e qualidade de vida · en

Association between cannabis use and insomnia symptoms among veterans with chronic pain. — Elliott JE, Schriemer D, Flegal H, Pal N, Niederhausen M, Lovejoy TI et al. (2026) · DOI 10.1093/sleepadvances/zpag026 · coorte · null · en

Beyond cannabis use severity: associations of cannabis product type with sleep quality and mental health. — Donate APG, Cousijn J, Rømer Thomsen K (2026) · DOI 10.1007/s00213-026-07103-x · coorte · uso de hash ou múltiplos produtos dominantes em THC está associado a mais problemas de sono em comparação ao uso de flor · en

Exploratory Prospective Study of Self-Titrated Medical Cannabis for Nonmotor Symptoms in Parkinson's Disease. — Anis O, Lassman S, Goldberg T, Saar A, Meiri D, Shapira A et al. (2026) · DOI 10.1177/25785125261458680 · coorte · melhora nos sintomas não motores (Δ 14.5, p = 0.001) · en

Behavioural Economic Demand for Medicinal and Recreational Cannabis Among People Who Use Over-The-Counter CBD Products, THC Only and CBD + THC. — González-Roz A, García-Pérez Á, Cuesta-López I, Alemán-Moussa L, Secades-Villa R (2026) · DOI 10.1111/dar.70073 · coorte · demanda por cannabis medicinal maior que recreativa · en

Measuring the Effects of Cannabis on Anxiety and Depression Among Cancer Patients. — Reddy AC, Hampton JM, Park SJ, Dickerson F, Shah J, Chewning B et al. (2025) · DOI 10.1002/cam4.71342 · coorte · ansiedade melhora com doses mais altas de CBD (>14.3 mg/dia) · en

Prevalence and reasons for using cannabidiol, delta-8 tetrahydrocannabinol, cannabinol, cannabigerol, and hexahydrocannabinol among US adults. — Satybaldiyeva N, Yang KH, Kepner W, Ferran K, Leas EC (2025) · DOI 10.1186/s42238-025-00359-8 · transversal · Background Since the passage of the 2018 US Farm Bill there has been a market for cannabinoid products derived from Cannabis sativa L. that contain  Methods We conducted a cross-sectional survey of 1,523 adults 18 years or older using the probability-based Ipsos KnowledgePanel, r · en

Real-world quality of life and sleep outcomes in patients treated with THC- and CBD-rich &lt;i&gt;Cannabis&lt;/i&gt; oil: a cross-sectional study. — Figueiredo JFLM, de Almeida Soares C, de Oliveira DA, Cassiano FR, Sacramento VM, de Melo-Júnior AF et al. (2026) · DOI 10.3389/fphar.2026.1862725 · transversal · associado a percepções favoráveis de qualidade de vida e sono · en

Perceived Impacts and Predictors of Cannabis Products Used by Patients with Rheumatologic Conditions in Alberta, Canada: A Multivariable Analysis of Cross-Sectional Survey Data. — Zhang S, Lowe SAJ, Sun F, Jones A, Turk T, Olson J et al. (2026) · DOI 10.1002/acr.80071 · transversal · THC-CBD produtos associados a aumento de impacto positivo (aOR 1.76) · en

Exploring Linalool-Based Phytotherapy for Excitatory/Inhibitory Imbalance in Alzheimer's Disease: A Review of Lavender and Cannabis Therapeutic Effects on Sleep, Seizures, and Cognition. — Piccialli I, Roviello G, Magliocca G, Esposito E, Pannaccione A (2026) · DOI 10.1002/ptr.70191 · revisao narrativa · Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory impairment, and behavioral disturbances. While its pathogenesis is complex, increasing evidence supports the role of an imbalance between excitatory and inhibitory (E/I · en

Therapeutically Motivated Cannabis Use for Anxiety: Daily and Longitudinal Reductions Vary Between Flower and Edible Products. — Rosa L, Lisano JK, Skrzynski CJ, Bryan AD, Bidwell LC (2026) · DOI 10.3390/ijerph23020224 · ensaio clinico · reduz ansiedade ~39.5% com THC + CBD vs THC · en

Frequency of cannabis use and symptoms of anxiety and depression: a cross-sectional analysis of the Colorado cannabis users health cohort. — Steeger CM, Tandukar P, Hoth KF, Aloia M, Wamboldt F, Castaldi P et al. (2025) · DOI 10.1186/s42238-025-00327-2 · ensaio clinico · uso frequente de cannabis associado a maior probabilidade de ansiedade (AOR=1.06) · en

Stellate Ganglion Block for the Management of Cannabis Use Disorder: A Case Series. — Charan N, Karanth V, Niraj S, Niraj G (2026) · DOI 10.7759/cureus.105898 · relato caso · reduz sintomas de abstinência em todos os pacientes · en

Relationships Between Motives for Cannabis and Cannabidiol Use in People Who Co-Use: Results From the European Web Survey on Drugs. — Fortin D, Leroy V, Carrieri P, Matias J, Barré T (2025) · DOI 10.1111/dar.14090 · ensaio clinico · CBD use was associated with reporting cannabis therapeutic-oriented motives · en

Green light to sleep: Does cannabis work for insomnia? A case report and brief review. — Mota-Rolim S, Melo PDC, Barroso VV, Amaral EJFD, Araujo JF, Ribeiro S (2025) · DOI 10.1016/bs.pbr.2025.07.005 · relato caso · insônia diminuiu após uso de óleo de Cannabis sativa · en

Mystery shopper assessments of cannabis retailer practices and regulatory compliance in five U.S. states, 2025. — Berg CJ, LoParco CR, Rossheim ME, McCready DM, Langan L, Platt E et al. (2026) · DOI 10.1016/j.drugalcdep.2026.113218 · outro · Objective This study used mystery shoppers to assess cannabis retail practices in 5 US states regulating legal nonmedical cannabis retail. Methods This mystery shopper study assessed 130 cannabis retailers in 5 cities (Los Angeles [LA], California; Las Vegas [LV], Nevada; Denver, · en

Sleep quality and duration following the use and co-use of alcohol and cannabis in the daily life of community adults. — Nance M, Miller MB, Ellingson JM, Carpenter RW (2025) · DOI 10.1016/j.drugalcdep.2025.112946 · ensaio clinico · cannabis use associado a 15min mais de sono · en

Chronic Insomnia and Excess Cannabis Ingestion in an Older Adult-A Clinical Report of Complex Geriatric Care. — Fraunberger E, von Maltzahn M (2026) · DOI 10.1111/jgs.70389 · relato caso · Cannabis use in older adults may have a broad range of effects in older adults impacting Mind, Mobility, Medications, Multi-complexity, and what Matters Most. · en

Cannabis sativa phytochemicals in cancer therapy: molecular mechanisms and therapeutic potential. — Montle R, More GK, Takaidza S, Mtunzi F (2026) · DOI 10.3389/fphar.2026.1768210 · revisao sistematica · Cannabinoids exhibit pathway-specific effects, including induction of apoptosis and inhibition of angiogenesis · en

Cannabidiol: Pharmaceutical formulations and biomedical applications. — Fadavi Eslam A, Mohtashami L, Moghimi P, Iranshahi M (2026) · DOI 10.22038/ijbms.2026.89134.19592 · revisao sistematica · CBD mostra potencial terapêutico promissor em várias condições · en

Tailored psychotherapy and AI-enhanced contingency management for co-occurring disorders in cannabis use disorder: a systematic review. — Mishra S, Mishra S, Rath S (2026) · DOI 10.1080/10550887.2026.2616726 · revisao sistematica · melhora sintomas psiquiátricos e reduz uso de cannabis · en

Efficacy, effectiveness and safety of medical cannabis in PTSD: a scoping review. — Aviram J, Belobrov R, Grinapol S, Fruchter E (2026) · DOI 10.1186/s42238-026-00451-7 · revisao sistematica · reduz pesadelos relacionados ao PTSD em um RCT · en

Cannabis Use Among Individuals Treated with Medication for Opioid Use Disorder: Correlates, Patterns, and Motivations for Use. — Leyde SE, Merrill JO, Treadway AJ, Pike KC, Price CJ (2026) · DOI 10.1177/29767342251401312 · ensaio clinico rct · frequent cannabis use associated com ansiedade e náusea · en

Assessing anxiety longitudinally among medical cannabis patients in Pennsylvania. — Ataiants J, Fedorova EV, Cocchiaro B, Kleber L, Sayyid A, Ardeleanu K et al. (2025) · DOI 10.1080/00952990.2025.2588273 · coorte · reduz ansiedade em perfis mínimos e moderados, mas não de forma clinicamente significativa · en

Radical Revelations: The Interplay of Nitrosative Stress, the Endocannabinoid System, and Treatment of Age-Related Disorders. — Davis A, Casmedes IY, Burton MD (2026) · DOI 10.3390/ijms27062813 · revisao narrativa · modulação do estresse nitrosativo e neuroinflamação em doenças neurodegenerativas · en

The Endocannabinoid System in PTSD: Molecular Targets for Modulating Fear and Anxiety. — Lyndon S (2026) · DOI 10.1055/a-2647-8030 · revisao narrativa · nabilone alivia pesadelos relacionados ao trauma · en

Post-Traumatic Stress Disorder & Cannabis: An Epidemiologic and Genetic Narrative Review — Sakusky HA, Keiser KE, Rodriguez A, Piper BJ (2026), Preprints.org · DOI 10.20944/preprints202606.0086.v1 · revisao narrativa · efetivo na redução de sintomas de PTSD a curto prazo · en

Posttraumatic stress disorder (PTSD) symptoms, solitary alcohol and cannabis use, and consequences among young adults. — Moskal KR, Traxler SM, Briles E, Miller MB, Teeters JB (2026) · DOI 10.1037/pha0000869 · outro · A substantial proportion of young adults experience alcohol- and cannabis-related consequences. One potential contributor to negative consequences of substance use is context; for example, solitary substance use, which may be more common for those who are experiencing mental heal · en

Clinical Experience and Student Support for Medical Cannabis Use: A Secondary Analysis. — Tong AW, DuBoux CJ, Seuferer RH, Clobes TA, Siu FW, Magana B et al. (2026) · DOI 10.26828/cannabis/2026/000386 · outro · estudantes com experiência clínica demonstraram suporte significativamente menor para uso de cannabis medicinal · en

Associations between posttraumatic cognitions and cannabis cravings among trauma-exposed individuals using cannabis. — Deguzman-Lucero RM, Le JU, Schmidt NB, Short NA (2026) · DOI 10.1111/bjc.70016 · ensaio clinico · elevated PTC associated with increased state cravings for cannabis (β=0.19, p=0.025) · en

Sociodemographic and health correlates of reimbursement authorizations for cannabis for medical purposes in Canadian veterans: A cross-sectional study linking the <i>Life After Services Studies 2019</i> and <i>Health Administrative Databases</i> — Kendzerska T, Reyes J, Poirier N, Poirier A, Cull A, Murkar A et al. (2026), medRxiv · DOI 10.64898/2026.06.10.26355368 · ensaio clinico · Background Evidence on factors associated with cannabis for medical purposes (CMP) authorizations among Veterans Affairs Canada (VAC) clients remains limited and inconsistent, particularly concerning mental health and posttraumatic stress disorder (PTSD), a leading indication fo · en

The Effects of Extended Cannabis Abstinence in Comorbid Posttraumatic Stress Disorder and Cannabis Use Disorder. — Rodas JD, Sorkhou M, Kloiber S, George TP, Hassan AN (2026) · DOI 10.4088/jcp.25m16099 · ensaio clinico · reduz severidade dos sintomas de PTSD de 36.2 para 10.5 entre abstinentes · en

Preclinical antitumor evaluation of a tetrahydrocannabinol and cannabidiol (1:6) cannabis extract in an MCF-7 xenograft model of estrogen receptor-positive breast cancer. — Meesiripan N, Thanasitthichai S, Sangrajrang S, Suwanpidokkul N, Prayakprom P, Bodhibukkana C et al. (2026) · DOI 10.14202/vetworld.2026.2496-2511 · pre clinico · reduz crescimento tumoral em todos os grupos tratados · en

Cannabis Use and Intimate Partner Violence During Pregnancy Are Associated with Poorer Postpartum Mental Health. — Marvin MJ, Ballinger AL, Stein SF, Fairchild JN, Bogat GA, Lonstein JS et al. (2026) · DOI 10.1055/a-2761-1601 · ensaio clinico · cannabis use during pregnancy é associado a PTSD, depressão e ansiedade elevadas · en

Structure-stability relationships of pure cannabinoids and their cocrystals under forced degradation conditions. — Koryťáková A, Chatziadi A, Heřt J, Rohlíček J, Zmeškalová E, Beránek J et al. (2026) · DOI 10.1186/s42238-026-00474-0 · outro · Cannabinoids have attracted increasing scientific interest due to their diverse activities and therapeutic potential. However, cannabinoids suffer from limited physicochemical properties, including low melting point, low aqueous solubility, and stability issues. Cocrystal formati · en

Cannabidiol modulates spontaneous recovery through distinct and conserved transcriptomic signatures in mPFC subregions. — Son M, Song I, Pradeep P, Chang B, Girgenti MJ, Girgenti MJ et al. (2026) · DOI 10.1038/s42003-026-10111-4 · pre clinico · reduz recuperação espontânea em modelos de camundongos · en

Predictors of Replacing Alcohol With Cannabis Among Adult Women. — Attonito J, Mueller JE, Villalba K (2025) · DOI 10.7759/cureus.95821 · outro · jovens substituem THC por álcool ~14% vs 7.8% em mulheres mais velhas · en

More high, less low? PTSD and the complex daily associations between cannabis use and depression in veterans. — Davis JP, Saba SK, Leightley D, Pedersen ER, Prindle J, Cantor J et al. (2026) · DOI 10.1016/j.addbeh.2025.108593 · ensaio clinico · associação bidirecional negativa entre uso de cannabis e depressão · en

"1, 2, 3, Release": Cannabis Consumption and Mental Health and Well-Being During Pregnancy, Lactation and Parenthood. — Greene S, Ion A, Maurice R, Griffith G, Vaccaro M, Bernier A et al. (2026) · DOI 10.26828/cannabis/2026/000355 · outro · mães acreditam que cannabis apoia saúde mental · en

Cannabidiol Reduces D1 and D2 Medium Spiny Neuron Excitability in the Nucleus Accumbens Core — Jarrett ZE, Grueter BA (2025), bioRxiv · DOI 10.64898/2025.12.02.691956 · ensaio clinico · reduz excitabilidade de neurônios D1 e D2 no núcleo accumbens · en

Cannabinoid use generalizes stress responses: involvement of astrocyte plasticity and activation of matrix metalloproteinases in the nucleus accumbens core. — Hodebourg R, Duncan L, Dereschewitz E, Kalivas P (2026) · DOI 10.1038/s41380-026-03687-0 · outro · promove sintomas semelhantes ao PTSD, como comportamentos de enfrentamento evitativos · en

Cross-species causal gene mapping reveals brain-region-specific targets of Cannabidiol for post-traumatic stress disorder treatment. — Rao H, Xie G, Wu N, Li J, Han X (2026) · DOI 10.1016/j.bbrc.2026.154347 · outro · identifica 7 alvos de CBD que respondem transcricionalmente em PTSD · en

Cannabis for Harm Reduction: Exploring Mental Health and Other Motivational Factors among Adults at Risk for Alcohol Use Disorder in Florida. — Attonito J, Mueller J, Villalba K, Chakraborty A (2026) · DOI 10.1080/10826084.2026.2670620 · outro · Background Prior research has suggested that cannabis may serve as a safer alternative to alcohol, this study examined "marijuana" (THC-dominant cannabis) and cannabidiol (CBD) use as strategies to reduce alcohol consumption among adults who report harmful levels of drinking. Met · en

Cannabinoid use generalizes stress responses by altering the astrocyte plasticity through extracellular matrix signaling in the nucleus accumbens core — Hodebourg R, Duncan L, Dereschewitz E, Kalivas P (2025), Research Square · DOI 10.21203/rs.3.rs-7254957/v1 · outro · promove comportamentos de enfrentamento evitativos e generaliza respostas ao estresse · en

ATTITUDES AND PRACTICE PATTERNS OF CANADIAN PHYSIATRISTS REGARDING MEDICAL CANNABIS. — Ethans K, Chaudhary H, Casey A, O'Connell C, Nankar M, Khandelwal A (2025) · DOI 10.2340/jrm-cc.v8.43254 · outro · Objective To assess practice patterns and attitudes of Canadian physiatrists, given their expertise in pain management and spasticity, conditions in which medical cannabis (MC) should be considered. Design A 24-item, survey questionnaire was sent to physiatrists across Canada. Su · en

Changes in sleep quality during the 12 months following medical cannabis initiation. — Short MM, Lent MR, McCalmont TR, Dugosh KL (2025) · DOI 10.1186/s42238-025-00376-7 · ensaio clinico · melhora na qualidade do sono ao longo de 12 meses · en

Multiple Roles of Cannabinoids in the Olfactory System. — Heinbockel T, Brown EA (2026) · DOI 10.3390/brainsci16020190 · revisao sistematica · The endocannabinoid system is a ubiquitous neuromodulatory network that links internal physiological state to neural circuit function across the brain. While its roles in memory, reward, pain, and motor control are well established, its contribution to olfactory processing has on · en

The potential of cannabinoids in managing cancer-related anorexia in older adults: a systematic review of the literature. — Ceolin C, De Rui M, Ravelli A, Papa MV, Devita M, Sergi G et al. (2024) · DOI 10.1016/j.jnha.2024.100299 · revisao sistematica · aumento significativo na ingestão calórica e consumo de carboidratos com nabilone em dose dupla · en

Risks of Cannabinoid Exposure on Birth Outcomes: A Systematic Review. — Reck AM, Reilly T, Vanegas SO, Shook NJ, Kinsey SG, Casavant SG (2025) · DOI 10.1089/can.2025.0027 · revisao sistematica · associado a menor peso ao nascer · en

The Role of Cannabinoids in Advancing Cancer Treatment: Insights from Evidence-Based Medicine. — Skórzewska M, Gęca K (2024) · DOI 10.1007/s11912-024-01589-4 · revisao sistematica · Purpose of review This document critically examines the role of cannabinoids in cancer care during an era marked by rapid advancements in oncology and changing perceptions on cannabis. It traces the historical context of cannabis in medicinal use, navigating its journey from wide · en

Reducing severe breathlessness with dronabinol in the group of patients with severe and very severe chronic obstructive pulmonary disease (BONG): a randomised, double-blinded, placebo-controlled, crossover study in an outpatient clinic in Denmark - a study protocol. — Wolsing SK, Hilberg O, Løkke A, Farver-Vestergaard I, Andersen CU, Hansen KK (2026) · DOI 10.1136/bmjopen-2025-104957 · ensaio clinico rct · Introduction Cannabis-based medicine may alleviate breathlessness. This study will investigate whether dronabinol, a synthetic form of Δ 9 -tetrahydrocannabinol (Δ 9 -THC), reduces breathlessness in patients with severe and very severe chronic obstructive pulmonary disease (sCOPD · en

Plasma cannabinoid pharmacokinetics following the inhalation of vaporised cannabis with and without cannabidiol. — Hall D, Chesney E, Mokrysz C, Caldwell A, Halket J, Petrilli K et al. (2026) · DOI 10.1016/j.drugalcdep.2026.113160 · ensaio clinico rct · aumento dos níveis plasmáticos de THC com CBD · en

Effects of Sativex&lt;sup&gt;®&lt;/sup&gt; Versus Placebo on Glucagon-like Peptide-1, Total Ghrelin, and Subjective Appetite in Older Adults with Poor Appetite: A Protocolized Secondary Analysis of a Double-Blind, Randomized, Placebo-Controlled Crossover Trial. — Bornæs O, Nielsen RL, Christensen LWS, Storgaard IK, Kallemose T, Juul-Larsen HG et al. (2026) · DOI 10.3390/nu18142274 · ensaio clinico rct · Sativex ® produced an estimated 2.38 pmol/L increase in GLP-1 vs placebo · en

Efficacy of cannabis oil on appetite and quality of life in systemic sclerosis patients: a randomized placebo-controlled trial. — Pisprasert V, Sripanichkulchai B, Khannongpho T, Jumnainsong A, Mahakkanukrauh A, Suwannaroj S et al. (2025) · DOI 10.1186/s42238-025-00342-3 · ensaio clinico rct · tendência de melhora na apetite e qualidade de vida · en

A National Survey of Marijuana Use Among U.S. Adults According to Obesity Status, 2016-2022. — Merrill RM (2026) · DOI 10.1089/can.2024.0069 · coorte · prevalência de uso de maconha é 35% menor em indivíduos obesos vs não obesos · en

Cannabinoid hyperemesis syndrome prevalence and risk factors in the U.S․. — Glodosky NC, Okey SA, Watson TD, Hammond D (2026) · DOI 10.1016/j.drugpo.2026.105307 · coorte · aproximadamente 6% relataram CHS no último ano · en

Self-Reported Cannabis Use and Symptom Burden Among Patients With Cancer Receiving Palliative Care. — Bramati PS, Abdelkhaleq H, Lopez Garayua G, Gilbey D, Manuel CM, Bruera E (2026) · DOI 10.1177/10499091261466675 · coorte · maior carga de sintomas associada ao uso de cannabis · en

[Cannabinoid system and feeding regulation]. — Arias Horcajadas F (2008) · DOI 10.20882/adicciones.281 · revisao narrativa · beneficial effect on metabolic syndrome · es

The Efficacy of Cannabis in Oncology Patient Care and Its Anti-Tumor Effects. — Shalata W, Abu Saleh O, Tourkey L, Shalata S, Neime AE, Abu Juma'a A et al. (2024) · DOI 10.3390/cancers16162909 · revisao narrativa · As the legalization of medical cannabis expands across several countries, interest in its potential advantages among cancer patients and caregivers is burgeoning. However, patients seeking to integrate cannabis into their treatment often encounter frustration when their oncologis · en

Cannabis: What We Use, Why It Matters, and When It Is Prescribed (Ethics, Policy, and Practice). — Mistry LN, Neelkanthan S, More S, Agarwal S, Jaiswal H, Sharma V (2025) · DOI 10.7759/cureus.89073 · revisao narrativa · Cannabis and its bioactive compounds, specifically tetrahydrocannabinol and cannabidiol, are rapidly growing in popularity for their therapeutic applications across a variety of medical specialties, including dentistry. This narrative review aims to explore the current and future · en

Age-Related Effects of Cannabis and Cannabinoids on Brain and Behavior. — Murray CH, Cassarino J, Cooper ZD (2026) · DOI 10.1177/25785125251372061 · revisao narrativa · Introduction The effect of cannabis use on health is likely to depend on individual differences. In particular, there is a growing need to understand the impact of cannabis and delta-9-tetrahydrocannabinol (THC) on brain and behavioral health across the lifespan. Materials and me · en

[The endocannabinoid system: a new paradigm in the metabolic syndrome treatment]. — de Godoy-Matos AF, Guedes EP, de Souza LL, Valério CM (2006) · DOI 10.1590/s0004-27302006000200025 · revisao narrativa · Rimonabant demonstrou ser útil no controle de peso e aspectos metabólicos · pt

The role of the endocannabinoid system in managing neuropsychiatric symptoms in Alzheimer's disease. — Rao JS, Alejandra Tangarife M, Venegas MM, Forero B, González Tamayo LL, Escobar-Gallego JP et al. (2025) · DOI 10.3389/fpsyt.2025.1709266 · revisao narrativa · The endocannabinoid system comprises cannabinoid receptors (CBRs) 1 & 2, endocannabinoids (eCBs) anandamide (AEA) and 2-arachidonoylglycerol (2-AG), and the enzymes that regulate their production and degradation. ECS plays a significant role in both health and disease. It influen · en

Cannabinoids in Alzheimer's disease: animal-human evidence and clinical pharmacology challenges. — Komedera M, Wojda U, Kiryk A (2026) · DOI 10.3389/fnbeh.2026.1833021 · revisao narrativa · melhora sintomas neuropsiquiátricos como agitação e distúrbios comportamentais · en

Pharmacotherapy for Cannabis Use Disorder: Preclinical and Clinical Models. — Bedillion MF, Moore CF, Weerts EM, Arout CA, Harris HM, Haney M (2026) · DOI 10.1007/7854_2025_598 · revisao narrativa · Cannabis use disorder (CUD) is increasingly prevalent, and there are no FDA-approved medications to facilitate its treatment. Research on the development of CUD pharmacotherapies lags compared to other substance use disorders (SUDs), partly due to the difficulty in establishing r · en

Phytocanabinoids and synthetic cannabinoids: from recreational consumption to potential therapeutic use - a review. — Teixeira HM (2024) · DOI 10.3389/ftox.2024.1495547 · revisao narrativa · Cannabinoids are part of the most popular group of illicit substances in the Western world. The word "cannabinoid" refers to any chemical substance, regardless of structure or origin, that binds to the body's cannabinoid receptors and that has effects similar to those produced by · en

Effects of prescribed medical cannabis and alcohol on real-world driving performance (CAN-TRACK): a study protocol for a two-phase trial. — Arkell TR, Hayley AC, Aitken B, Hu X, Manning B, Downey LA (2026) · DOI 10.1186/s13063-026-09512-x · ensaio clinico · Background Medical cannabis is now commonly prescribed for a range of chronic health conditions. Many medical cannabis products contain delta-9-tetrahydrocannabinol (THC), the intoxicating component in cannabis, though it is unclear whether these products produce impairment when · en

Effects of Voluntary Ingestion of Synthetic Delta-9-Tetrahydrocannabinol on the Hedonic Value of Rewarding and Aversive Substances and CB1 Receptor Expression. — Laux DA, Cain ME (2026) · DOI 10.1177/25785125251390206 · ensaio clinico · aumenta reações hedônicas a substâncias recompensadoras · en

Multifaced roles of cannabinoid therapy in cancer: balancing analgesia, antitumor potential, and systemic toxicity. — Creanga-Murariu I, Ciorpac M, Gogu RM, Pricope CV, Bild V, Ababei DC et al. (2025) · DOI 10.3389/fphar.2025.1691893 · ensaio clinico · alivia dor neuropática com NC1 mais eficaz (72% e 100%) · en

SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r(G894C) Zebrafish Model of Obesity. — Angel I, Periyasamy K, Joseph B, Aminov E (2026) · DOI 10.3390/ijms27104321 · ensaio clinico · produz perda de peso e normalização lipídica · en

Cannabis produces acute hyperphagia in humans and rodents via increased reward valuation for, and motivation to, acquire food. — Hume C, Cuttler C, Baglot SL, Javorcikova L, McLaughlin RJ, Hill MN (2025) · DOI 10.1073/pnas.2518863122 · ensaio clinico · aumenta a ingestão de energia de forma aguda · en

Δ&lt;sup&gt;9&lt;/sup&gt; Tetrahydrocannabinol and cannabis extracts differentially improve adipoinsular dysfunction in diet-induced obesity. — Avalos B, Olmos M, Wood CP, Alvarez C, Read HM, Udompholkul P et al. (2026) · DOI 10.1113/jp290431 · ensaio clinico · reduz peso corporal e massa gorda em camundongos obesos · en

Edible Cannabis and Pain, Sleep, and Mental Health Management in Older Adults. — Delaney RK, Watt MH, Stanger M, Hong I, Bakshi NK, Fagerlin A et al. (2026) · DOI 10.1001/jamanetworkopen.2026.11718 · outro · Importance Older adults are the fastest-growing group of cannabis consumers in the US, seeking relief from age-related ailments (eg, pain or difficulty sleeping) and improved quality of life. However, little is known about the motivations and factors that influence their use of e · en

A Feasibility Assessment of the FDA Adverse Event Reporting System for the Detection of Cannabis-Related Safety Signals. — Lopes POMV, Harris CS, Gravel CA (2026) · DOI 10.1002/pds.70392 · outro · Background The applicability of spontaneous reporting systems such as the US Food and Drug Administration Adverse Event Reporting System (FAERS) to detect cannabis-related safety signals remains unclear due to the potential for discrepant reporting patterns between pharmaceutical · en

Progressive weight loss is attenuated by THC treatment in rats with activity-based anorexia. — Joyner SS, Eckel LA (2026) · DOI 10.1016/j.physbeh.2026.115448 · pre clinico · atenua perda de peso em ratos com anorexia ~23% vs controle · en

Racial diversity in cannabis use disorder research: A systematic review. — Reid MR, Reynolds B, Cape J, Ahmed Z, Ali H, Jaimes-Bautista E et al. (2026) · DOI 10.1016/j.drugalcdep.2025.113008 · revisao sistematica · Background Several groups of people of color have a higher prevalence and more severe cases of cannabis use disorder (CUD) compared to White people. They also endure unique issues like racial discrimination, which are linked with an increased likelihood of CUD. We conducted a sys · en

Trends in US adolescent cannabis use, 1991-2023. — Amrock SM, Sajkiewicz AJ (2026) · DOI 10.1016/j.addbeh.2026.108634 · revisao sistematica · lifetime cannabis use diminuiu de 47.3% em 1999 para 30.1% em 2023 · en

Racial Differences in Prenatal Cannabis Screening Among Women at Elevated Risk for Substance Use and Sexually Transmitted Infections. — Countryman K, Sen A, Chen D, Zlotnick C, Mmeje O, Gold KJ et al. (2026) · DOI 10.1111/jmwh.70105 · ensaio clinico rct · Black women 4.09 vezes mais propensas a serem questionadas sobre uso de cannabis · en

U.S. Cannabis Use Trends at the Intersection of Serious Psychological Distress and Race/Ethnicity, 2008-2019. — Rubenstein D, Vilardaga R, Evins AE, McClernon FJ, Pacek LR (2026) · DOI 10.1007/s40615-025-02360-6 · coorte · prevalência de uso de cannabis em 2019 foi de 27.9% com SPD vs 10.7% sem SPD · en

Medical Marijuana Initiation and Simulated Driving Performance Among Mid-to-Late-Life Adults With Chronic Pain: Prospective Observational Feasibility Cohort Study With Matched Controls. — Ennis N, Hou Y, Kloss K, Rogers J, Classen S (2026) · DOI 10.2196/79735 · coorte · reduz tempo de reação em situação de atenção dividida ~56% vs controle · en

Racial and Ethnic Disparities in Cannabis Use Among U.S. Youth Who Use Tobacco: Findings From the Population Assessment of Tobacco and Health Study. — Temourian AA, Ling PM, Do VV, Nguyen N (2025) · DOI 10.1016/j.focus.2025.100392 · coorte · cannabis-use prevalence >36% entre jovens que usam qualquer produto de tabaco · en

Trends in cannabis use disorder and treatment by race and ethnicity, 2002-2019. — Triguero Roura M, Vora A, Eschliman EL, Mauro PM (2025) · DOI 10.3389/fpsyt.2025.1689719 · coorte · Black people with CUD had 21% lower odds of any treatment than white people · en

Trends in cannabis urine drug screen testing in Colorado's largest health system: a retrospective cohort study. — Gilsdorf BJ, Helmkamp LJ, Page RL 2nd, Allen LA, McIlvennan CK (2026) · DOI 10.1186/s42238-026-00418-8 · coorte · positividade para cannabis aumentou de 14% em 2008 para 30% em 2015 · en

Binge alcohol and cannabis co-use associated with depression in Black men. — Mbaba M, Kearse TA, Massie J, Bowleg L (2026) · DOI 10.1037/adb0001158 · coorte · co-use linked to greater depressive symptoms · en

A Tale of Two Countries: Racially Targeted Arrests in the Era of Marijuana Reform — American Civil Liberties Union (ACLU) (2020), ACLU Research Report · dados administrativos · Risco relativo de prisão 3,64x (negros vs brancos) · en

Do motives for and contexts of cannabis use interact to predict heavy cannabis use at the event-level? — Dyar C, Green E, Lee CM (2026) · DOI 10.1111/ajad.70174 · ensaio clinico · coping motives in solitary settings associated with longer and higher subjective intoxication · en

Local availability of cannabis retail outlets on parents' cannabis use, acceptability, and perceived addictiveness: A longitudinal study in Washington State. — Le VT, Bailey JA, Epstein M, Dunbar MD, Satchell AK, Pandika DM (2026) · DOI 10.1371/journal.pone.0348182 · ensaio clinico · maior aceitação do uso de cannabis em áreas com mais pontos de venda · en

Urban-rural and racial/ethnic disparities in modes of preconception cannabis use among insured patients receiving prenatal care at an integrated healthcare system in Northern California from 2020 to 2023. — Brown QL, Cortez CA, Nugent JR, Adams SR, Soroosh AJ, Padon AA et al. (2026) · DOI 10.1016/j.drugalcdep.2026.113281 · ensaio clinico · prevalência de uso de cannabis 1.55x maior em cidades vs áreas rurais · en

State adult-use cannabis policy effects on law enforcement efforts to disrupt drug markets. — Montgomery BW, Athimuthu P, Richardson N, Ray B (2025) · DOI 10.1016/j.drugpo.2025.104802 · ensaio clinico · reduz apreensões de drogas, especialmente cannabis · en

Ethnic variations in sedentary behavior and marijuana use among U.S. adults: A cross-sectional analysis. — Li Y, Zhong L, Zhou H, Zeng F, Huang W, Rao J et al. (2025) · DOI 10.1097/md.0000000000046348 · ensaio clinico · associação negativa entre tempo sentado e uso de maconha, com redução de 40% no risco na categoria de 6 a 8 horas · en

Exploring Factors Shaping Tobacco and Marijuana Use Among Sexual Minority Adolescents. — Lin MY, Lockhart D, Denlinger-Apte R (2025) · DOI 10.1093/ntr/ntaf097 · outro · Purpose This study sought to identify the predominant factors associated with tobacco and marijuana/cannabis use among adolescents according to their sexual identity. Methods Using the 2023 National Youth Tobacco Survey, we examined current use of e-cigarettes, cigarettes, and ma · en

Psychometric evaluation of the perceived barriers to cannabis reduction and cessation scale. — Buckner JD, Jo D, Shepherd JM, Clausen BK, Garey LL, Zvolensky MJ (2026) · DOI 10.1016/j.addbeh.2026.108728 · ensaio clinico · Cannabis use remains high, with nearly one-third of people who use cannabis meeting criteria for a cannabis use disorder (CUD). Despite the availability of evidence-based psychosocial interventions for CUD, the vast majority of individuals with CUD do not seek treatment, and attr · en

Cannabis Expectancies as a Mediator in the Relationship Between Cannabis Use and Psychiatric Symptoms in Women With Post-traumatic Stress Disorder (PTSD) Symptoms. — Villalba K, Attonito J, Newins A (2026) · DOI 10.7759/cureus.108318 · ensaio clinico · mediador positivo entre uso de cannabis e sintomas de ansiedade e depressão · en

Same Story, Different Seller: Teaching the Public How Cannabis Models Driven by Profit Create the Same Injustices as Prohibition. — Allen JA, Title S, Bradfield B (2025) · DOI 10.26828/cannabis/2025/000299 · ensaio clinico · maior concordância sobre políticas de cannabis equitativas · en

Associations between neighborhood disadvantage, cannabis use, and patient-reported outcomes among patients with cancer. — Greene B, Ghosh S, Colder C, Meghani S, Worster B, Ashare R (2026) · DOI 10.1016/j.dadr.2026.100449 · ensaio clinico · cannabis route significantly moderated the relationship between neighborhood disadvantage and anxiety (b = -5.32) · en

Cannabis and Tobacco Product Use Classes and Psychosocial Correlates Among US Young Adults. — Speer M, Cui Y, McCready DM, LoParco CR, Romm KF, Wang Y et al. (2026) · DOI 10.1093/ntr/ntaf238 · outro · Introduction This study examined US young adults' cannabis-tobacco use classes. Methods Latent class analysis used 2023 data among young adults (ages 18-34, purposively recruited via Facebook to represent ~50% past-month cannabis use), specifically the 2267 reporting past-month c · en

Disparities in Exposure to Cannabis Marketing and Perceptions of Inequalities in Possession Treatment: Differences Across Intersections of Sociodemographic Subgroups. — LoParco CR, Romm KF, Cui Y, Cavazos-Rehg PA, Berg CJ (2026) · DOI 10.1007/s40615-026-02866-7 · outro · Background Cannabis-related concerns include young adult use and sociodemographic disparities. We examined sociodemographic subgroup perceptions of targeted cannabis-related law enforcement and marketing. Methods US young adults (N = 4,031) aged 18-34 were recruited via Facebook · en

State Medical Cannabis Policy Implementation and Racial Disparities in Opioid Prescribing Among Medicare Beneficiaries: A Policy Impact Analysis. — Dunn TJ, Holmes E, Yang Y, Bentley JP, Kashmiri S, Ramachandran S (2025) · DOI 10.1016/j.focus.2025.100391 · outro · Introduction U.S. cannabis policies have a history of racial disparities, highlighting the need for research surrounding racial inequities, particularly within the context of medicalization of cannabis and opioid prescribing. This study evaluated racial disparities in the relatio · en

Decreasing Criminal Legal System Referrals to Cannabis Treatment in the U.S.: Adolescent Trends by Race and Ethnicity Between 2010 and 2022. — Mauro PM, Miller M, Annunziato EM, Pamplin JR 2nd, Krawczyk N (2026) · DOI 10.1016/j.amepre.2026.108351 · observacional · taxa de tratamento referida pelo sistema legal criminal diminuiu 81.6% de 2010 a 2022 · en

Are cannabinoids effective for the management of chemotherapy induced nausea and vomiting? — Morales M, Corsi O, Peña J (2017) · DOI 10.5867/medwave.2017.09.7119 · meta analise · Introduction Nausea and vomiting are common side effects in cancer patients treated with chemotherapy. Proper control of these symptoms might improve quality of life in these patients. Addition of cannabinoids to standard antiemetic treatment has been proposed in order to improve · es

Cannabinoids and opioid consumption in cancer pain: a systematic review and meta-analysis. — Creangă-Murariu I, Alexa-Stratulat T, Rusu MI, Chiru S, Dascalu C, Dobre CE et al. (2026) · DOI 10.1007/s00520-026-10856-y · meta analise · não há diferenças significativas em uso de opioides entre canabinoides e placebo · en

Therapeutic Use of Cannabis and Cannabinoids: A Review. — Hsu M, Shah A, Jordan A, Gold MS, Hill KP (2026) · DOI 10.1001/jama.2025.19433 · meta analise · reduz náuseas e vômitos com SMD -0.29 · en

Potential antitumor effect of cannabidiol (CBD) in canine oncology: a systematic review. — Medina FJ, Torres CG (2026) · DOI 10.3389/fvets.2026.1800410 · revisao sistematica · exibe efeitos antiproliferativos e proapoptóticos · en

Cannabinoids in the Treatment of Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review of Randomized Controlled Trials. — Datta A, Erridge S, Mukherjee A, Acharya I, Vasooja D, Anand U et al. (2026) · DOI 10.1080/15360288.2026.2664668 · revisao sistematica · Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating toxicity of cancer treatment. Effective pharmacological treatments remain limited. Preclinical studies suggest cannabinoids reduce neuropathic pain through modulation of neurotransmission, neuroinflamm · en

Efficacy and Safety of Cannabis Derivates and Their Synthetic Analogs. Overview of Systematic Reviews. — Leite Pacheco R, Rêgo DF, de Oliveira Cruz Latorraca C, de Carvalho Nascimento MA, Daher AB, Riera R (2026) · DOI 10.1002/ptr.70403 · revisao sistematica · benefits for ulcerative colitis, chronic non-cancer pain, Crohn's disease, multiple sclerosis, and post-chemotherapy nausea and vomiting · en

Higher THC Concentration Medicinal Cannabis Products Efficacy and Safety Considerations: A Rapid Review. — Graham M, Assefa D, Cong-Lem N, Nielsen S (2026) · DOI 10.1111/dar.70145 · revisao sistematica · Issues Higher delta-9-tetrahydrocannabinol (THC) concentration medicinal cannabis products are characterised by a higher THC and minimal cannabidiol (CBD) content. This rapid review aims to systematically summarise and evaluate the available evidence regarding the efficacy and sa · en

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy — Smith LA, Azariah F, Lavender VTC, Stoner NS, Bettiol S (2015), Cochrane Database of Systematic Reviews · DOI 10.1002/14651858.CD009464.pub2 · revisao sistematica · Mais chance de resposta completa vs placebo (náusea/vômito) · en

Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial — Portenoy RK et al. (2012), The Journal of Pain · DOI 10.1016/j.jpain.2012.01.003 · ensaio clinico rct · Analgesia superior ao placebo em doses baixas/médias · en

Paradox of protection: Re-examining cannabis use disorder in sepsis outcomes among cancer patients. — Qiu WS, Chen HD, Yang WJ, Chen MM (2025) · DOI 10.5492/wjccm.v14.i4.106085 · coorte · reduz odds de mortalidade em 17% e de falência respiratória em 20% em pacientes com CUD · en

Survey of MaineHealth Cancer Care Network Providers on Cannabis Use: Preparation for Studies Sponsored by the National Cancer Institute. — Prescott JM, Saunders JG, Bradford LS, Remick SC (2026) · DOI 10.46804/2641-2225.1245 · transversal · Introduction Cannabis and cannabinoid use in patients with cancer has rapidly scaled up over the past decade and is a topic of considerable clinical, research, and public health interest. Methods We conducted a cannabis landscape survey among front-line providers in the MaineHeal · en

Phytocannabinoids and Male Fertility: Implications of &lt;i&gt;Cannabis sativa&lt;/i&gt; and the Endocannabinoid System in Reproductive Regulation. — Erukainure OL, Nambooze J, Chukwuma CI (2026) · DOI 10.3390/plants15030473 · revisao narrativa · exposição crônica a fitocanabinoides pode afetar negativamente a fertilidade masculina · en

From farm to bedside: Potential of medical cannabis in global health. — Tendwa MB, Appidi T, Chitsunge B, Moreau M, Okole B, Kalombo L et al. (2025) · DOI 10.1016/j.ctim.2025.103205 · revisao narrativa · potencial para reduzir mortalidade relacionada a opioides · en

Cannabinoids for Dermatological Applications: Mechanistic Insights, Clinical Evidence, and Emerging Nanotechnology-Enabled Delivery Strategies. — Pareek A, Kumari L, McMahon LR, Chuturgoon A, Pareek A (2026) · DOI 10.3390/pharmaceutics18040469 · revisao narrativa · melhora prurito e gravidade das lesões em estudos iniciais · en

Medical marijuana for management of cancer pain: a narrative review. — Mendelson AM, Nguyen A, Kohan LR (2026) · DOI 10.21037/apm-25-85 · revisao narrativa · Background and objective The increasing legalization of medical marijuana in the United States (US) has spurred ongoing interest in its clinical application for the management of cancer-related pain. Although medical marijuana is legal in 40 states and the District of Columbia, i · en

Perioperative Repercussions of Cannabis Use-Implications for GI Endoscopy Sedation. — Goudra B, Green M (2025) · DOI 10.3390/jcm14197028 · revisao narrativa · usuários de cannabis podem necessitar de doses mais altas e imprevisíveis de sedativos · en

Cannabinoids and drug-drug pharmacokinetic interactions: Deciphering the risks. — Papakyriakopoulou P, Valsami G, Ismailos G (2026) · DOI 10.1002/bcp.70430 · revisao narrativa · The relationship between cannabinoids and mental health has become a major focus of scientific inquiry and public discourse. Cannabinoids are diverse chemical compounds from the Cannabis species that have been explored for their therapeutic applications in treating chronic pain, · en

Cannabis Use and Outcomes in Breast Surgery. — Hamzeh BF, Haas EJ, Egan KG, Winocour J, Yu JW, Mathes DW et al. (2026) · DOI 10.1097/gox.0000000000007573 · revisao narrativa · aumenta risco perioperatório em reconstrução mamária ~hematoma, infecção, tromboembolismo · en

Toxicity and health effects of delta-8, delta-9, and delta-10-tetrahydrocannabinol and unregulated cannabinoids in vaping products. — Lin K, Sun Y, Raghu R, Suharu P, Effah F, Rahman I (2026) · DOI 10.1016/j.toxrep.2026.102202 · revisao narrativa · exposição crônica ao vapor de cannabis pode causar efeitos adversos no cérebro e pulmões · en

Medical Cannabis for Best Supportive Care of Patients Affected by Cancers of the Head and Neck: A Narrative Review. — Perri F, Marciano ML, Zotta A, Pontone M, Piccirillo A, Casale M et al. (2026) · DOI 10.21873/invivo.14172 · revisao narrativa · efetivo na gestão de sintomas como dor crônica e náusea · en

Therapeutic potential of acidic cannabinoids: an update. — Singh SK, Antoine C, Tse C, Ji L, Reed M, Carter WG et al. (2026) · DOI 10.1186/s42238-026-00387-y · revisao narrativa · Cannabis sativa yields a wide range of bioactive compounds, including terpenes, flavonoids, and cannabinoids. Tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), cannabigerolic acid (CBGA), and cannabichromenic acid (CBCA) are the acidic biosynthetic precursors of the · en

Transcriptomic comparison on the mechanism of action of four major constituent cannabinoids in hemp extract. — Gao X, Yourick MR, Campasino K, Zhao Y, Sepehr E, Vaught C et al. (2026) · DOI 10.1186/s42238-026-00432-w · pre clinico · impacta metabolismo e tem efeitos benéficos em doenças cardiovasculares, mas efeitos adversos no sistema neural · en

Cannabinoids: Therapeutic Applications, Mechanisms, and Challenges in Modern Medicine. — Gasmi A, Noor S, Piscopo S, Bjørklund G (2026) · DOI 10.2174/0109298673390667251201115054 · pre clinico · Cannabinoids are the active compounds of Cannabis sativa, and they are known to be substitutes for meroterpenes. Almost 480 cannabinoids of different types have been discovered, and among them, 110 are known as phytocannabinoids. Several derivatives of cannabinoids are also produ · en

Health claims about cannabidiol (CBD) at the point-of-sale in three U.S. states with disparate cannabis policies. — Wagoner KG, Horton OE, Suerken CK, Romero-Sandoval EA, Lazard AJ, Cork K et al. (2026) · DOI 10.1016/j.pmedr.2026.103472 · outro · Objectives We assessed point-of-sale advertising for CBD in three states with different cannabis laws (i.e., medical/recreational use; medical only; CBD/low THC) to determine if CBD is marketed in ways that are prohibited by the U.S. Food and Drug Administration (FDA). Under FDA · en

Durable complete response of advanced hepatocellular carcinoma using cannabis oil: a report of two cases. — van den Berg PF, van der Heide F, Ruiter SJS, Slangen JJG, de Groot DJA, van den Broek E et al. (2025) · DOI 10.1186/s42238-025-00353-0 · relato caso · regressão completa em 2 casos de HCC avançado · en

A Cross-Sectional Survey of Cannabis Use and Utility Among Patients Experiencing Dizziness. — Elmi P, Mavedatnia D, Berberi G, Lawrence M, Tohmé A, Hong X et al. (2026) · DOI 10.3390/brainsci16040360 · ensaio clinico · aproximadamente 21% relataram alívio moderado-grande da tontura após uso de cannabis · en

Ewing sarcoma-related pain: potential role of medical cannabis monotherapy in symptom management - a case report. — De Virgilio Suglia C, Spaccavento FA, Turco F, De Trizio A, Giannuzzi R, Tafuri S (2026) · DOI 10.1186/s42238-026-00388-x · relato caso · reduz níveis de dor de VAS 9-10 para 2-3 com cannabis · en

Readiness to Use Medicinal Marijuana in the Practices of Polish Family Physicians. — Florek-Łuszczki M, Lachowski S, Choina P, Chmielewski J, Łuszczki JJ (2026) · DOI 10.3390/jcm15072670 · outro · Background/Objectives : Although therapeutic use of medicinal marijuana by patients in Poland became legal in 2017, there remains doubt among primary care physicians (PCPs) related to prescribing medicinal marijuana to their patients. In this study, we aimed to investigate the at · en

Nanotechnology for the Efficacious Delivery of Medicinal Cannabis and Pharmaceutical Medicines. — Vitetta L, Henson JD, Hayes E, Rutolo D, Hall S (2025) · DOI 10.3390/ph18091385 · outro · The application of nanoparticles as nanomedicines, particularly for the targeted and efficacious delivery of drugs is an expanding platform in the field of cannabinoid and pharmaceutical drug delivery. By refocusing the route of drug administration beyond the oral gut pathway, th · en

A pilot study of dronabinol for the treatment of pain in sickle cell disease. — Curtis SA, Jhawar R, Bellis J, McCuskee S, Devine L, Roberts JD (2025) · DOI 10.1186/s40814-025-01705-6 · ensaio clinico · Background Many adults living with sickle cell disease (SCD) suffer from chronic pain, turning to cannabis for relief. However, there are few studies that examine the efficacy of cannabis in treating pain associated with SCD. Prior to an efficacy study, a feasibility study is nec · en

Quantitative Analysis of Cannabinoid Therapy in Prostate Cancer: Integrating Biomarkers, Imaging, and Patient Outcomes. — Gallow S, Adrian Ross AH, Mkhize BT, Pillay P, Tonkin K (2026) · DOI 10.1159/000550792 · ensaio clinico · cannabis associado a maior redução da dor e melhora no bem-estar emocional · en

Does Cannabinoid Use Reduce Opioid Utilization Among Patients with Gastrointestinal Cancer? Evidence from Epic COSMOS. — Worku EB, Woldesenbet SA, Pawlik TM (2026) · DOI 10.3390/cancers18071110 · outro · Purpose Whether medical cannabis reduces opioid use during early chemotherapy remains unclear. We examined cannabinoid and opioid prescribing among patients with GI cancers initiating chemotherapy. Methods Patients with GI cancers initiating chemotherapy (2016-2025) were identifi · en

Is cannabidiol an effective treatment for schizophrenia? — Guinguis R, Ruiz MI, Rada G (2017) · DOI 10.5867/medwave.2017.07.7010 · meta analise · provavelmente não melhora sintomas em esquizofrenia · es

Cannabidiol for psychotic disorders: A meta-analysis of randomized controlled trials. — Marchi M, Rachedi K, Bof A, Mele G, Pingani L, Ferrari S et al. (2026) · DOI 10.1177/02698811261430501 · meta analise · Background Cannabidiol (CBD) is being investigated as a novel antipsychotic treatment, but its effects on psychosis are mainly drawn from pre-clinical studies, leading to uncertainty about its clinical impact. Aims To evaluate the efficacy and tolerability of CBD in patients with · en

Cannabidiol for the treatment of positive and negative symptoms in schizophrenia spectrum disorders: a systematic review and meta-analysis. — Di Francesco A, Cutrufelli P, Chiarenza C, Zambuto L, Concerto C, Mineo L et al. (2026) · DOI 10.1007/s00406-026-02249-3 · meta analise · reduz sintomas positivos e gerais ~1.91 vs placebo · en

The Relationship Between Cannabis Use and Schizophrenia As a Risk Factor or For Its Therapeutic Potential: A Systematic Review of Evidence. — Rajput J, Narahari S, Arif T, Iftikhar R, Arpan T, Tariq A et al. (2025) · DOI 10.7759/cureus.92793 · revisao sistematica · risco de desenvolver esquizofrenia significativamente maior com uso de cannabis rica em THC · en

The differential effects of medicinal cannabis on mental health: A systematic review. — de Bode N, Kroon E, Sznitman SR, Cousijn J (2025) · DOI 10.1016/j.cpr.2025.102581 · revisao sistematica · alta dose de CBD alivia ansiedade aguda · en

The endocannabinoid system as a therapeutic target in prodromal psychosis: From molecular mechanisms to clinical applications. — Ricci V, Sarni A, De Berardis D, Martinotti G, Maina G (2026) · DOI 10.1177/02698811251389574 · revisao sistematica · promising results with ECS-targeted interventions · en

Cannabidiol and cognition: a literature review of human randomized controlled trials. — Singh J, Ellingson CJ, Shafiq MA, Alcorn J, Neary JP (2025) · DOI 10.1097/fbp.0000000000000837 · revisao sistematica · mild improvements em atividades diárias com 75-300 mg CBD · en

Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial — McGuire P, Robson P, Cubala WJ, et al. (2018), American Journal of Psychiatry · DOI 10.1176/appi.ajp.2017.17030325 · ensaio clinico rct · Menos sintomas positivos vs placebo · en

A single dose of cannabidiol modulates the relationship between hippocampal glutamate and learning-related prefrontal activation in individuals at Clinical High Risk of Psychosis. — Shi Y, Davies C, Wilson R, Appiah-Kusi E, Lythgoe DJ, Modinos G et al. (2026) · DOI 10.1016/j.pscychresns.2025.112095 · ensaio clinico rct · normaliza a relação entre glutamato hipocampal e ativação pré-frontal em indivíduos em risco de psicose · en

Does cannabidiol reduce the adverse effects of cannabis in schizophrenia? A randomised, double-blind, cross-over trial. — Chesney E, Oliver D, Sarma A, Lamper AD, Slimani I, Lloyd M et al. (2025) · DOI 10.1038/s41386-025-02175-3 · ensaio clinico rct · não atenua efeitos agudos da cannabis e pode exacerbar sintomas psicóticos · en

Effects of cannabidiol on behavioral and psychological symptoms of vascular dementia: A randomized, double-blind, placebo-controlled clinical trial. — Pessoa RMP, Zuardi AW, Martins-Filho RKV, Rodrigues GR, Hallak JEC, Crippa JAS et al. (2026) · DOI 10.1177/02698811251390974 · ensaio clinico rct · reduz BPSD significativamente em comparação ao placebo · en

Placebo effects in a RCT assessing 30 days of low dose Cannabidiol (CBD) treatment for psychological distress in stressed students at risk for depression. — Winkler A, Meis AC, Hermann C (2025) · DOI 10.1186/s42238-025-00366-9 · ensaio clinico rct · sem diferença significativa entre CBD e placebo · en

CB1 receptor-enriched functional connectivity analysis revealed target-specific modulation by cannabidiol in early psychosis. — Lombardi G, Shatalina E, O'Neill A, Wilson R, Mehta M, Bhattacharyya S (2026) · DOI 10.1177/02698811261470456 · ensaio clinico rct · reduz FC do córtex insular direito em comparação ao placebo · en

The Paradoxical Effect of Cannabis Use on Cognition in Chronic Psychotic Disorders. — Gorea F, Pelle M, Fiori Nastro F, Gelormini C, Elezi F, Ribolsi M et al. (2026) · DOI 10.3390/pathophysiology33010011 · coorte · cannabis users demonstraram maiores escores no MoCA · en

The Brain Endocannabinoid System is Differentially Regulated in Male and Female Patients with First-Episode Psychosis. — Laurikainen H, Armio RL, Tuominen L, Nyman M, Kirjavainen A, Rajander J et al. (2026) · DOI 10.1093/schbul/sbag038 · caso controle · CB1R disponibilidade é menor em homens com FEP em comparação a homens saudáveis · en

Cannabis and psychosis: minimising harm while maximising therapeutic potential. — Patel R (2026) · DOI 10.1192/bjp.2025.10389 · revisao narrativa · Cannabis use increases the risk of psychosis, but cannabis-based medicinal products may provide additional therapeutic opportunities. Decriminalisation of cannabis has led to wider availability in certain jurisdictions, while in the UK regulated medicinal preparations are not rea · en

[Therapeutical use of the cannabinoids in psychiatry]. — Crippa JA, Zuardi AW, Hallak JE (2010) · DOI 10.1590/s1516-44462010000500009 · revisao narrativa · Cannabidiol tem potencial terapêutico com propriedades antipsicóticas, ansiolíticas e antidepressivas · pt

Psychiatric effects of cannabidiol, cannabinol, and tetrahydrocannabinol: A narrative review of clinical evidence and risk profiles. — Kishi Y, Takumi I, Nakajima-Ohyama KC (2026) · DOI 10.1002/pcn5.70383 · revisao narrativa · nenhum benefício clínico consistente observado · en

Cannabis and Mental Health: A Review. — Kansagara D, Terry GE, Ayers CK, D'Souza DC (2026) · DOI 10.1001/jamainternmed.2025.8215 · revisao narrativa · cannabidiol pode reduzir ansiedade em pacientes com transtornos de ansiedade · en

The Endocannabinoid System in Neuropsychiatric Disorders: Mechanisms, Dysregulation and Therapeutic Potential. — Mušić T, Turnšek TL (2026) · DOI 10.3390/biomedicines14050968 · revisao narrativa · The endocannabinoid system (ECS) is a fundamental regulator of brain and body homeostasis, integrating neural, immune, and stress-related signaling pathways. Dysregulation of ECS components, including cannabinoid receptors (CB1 and CB2), endocannabinoids such as anandamide (AEA) · en

Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug — Zuardi AW, Crippa JAS, Hallak JEC, Moreira FA, Guimarães FS (2006), Brazilian Journal of Medical and Biological Research · DOI 10.1590/S0100-879X2006000400001 · revisao narrativa · Evidência pré-clínica e clínica inicial de ação antipsicótica · pt

Unraveling Cannabidiol's Dual Modulatory Role in Schizophrenia: Network Pharmacology and In Vivo Validation of Neuroinflammatory and Behavioral Modulation. — Wei Y, Liu X, Lin S, Jia Z, Liu L, Wang B et al. (2025) · DOI 10.1007/s12035-025-05608-8 · pre clinico · alivia sintomas de SCZ e melhora comportamento social (p<0.0001) · en

The Role of Fatty Acid Amide Hydrolase, a Key Regulatory Endocannabinoid Enzyme, in Domain-Specific Cognitive Performance in Psychosis. — Weidenauer A, Garani R, Lalang N, Watts J, Lepage M, Rusjan PM et al. (2025) · DOI 10.1093/schbul/sbae212 · ensaio clinico · associações entre alterações endocanabinoides e desempenho cognitivo específico · en

Genetic Insights into Cannabis-induced Psychosis: Role of CNR1 Gene Mutation (rs1049353) and Implications- A Cross-sectional Study. — Sahoo S, Swain SP, Samal A, Jena M, Das PP (2025) · DOI 10.1177/02537176251377498 · ensaio clinico · CIP patients showed a significant rise in homogenous allele expression vs schizophrenia cases · en

Cannabidiol attenuates methamphetamine-induced psychosis via anti-oxidative stress: σ1R-mediated mitochondrial dysfunction as a critical pathway. — Liu L, Wang C, Tian Y, Yin Y, Rao M, Tao H et al. (2026) · DOI 10.1016/j.phymed.2026.158015 · ensaio clinico · alivia comportamentos ansiosos induzidos por METH · en

Acceptability of cannabidiol as a treatment for people at clinical high risk for psychosis — Oliver D, Chesney E, Wallman P, Estradé A, Azis M, Provenzani U et al. (2026), medRxiv · DOI 10.64898/2026.03.05.26347694 · outro · null · en

Cannabidiol (CBD) does not reduce cocaine reward or self-administration in a mouse model of schizophrenia genetic susceptibility. — Chesworth R, Watt G, McLemon E, Karl T (2026) · DOI 10.1016/j.pnpbp.2026.111676 · pre clinico · CBD não reduz auto-administração de cocaína em camundongos Nrg1 TM HET · en

Specific psychiatric symptoms during cannabis use and their relation to psychotic disorders. — Buciuta A, Coman HG, Nemeș B, Oroian R, Lesinschi A, Caranfil N et al. (2026) · DOI 10.4103/indianjpsychiatry_190_25 · ensaio clinico · possibilidade de utilizar CEQ-6 como ferramenta de triagem para identificar usuários em alto risco de psicose · en

Acceptability of cannabidiol as a treatment for people at clinical high risk for psychosis. — Oliver D, Chesney E, Wallman P, Estradé A, Azis M, Provenzani U et al. (2026) · DOI 10.3389/fpsyt.2026.1823912 · outro · 75% dispostos a usar CBD para problemas de saúde mental · en

Psychotic Risk Associated With Cannabinoid Use: A Case Report of Ekbom-Like Delusional Infestation. — Pao Trigo M, Cavaco Rogrigues J, Luz B, Sá Couto J, Mota Oliveira M (2026) · DOI 10.7759/cureus.100945 · relato caso · aumenta risco de psicose com uso crônico de canabinoides · en

Effects of pimavanserin, xanomeline and highly-purified plant-derived cannabidiol on MK-801-induced behaviours in mice relevant to psychosis. — Cilia J, Guillermin-Escobar O, McCreary AC, Virley D, Li J (2026) · DOI 10.1177/02698811261456216 · outro · Background Psychosis, as a comorbidity, is seen in many neuropsychiatric and neurodegenerative disorders and is often treated with dopamine D 2 receptor (D 2 R) antagonists, which could aggravate Alzheimer's disease and Parkinson's disease (PD) symptoms. Hence, there is a need fo · en

The endocannabinoid system and ophthalmic pathologies: a review of molecular mechanisms and its implications for clinical practice. — Charytoniuk T, Półjanowski S, Michalak M, Kaźmierczak K, Kałużny B (2025) · DOI 10.3389/fmed.2025.1500179 · revisao sistematica · Within the last decade the role of the endocannabinoid system (ECS) has been a significant part of ophthalmic research, including both ocular physiology and the development of eye pathologies. It is known that this widespread cell-signaling system is involved in retinal neurobiol · en

&lt;i&gt;Cannabis&lt;/i&gt; Medicine 2.0: Nanotechnology-Based Delivery Systems for Synthetic and Chemically Modified Cannabinoids for Enhanced Therapeutic Performance. — Żółnowska I, Gostyńska-Stawna A, Jelińska A, Stawny M (2025) · DOI 10.3390/nano15161260 · revisao sistematica · The therapeutic potential of cannabinoids and other ligands of cannabinoid receptors attracts considerable attention due to their diverse pharmacological effects and utility in various medical applications. However, challenges such as low solubility, limited bioavailability, and · en

Short-Term Daily Oral Administration of Cannabidiol Does Not Impact Rebound Tonometry Intraocular Pressure or Schirmer Tear Test Values in Healthy Adult Horses. — Diehl K, Sheridan C, Reed R (2026) · DOI 10.1111/vop.70188 · ensaio clinico rct · não impacta IOP ou STT · en

Single oral administration of dronabinol increases ocular blood flow in patients with glaucoma. — Lindner T, Pai V, Janku P, Hommer N, Hommer A, Abensperg-Traun M et al. (2026) · DOI 10.1111/aos.17573 · ensaio clinico rct · aumenta fluxo sanguíneo ocular em 10 mg dronabinol ~10.8% vs placebo · en

[Cannabinoid applications in glaucoma]. — Pinar-Sueiro S, Rodríguez-Puertas R, Vecino E (2011) · DOI 10.1016/j.oftal.2010.11.015 · revisao narrativa · reduz pressão intraocular e tem efeito neuroprotetor · es

Adverse Ocular Impact and Emerging Therapeutic Potential of Cannabis and Cannabinoids: A Narrative Review. — Bondok M, Nguyen AX, Lando L, Wu AY (2024) · DOI 10.2147/opth.s501494 · revisao narrativa · reduz pressão intraocular a curto prazo · en

Pharmacokinetics of Cannabinoids Delivered by Diverse Routes in Rodents. — Godbole SS, Raup-Konsavage WM, Vrana KE (2026) · DOI 10.1159/000551979 · revisao narrativa · Background The rising popularity of medicinal and recreational use of Cannabis sativa L. has prompted a parallel increase in the number of studies administering the plant and extracts of its constituent compounds to animal models. Typical routes of administration of Cannabis to a · en

From Plant to Extract: Different Factors in the Extraction of &lt;i&gt;Cannabis sativa&lt;/i&gt; L. Inflorescences. — Lima SNA, de Souza ML, Andrade MEN, Lima KRS, Rolim Neto PJ, Rolim LA (2026) · DOI 10.1177/25785125261454834 · revisao narrativa · Introduction Cannabis sativa presents a highly complex phytochemical matrix, with numerous bioactive constituents, especially phytocannabinoids and terpenes, which justify the growing medicinal and industrial interest. As extraction strongly influences the chemical profile of the · en

Cannabinoids as Multitarget Drugs for the Treatment of Autoimmunity in Glaucoma. — Pk L, Pawar RS, Katare YK, Sudheesh MS (2025) · DOI 10.1021/acsptsci.4c00583 · revisao narrativa · Diseases of multifactorial origin like neurodegenerative and autoimmune diseases require a multitargeted approach. The discovery of the role of autoimmunity in glaucoma and retinal ganglionic cell (RGC) death has led to a paradigm shift in our understanding of the etiopathology o · en

Elevated relative humidity significantly decreases cannabinoid concentrations while delaying flowering development in &lt;i&gt;Cannabis sativa&lt;/i&gt; L. — Corredor-Perilla IC, Kwon TH, Park SH (2025) · DOI 10.3389/fpls.2025.1678142 · ensaio clinico · reduz concentrações de canabinoides sob alta umidade · en

Feasibility of medicinal cannabis cultivation in outdoor conditions using municipal reclaimed water. — Bosco T, Lozada M, Faleschini M, Bigatti G (2026) · DOI 10.1186/s42238-026-00433-9 · ensaio clinico · dried flower yields ~267.77 g/plant · en

An assessment of the prevalence of cannabis use in eye clinic patients and its implications on glaucoma diagnosis and management. — Adamek AJ, Hussein MA, Abdulkarim I, Orengo-Nania S, Sheheitli H (2025) · DOI 10.1007/s10792-025-03846-2 · ensaio clinico · 15.7% dos pacientes relataram uso recente de maconha · en

Targeted phytocannabinomics provides new insights into the biosynthetic origin of cis-Δ⁹-THCA in Cannabis sativa L. — Buccolieri L, Paris R, Fulvio F, Alberti I, Citti C, Cannazza G (2026) · DOI 10.1016/j.jpba.2026.117510 · outro · Recent studies have reported the occurrence of cis-Δ⁹-tetrahydrocannabinol (cis-Δ⁹-THC) and its carboxylated precursor, cis-Δ⁹-tetrahydrocannabinolic acid (cis-Δ⁹-THCA), minor isomers of the well-known trans counterparts. However, their origin remains unclear and several hypothes · en

Vapor pressure measurements on Δ&lt;sup&gt;9&lt;/sup&gt;-tetrahydrocannabinol, cannabidiol, and cannabinol to inform cannabis breathalyzer development. — Beuning CN, Berry JL, Paulechka E, Huber ML, Jeerage KM, Widegren JA et al. (2026) · DOI 10.1088/1752-7163/ae3794 · outro · Δ 9 -tetrahydrocannabinol (THC), the main psychoactive compound in cannabis, and other drug molecules that have large molar masses, are often described as 'nonvolatile' and are presumed to be carried in exhaled breath aerosols. Large variabilities in THC concentrations in breath · en

Factors influencing the recovery of Δ&lt;sup&gt;9&lt;/sup&gt;-tetrahydrocannabinol, cannabidiol, and cannabinol from a breath sampling device. — Berry JL, Gregg ME, Jeerage KM (2026) · DOI 10.1088/1752-7163/ae6d2c · ensaio clinico · recuperação de canabinoides melhorada com microeluição · en

Liquisolids as a platform for the formulation of cannabis tablets. — Appelhaus J, Wagner KG, Steffens KE (2026) · DOI 10.1016/j.ijpx.2026.100508 · outro · Mesoporous silica-based liquisolids offer an effective method for transforming liquid or sticky actives, such as cannabis extracts, into free-flowing powders. This approach broadens the formulation strategies available for these actives, which are typically limited to liquid form · en

Cannabidiol inhibits TGF-β1-induced epithelial-mesenchymal transition in human conjunctival epithelial cells by interrupting TGF-β/Smad signaling. — Baskan A, Awad EM, Elahi A, Pervaiz J, Barisani-Asenbauer T (2025) · DOI 10.1038/s41598-025-25216-9 · outro · previne EMT e secreção de IL-6 · en

Genetic architecture of phenological, morphological, and phytochemical traits in Cannabis landraces. — Babaei M, Torkamaneh D (2026) · DOI 10.1002/tpg2.70243 · outro · Despite its long history of cultivation and diverse applications, Cannabis sativa remains underexplored at the genomic level, particularly in landrace populations that harbor untapped genetic diversity. In this study, we investigated the genetic architecture of 145 Iranian cannab · en

The interplay of maturity-onset diabetes of the young, obesity, uncontrolled hypertension, and cannabinoid hyperemesis in the progression to end-stage renal disease: a case report. — Ngardig Ngaba N, Lovallo V, ONeil A, Quidet XLT, Asare M, Nabeta H et al. (2026) · DOI 10.3389/fmed.2026.1755934 · relato caso · null · en

The Structure of the Chemotype Determining Locus in &lt;i&gt;Cannabis sativa&lt;/i&gt;. — Allen K, Torres A, Gaudino R (2026) · DOI 10.1002/pld3.70166 · outro · The chemical phenotype (chemotype) of Cannabis sativa is defined by the ratio of cannabidiolic acid (CBDA) to Δ9-tetrahydrocannabinolic acid (THCA). Although the Mendelian segregation of these traits suggests a single-locus biallelic system, recent sequencing and phylogenetic evi · en

In silico receptor binding and ex vivo nasal epithelial membrane permeation studies of selected phytocannabinoids. — Van Niekerk SE, Cloete T, Van der Kooy F, Hamman JH (2026) · DOI 10.1186/s42238-025-00363-y · outro · identificados compostos com afinidade para o receptor CB2 que podem ter atividade contra enxaqueca · en

Effect of orally administered cannabidiol oil on daily tonometric curve in healthy Italian Saddle horses. — Bazzano M, Laus F, Cerquetella M, Spaterna A, Marchegiani A (2025) · DOI 10.1371/journal.pone.0325191 · ensaio clinico · reduz pressão intraocular significativamente em cavalos · en

Effect of &lt;i&gt;O&lt;/i&gt;-acetylation on ketene and carbonyl yields from conventional and emerging cannabinoids. — Evans RL, Corley CN, Hunsaker HC, Nicklisch SCT, Ehrlich AK, Nguyen TB (2026) · DOI 10.1039/d6an00190d · outro · produz ketene e carbonilos a partir de canabinoides acetilados · en

Impacts of Global Cannabis Policy Changes on Substance Use: A Systematic Review of Quasi-Experimental Studies. — Windle SB, Socha PM, Arneja J, Harper S, Gore G, Gariépy G et al. (2026) · DOI 10.1111/1468-0009.70108 · revisao sistematica · aumenta prevalência de uso de cannabis entre adultos · en

Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis — Nielsen S et al. (2017), Neuropsychopharmacology · DOI 10.1038/npp.2017.51 · meta analise · Redução significativa da dose de opioide (pré-clínico/clínico) · en

Global burden of disease due to opioid, amphetamine, cocaine, and cannabis use disorders, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. — Zhu DT, Kwon YIC, Lai A, Park AM, Barnes AJ, Chapman DA (2025) · DOI 10.1371/journal.pone.0328276 · revisao sistematica · Drug use disorders (DUDs) represent a major global health challenge, leading to substantial morbidity and mortality, while also being compounded by social and structural barriers. In this study, we examined global epidemiological trends in DUDs over the past three decades to info · en

Association between state cannabis laws and opioid outcomes: A systematic review. — Fink DS, Gorfinkel L, Gutkind S, Bachowski D, Mannes ZL, Livne O et al. (2026) · DOI 10.1016/j.drugalcdep.2026.113167 · revisao sistematica · Background Through increasing cannabis availability, state cannabis legalization has been posited as one potential solution to the opioid crisis by providing an alternative to long-term opioid use for treating chronic pain. Forty U.S. states have legalized cannabis for medical us · en

Medical cannabis authorization and opioid milligram equivalents over time in patients with chronic pain: a retrospective analysis. — Sexton M, Glodosky NC, Cleveland M, Cuttler C, Lee E, Polston GR et al. (2026) · DOI 10.1093/pm/pnaf113 · coorte · null · en

The role of prescription opioid and cannabis supply policies on opioid overdose deaths. — Cerdá M, Wheeler-Martin K, Bruzelius E, Mauro CM, Crystal S, Davis CS et al. (2025) · DOI 10.1093/aje/kwae210 · coorte · legal cannabis supply não associado a mortes por overdose · en

Co-use of opioids and cannabis versus single-substance use: a national analysis of US adults. — Kang H, Tian J, Milavetz G (2025) · DOI 10.3389/fpubh.2025.1623420 · coorte · Background While many studies have explored the relationship between cannabis and opioid use, few have examined how individuals who use opioids only, cannabis only, or both substances differ in terms of sociodemographic and health-related characteristics. Understanding these diff · en

Medical Cannabis and Opioid Receipt Among Adults With Chronic Pain. — Slawek DE, Zhang C, Dahmer S, Sohler N, Zolotov Y, Starrels JL et al. (2026) · DOI 10.1001/jamainternmed.2025.6496 · coorte · reduz a recepção de opioides prescritos · en

Adverse Effects of Non-Medical Use of Cannabis or Opioids Associated with Adverse Childhood Experiences. — Aslam MV, Rooks-Peck C, Florence C, Barnett SBL, Gaffney C, Swedo EA (2026) · DOI 10.3390/ijerph23050574 · coorte · aumenta risco de efeitos adversos em usuários de NmC e NmO com ≥2 ACEs (aRR = 3.54 e 3.64) · en

Medical Cannabis as an Opiate Alternative: A Prospective Observational Cohort Study. — Caldera FE, Caldera Z, Shofer F, Abramoff B, Lenrow D, Hampton S et al. (2026) · DOI 10.7759/cureus.107248 · coorte · reduz uso diário de opioides em 65% e melhora na dor · en

Early onset of cannabis use and risk for opioid use disorder across two decades in the United States. — Agrawal A, Nelson EC (2026) · DOI 10.1016/j.addbeh.2026.108703 · coorte · Background Opioid use disorder (OUD) and other risky forms of opioid engagement significantly impact the health of Americans. Those who use cannabis at an early age may be at greater likelihood of OUD and riskier forms of opioid misuse. Methods We used data on individuals aged 18 · en

Associations of Cannabis and Tobacco Use With Suicide Attempt, Suicide Death, and Overdose Death Among Veterans Prescribed Opioid Analgesics. — Nguyen N, Leonard S, Byers AL, Austin PC, Krebs EE, Sandbrink F et al. (2026) · DOI 10.1016/j.amepre.2026.108309 · coorte · Introduction Little is known whether cannabis and tobacco use are indicators of suicide-related risks. This longitudinal study examined the associations of cannabis and tobacco use with risks of suicide attempt/death and overdose death over a 2-year follow-up in a cohort of veter · en

Medical Cannabis Use Is Associated With Decreased Opiate Medication Use in a Retrospective Cross-Sectional Survey of Patients With Chronic Pain — Boehnke KF, Litinas E, Clauw DJ (2016), The Journal of Pain · DOI 10.1016/j.jpain.2016.03.002 · transversal · −64% no uso de opioides (auto-relato) · en

Medical Cannabis Laws and Opioid Analgesic Overdose Mortality in the United States, 1999-2010 — Bachhuber MA et al. (2014), JAMA Internal Medicine · DOI 10.1001/jamainternmed.2014.4005 · ecologico · −24,8% na taxa de mortalidade por overdose de opioides · en

Effects of oral cannabidiol (CBD) on spontaneous opioid withdrawal in male and female rats — Jenkins BW, Pang C, Kuang RY, Weerts EM, Moore CF (2025), bioRxiv · DOI 10.1101/2025.10.08.680984 · ensaio clinico · CBD não afetou sintomas físicos de abstinência de opioides · en

Effects of oral cannabidiol (CBD) on spontaneous opioid withdrawal in male and female rats. — Jenkins BW, Pang C, Kuang RY, Weerts EM, Moore CF (2026) · DOI 10.1037/pha0000826 · ensaio clinico · CBD não afetou sintomas de abstinência de opioides · en

The Impact of Medical Cannabis Laws on Cannabis and Opioid Use Disorder Treatment and Overdose-Related Health Care Utilization Among Adults With Chronic Noncancer Pain. — McGinty EE, Wagle P, Luo CL, Seewald NJ, Stuart EA, Tormohlen KN (2025) · DOI 10.1111/1468-0009.70052 · outro · Policy Points Among patients with chronic noncancer pain, state medical cannabis laws did not impact health care use for opioid use disorder. There were no changes in health care use for opioid overdose attributable to medical cannabis laws. Medical cannabis laws do not appear to · en

Motivation and experiences of individuals with opioid use disorder and chronic pain using medical cannabis for 12 months. — Lent MR, Dugosh KL, Varsani K, Jonsson A, Kung T, Galluzzi KE (2025) · DOI 10.1186/s12954-025-01306-9 · outro · reduções nos níveis de dor · en

The association between state cannabis legalization and non-fatal opioid poisonings among adults with employer-sponsored insurance in the United States. — Hou J, Talbert JC, Jayawardhana J (2026) · DOI 10.1016/j.pmedr.2026.103497 · ensaio clinico · reduz não-fatalidades por overdose de opioides ~15.47% com MCD e ~11.92% com RCL · en

Self-reported cannabis use to manage opioid withdrawal symptoms and reductions in opioid use among people who use unregulated opioids: a cross-sectional analysis. — McAdam E, Reddon H, Socías ME, Lake S, Hayashi K, DeBeck K et al. (2026) · DOI 10.1186/s42238-026-00458-0 · ensaio clinico · associado a reduções no uso de opioides (AOR=2.16) · en

Neighbourhood risk factors and spatiotemporal trends for overdoses following cannabis legalization and pandemic restrictions in Toronto, Canada. — Law J, Petric AT (2025) · DOI 10.1016/j.healthplace.2025.103557 · outro · Drug & opioid overdoses in Toronto, Canada, have risen substantially in recent years. To explore possible causes, we spatially analyze associations between overdose incidence data over 2019-2022 and select socioeconomic & built-environment variables among Toronto neighbourhoods. · en

Cannabis legalization and cannabis and opioid use in a large, multistate sample of people who inject drugs: A staggered adoption difference-in-differences analysis. — Haley DF, Beane S, Beletsky L, Yarbrough CR, Linton S, Ibragimov U et al. (2026) · DOI 10.1016/j.drugalcdep.2026.113040 · outro · MCL+RCL associado a 9-11% de redução na probabilidade de uso diário de opioides · en

Intranasal naloxone to treat suspected synthetic cannabinoid overdose: A case report and literature review. — Dickinson J, Buckley T (2025) · DOI 10.9740/mhc.2025.10.248 · relato caso · sugere eficácia do naloxone em overdose por canabinoides sintéticos · en

Relative Risk of All-Cause Mortality Associated With Cannabis Use: A Systematic Review and Meta-Analysis of Cohort Studies. — Alimoradi Z, Lin CY, Myran DT, Solmi M, Pakpour AH (2025) · DOI 10.1002/hsr2.71212 · meta analise · aumenta risco de mortalidade ~53% entre usuários de cannabis vs não usuários · en

Cannabis use patterns, prevalence, and risk factors in Nigeria: a systematic review and meta-analysis. — Odeigah OW, Dumbili EW, Nelson EU (2025) · DOI 10.1186/s42238-025-00337-0 · meta analise · prevalência de uso de cannabis entre adultos é 8.28% · en

Cannabis use among Arab students: a systematic review. — Sabalbal A, Eid M, Kobeissy F, Baroud E, El Hayek S (2025) · DOI 10.3389/fpsyt.2025.1511563 · revisao sistematica · Introduction The rising global prevalence and potential harms of cannabis use among adolescents and young adults are cause for concern. This systematic review focuses on the Arab world, compiling research on cannabis consumption among school and university students, where use has · en

Decriminalization of cannabis use in South Africa: The perspectives and health outcomes among medical students; A systematic qualitative review. — Mokhwelepa LW, Olivia Sumbane G (2025) · DOI 10.1177/22799036251373016 · revisao sistematica · Background The decriminalization of cannabis in South Africa has sparked growing concern within the medical community, particularly among medical students. As future healthcare providers, they must navigate evolving legal and professional landscapes while forming beliefs about th · en

Cannabis use and Cancer: Dissecting genetic causality for site-specific risks through two-sample Mendelian Randomization — Lukhere E, Kachingwe B, Kipandula W, Chiphangwi N, Singini MG, Kamiza AB (2026), medRxiv · DOI 10.64898/2026.08.12.26360176 · ensaio clinico rct · associado a câncer esofágico (OR=1.74) e câncer de pulmão (OR=1.35), efeito protetor contra câncer pancreático (OR=0.77) · en

Association Between Cannabis Use and Tinnitus: A Multi-Center Propensity-Score-Matched Cohort Study. — Ayo-Ajibola O, Jung T, Gonzalves D, Park AC, Lin ME, Kim I et al. (2026) · DOI 10.1002/oto2.70251 · coorte · aumenta risco de tinnitus em 30% vs controle · en

Impact of Preoperative Marijuana Use on Functional Recovery and Complications After Spinopelvic Fusion in Adult Spinal Deformity. — Rostami M, Bagherzadeh S, Soto Rubio D, Saleh D, Kumar J, Kim P et al. (2026) · DOI 10.1227/neuprac.0000000000000218 · coorte · maior melhora no ODI (43.7 vs 37.1, P = .003) · en

Associations between cannabis use, cannabis use motivations and past year polysubstance use among people living with HIV in Florida. — McNeely KV, Seegulam VL, Cook RL, Zhou Z, Wang Y, Porges EC et al. (2026) · DOI 10.1080/09540121.2026.2614344 · coorte · cannabis use associated with significantly higher use of most substances · en

Cigarette and cannabis use and co-use among U.S. adults: An examination of prevalence and trends during 2015-2023. — Constantin J, Jayawardhana J (2026) · DOI 10.1016/j.addbeh.2025.108521 · coorte · aumento do uso apenas de cannabis de 3.9% para 10.6% entre 2015-2023 · en

What Can We Learn From The Portuguese Decriminalization of Illicit Drugs? — Hughes CE, Stevens A (2010), British Journal of Criminology · DOI 10.1093/bjc/azq038 · dados administrativos · Sem aumento de uso problemático; queda de mortes e DST · en

Public Attitudes Toward the Drug Enforcement Administration's Proposal to Reschedule Marijuana: A Cross-Sectional Mixed-Methods Analysis. — Lucas RH, Nahirnyak A, Piliero J, Peterson AM (2025) · DOI 10.1159/000546538 · transversal · Introduction On May 21, 2024, the Drug Enforcement Administration (DEA) published a proposed rule to reschedule marijuana from schedule I to III under the Controlled Substance Act (CSA), followed by a 60-day open comment period. The purpose of this study was to analyze the public · en

Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. Adults. — Yang KH, Satybaldiyeva N, Kepner W, Friedman J, Ping S, Leas EC (2026) · DOI 10.1016/j.amepre.2026.108381 · transversal · Introduction Microdosing involves consuming low doses of psychoactive substances, typically between 1/5th and 1/20th of a recreational dose. Despite increasing public attention to cannabis and psychedelics amid evolving drug policies, epidemiologic data on microdosing remain limi · en

Association Between Recreational Marijuana Legalization and Increases in Cannabis Use and CUD — Cerdá M et al. (2020), JAMA Psychiatry · DOI 10.1001/jamapsychiatry.2019.3254 · ecologico · Aumento modesto de uso/CUD (adultos/adolescentes específicos) · en

Medical Marijuana Laws and Teen Marijuana Use — Anderson DM, Hansen B, Rees DI (2015), American Law and Economics Review · DOI 10.1093/aler/ahv002 · ecologico · Sem aumento estatístico do uso adolescente · en

Cannabis and Psychedelics Among U.S. Young Adults: Use, Messaging Exposure, Perceptions, and Legalization Support. — Berg CJ, LoParco CR, McCready DM, Schubel LC, Cavazos-Rehg PA, Kasson E et al. (2026) · DOI 10.3390/ijerph23020255 · outro · null · en

What Do Thirty Years of Neuroimaging Research Tell Us About Recreational Cannabis Use and Brain Integrity? A Narrative Review of the Multimodal Neuroimaging Evidence to Date. — Murphy E, Suo C, Poudel G, Thomson H, Lorenzetti V (2026) · DOI 10.2147/sar.s584766 · revisao narrativa · menor volume do hipocampo e microestrutura da substância branca · en

Current Status of Cannabis Legalization and Decriminalization Efforts in Nepal. — Pathak N, Dhungana S, Basyal B, Jha PK, Shrestha S, Thapa P et al. (2024) · DOI 10.2147/sar.s466728 · revisao narrativa · The unique historical and cultural background of Nepal has shaped its perspective on cannabis usage. Narcotic Drugs Control Act 1976 of Nepal prohibits the cultivation, production, manufacture, sales, and distribution of narcotic drugs, which also include various forms of cannabi · en

Current recommendations in the diagnosis and management of cannabinoid hyperemesis syndrome. — Meyer J, Burns MM (2025) · DOI 10.1097/mop.0000000000001464 · revisao narrativa · Purpose of review Legalization and decriminalization of marijuana over recent years has led to a significant increase in the prevalence of cannabinoid hyperemesis syndrome (CHS). CHS can be a debilitating syndrome that provides unique challenges to healthcare providers in the bot · en

Adolescents and cannabis in the 21st century: Current Problems in Pediatric and Adolescent Health Care. — Itriyeva K (2025) · DOI 10.1016/j.cppeds.2025.101754 · revisao narrativa · The past 30 years in the United States have seen a shift towards increasing decriminalization and legalization of cannabis products. Despite the evolving legal landscape, adolescent cannabis use appears to have remained relatively stable, while use among young adults has increase · en

Turning over a New Leaf: Medical Cannabis in the Age of Legalization. — Palladino K, Song C, Pierce D (2026) · DOI 10.1016/j.pop.2026.03.012 · revisao narrativa · As medical cannabis becomes more widely legalized, clinicians face growing pressure to advise patients amid limited, inconsistent evidence. This article explores the evolving role of cannabis in treating multiple conditions while highlighting known risks like psychosis, cannabino · en

Protective psychological mechanisms against adolescent cannabis and kratom use: A mixed-methods study. — Mahathamnuchock S (2026) · DOI 10.1177/13591053261472712 · pre clinico · This mixed-methods study examined protective mechanisms against cannabis and kratom use among adolescents in northern Thailand following recent policy changes. Quantitative survey data were collected from 205 students aged 12-16 years, while qualitative focus group discussions we · en

Considerations before the legalization of recreational and medical cannabis in Iran. — Shamabadi A, Akhondzadeh S (2024) · DOI 10.1016/j.ajp.2024.104237 · outro · Cultural perspectives on marijuana consumption have undergone substantial reforms in recent years, and the decriminalization and legalization of cannabis are a matter of debate now. The conditions of determining factors are not the same among societies; therefore, each society sh · en

Decriminalizing and Legalizing Cannabis for Clinical Benefits in Malaysia: Perspective Among Pharmacists (A Qualitative Study). — Koh JA, Loo XJ, Tay JW, Haw Liew BY, Mohammed AH, Rini R et al. (2025) · DOI 10.1080/02791072.2024.2420065 · qualitativo · Cannabis, often criticized, has active compounds that indicate multiple medical benefits. However, before the potential decriminalization and legalization of medical cannabis, pharmacists play a crucial role in the decision-making for personalized therapy and evidence-based medic · en

Exploring perceptions of cannabis use and employment implications among healthcare workers: a single-institution experience. — Lichtenberg AB, Mankabady RE, Mansour M, Wang A, Wagner C, Bay C et al. (2026) · DOI 10.1186/s42238-026-00399-8 · outro · apoia remoção de cannabis da triagem pré-emprego · en

Cannabis Use and Adverse Childhood Experiences Among Cancer Survivors. — Gao MZ, Babatunde OA, Jefferson MS, Adams SA, Hughes Halbert C, Osazuwa-Peters N et al. (2025) · DOI 10.1002/cam4.71400 · ensaio clinico · aumenta as chances de uso de cannabis em sobreviventes de câncer com 2-3 ACEs (aOR: 2.56) e ≥4 ACEs (aOR: 4.10) · en

Tribal Marijuana Possession Laws: Prohibition to Legalization Among Native American Nations. — Ebling T, Hall M, Jensen JK, Azagba S (2025) · DOI 10.1016/j.amepre.2025.108046 · outro · Introduction Amid the significant evolution of marijuana policy in the U.S., with numerous states adopting more permissive regulations, a notable gap exists in understanding how American Indian/Alaska Native tribes govern marijuana within tribal jurisdictions. This study aims to · en

Beyond the high: exploring socioecological influences on cannabis use in older women with and without HIV. — Bobitt J, Franceschini D, Hernandez-Vallant A, Afridi M, Ross RD, Daubert E et al. (2025) · DOI 10.1093/geront/gnaf250 · outro · Background and objectives Cannabis use among older adults in the United States is increasing. While prior research has examined motives and impacts among older adults generally, less attention has focused on women living with HIV. The study examines the experiences and perspectiv · en

Association between marijuana use and erectile dysfunction in a sample of sexual minority men: a cross-sectional analysis. — Otieno M, Zhao Y, Tran A (2026) · DOI 10.1186/s42238-026-00411-1 · ensaio clinico · usuários de marijuana têm 1.83 vezes mais chances de relatar disfunção erétil · en

Cannabis knowledge and health literacy among Thai vocational students: a cross-sectional study following policy liberalization. — Orosram J, Thanawiroon C, Soontara C, Kaewrongkham P, Tangsakul N, Phohom T et al. (2026) · DOI 10.1186/s42238-026-00467-z · ensaio clinico · Background Thailand's decriminalization of cannabis in June 2022 substantially increased adolescent exposure. Cannabis knowledge and health literacy among vocational students remain poorly characterized. Methods A cross-sectional online survey was conducted from January to March · en

Does the total consumption model apply to cannabis use? — Norström T, Leifman H (2026) · DOI 10.1111/add.70353 · outro · Aims To test whether the total consumption model and its extension, the theory of collectivity, apply to adolescent cannabis use. We estimated: (1) whether the distribution of cannabis use frequency was stable over time; (2) whether changes in average cannabis use were mirrored a · en

Long-term effects of adolescent THC exposure on anxiety-like behavior and cognitive function in male rats. — Lumor JS, Nyberg H, Nerem E, Andersen JM, Bogen IL (2026) · DOI 10.1007/s00213-026-07067-y · ensaio clinico · aumenta vulnerabilidade a comportamentos relacionados à ansiedade · en

Cannabis use, sexual behaviors, and HIV prevention behaviors among young adults attending key-population-led sexual health clinics in Bangkok, Thailand: A mixed-method study. — Yimsaard P, Lancaster KE, Ratchatasitthigul T, Janamnuaysook R, Samitpol K, Phanuphak N et al. (2026) · DOI 10.1371/journal.pone.0352395 · outro · associado ao sexo sob influência de substâncias (PR=1.24) · en

Therapeutic effects of cannabinoids on Parkinson's disease: an updated systematic review and meta-analysis of randomized controlled trials. — Messak M, Abdelmageed A, Abbas AN, Mandour Y, Talkhan A, Eltohami MF et al. (2026) · DOI 10.1007/s13760-026-03082-0 · meta analise · não melhora a gravidade da PD (SMD=0.16, p=0.27) · en

Applications of Cannabinoids in Neuropathic Pain: An Updated Review. — Arthur P, Kalvala AK, Surapaneni SK, Singh MS (2024) · DOI 10.1615/critrevtherdrugcarriersyst.2022038592 · revisao sistematica · beneficial for neuropathic pain · en

CBD's potential impact on Parkinson's disease: An updated overview. — Hafida EG, Rachid S, Halima G, Najib K (2024) · DOI 10.1515/med-2024-1075 · revisao sistematica · Background Parkinson's disease (PD) is primarily known as a motor disorder; however, its debilitating non-motor symptoms have a significant impact on patients' quality of life. The current standard treatment, l-DOPA, is used to relieve motor symptoms, but prolonged use is often a · en

Assessing effects of Cannabis on various neuropathologies: A systematic review. — Pathak S, Jeyabalan JB, Liu K, Cook P, Lange B, Kim S et al. (2024) · DOI 10.1016/j.jaim.2024.100911 · revisao sistematica · Natural bioactives possess a wide range of chemical structures that can exert a plethora of pharmacological and toxicological actions, resulting in neuroprotection or neurotoxicity. These pharmacodynamic properties can positively or negatively impact human and animal global healt · en

Cannabidiol (CBD): A Systematic Review of Clinical and Preclinical Evidence in the Treatment of Pain. — Cásedas G, Yarza-Sancho M, López V (2024) · DOI 10.3390/ph17111438 · revisao sistematica · suficiente evidência clínica e pré-clínica de CBD na redução da dor · en

Randomized Laboratory Study of Single-Dose Cannabis, Dronabinol, and Placebo in Patients With Schizophrenia and Cannabis Use Disorder. — Brunette MF, Roth RM, Trask C, Khokhar JY, Ford JC, Park SH et al. (2025) · DOI 10.1093/schbul/sbae097 · ensaio clinico rct · oral dronabinol SCZ-CUD grupo piorou verbal learning ~10 pontos vs placebo · en

Cannabidiol and cognitive functions/inflammatory markers in Parkinson's disease: A double-blind randomized controlled trial at Buriram Hospital (CBD-PD-BRH trial). — Mitarnun W, Kanjanarangsichai A, Junlaor P, Kongngern L, Mitarnun W, Pangwong W et al. (2025) · DOI 10.1016/j.parkreldis.2025.107841 · ensaio clinico rct · melhora nas pontuações de nomeação (diferença média: 0.37) · en

A Phase Ib, Double Blind, Randomized Study of Cannabis Oil for Pain in Parkinson's Disease. — Di Luca DG, Gilmour GS, Fearon C, Swinkin E, Freitas E, Kuhlman G et al. (2023) · DOI 10.1002/mdc3.13754 · ensaio clinico rct · Background Pain is common in Parkinson's disease (PD), but effective therapies are limited. Objectives To determine the maximum tolerated dose (MTD) and safety of formulations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) for pain in PD. Methods In this phase 1b, do · en

Cannabis-Based Oil for Pain and Other Non-Motor Symptoms in Parkinson's Disease: A Randomized Controlled Trial. — Kubota GT, Parmera JB, Deltreggia M, Martins PN, Alves ALM, de Falcone ACM et al. (2026) · DOI 10.1002/mds.70449 · ensaio clinico rct · não melhora dor ou outros sintomas não-motores vs placebo · en

Double-Blind, Randomized, Placebo-Controlled, Crossover Study of Oral Cannabidiol and Tetrahydrocannabinol for Essential Tremor. — Longardner K, Shen Q, Castellanos FX, Tang B, Gandhi R, Wright BA et al. (2025) · DOI 10.5334/tohm.1005 · ensaio clinico rct · Background Essential tremor (ET) is characterized by often disabling action tremors. No pharmacological agent has been developed specifically for symptomatic treatment. Anecdotal reports describe tremor improvement with cannabis, but no evidence exists to support these claims. We · en

Oral Cannabidiol for Seborrheic Dermatitis in Patients With Parkinson Disease: Randomized Clinical Trial. — Weber I, Zagona-Prizio C, Sivesind TE, Adelman M, Szeto MD, Liu Y et al. (2024) · DOI 10.2196/49965 · ensaio clinico rct · não houve efeito do CBD na gravidade da dermatite seborreica · en

Concomitant use of medical cannabis and drugs associated with risks of interaction in older patients: a longitudinal cohort study. — Bérété ZC, Sebgo AA, Eurich DT, Dubois C, Dyck JR, Hanlon JG et al. (2025) · DOI 10.1093/ageing/afaf359 · coorte · risco de intoxicação 2.61 vs controles · en

Operationalizing ASSIST-based indicators to estimate the prevalence and correlates of problematic cannabis involvement among U.S. college students. — Qeadan F, McCunn A, Aravindan A, Tingey B (2026) · DOI 10.1186/s42238-026-00446-4 · coorte · prevalência de envolvimento problemático com cannabis de 8.66% entre todos os estudantes · en

Acceptability of and attitudes to the therapeutic use of cannabis and cannabidiol in people with Parkinson's disease: A French survey. — Barré T, Cazorla G, Di Beo V, Lopez F, Radoszycki L, Maradan G et al. (2024) · DOI 10.1016/j.prdoa.2024.100286 · transversal · aceitabilidade alta de cannabis ~81.7% e CBD ~87.4% · en

Evaluating the Supporting Evidence of Medical Cannabis Claims Made on Clinic Websites: Cross-Sectional Study. — O'Neill B, Ferguson J, Dalueg L, Yusuf A, Kirubarajan A, Lloyd T et al. (2023) · DOI 10.2196/45550 · transversal · Background Since the legalization of medical cannabis in Canada in 2013, prescription of cannabis for medical purposes has become commonplace and a multibillion dollar industry has formed. Much of the media coverage surrounding medical cannabis has been positive in nature, leadin · en

Cannabinoids and cognition in Parkinson's disease: Insights from animal models and emerging clinical evidence. — Kitchigina VF, Shubina L (2026) · DOI 10.1016/j.neuroscience.2026.03.023 · revisao narrativa · Parkinson's disease (PD) is a progressive, multisystem neurodegenerative disorder characterized not only by motor impairments but also by a broad spectrum of debilitating non-motor symptoms, including cognitive decline. The cognitive function depends on neuronal plasticity, which · en

Recent Preclinical Evidence on Phytocannabinoids in Neurodegenerative Disorders: A Focus on Parkinson's and Alzheimer's Disease. — Blebea NM, Pușcașu C, Hancu G, Stăniguț AM, Chiriță C (2025) · DOI 10.3390/ph18060890 · revisao narrativa · The endocannabinoid system (ECS) is a vital biological network essential for maintaining homeostasis and supporting various physiological functions. It comprises cannabinoid receptors, endogenous lipid-based ligands, known as endocannabinoids, as well as metabolic enzymes and ass · en

Review of the current ongoing clinical trials exploring the possible anti-anxiety effects of cannabidiol. — Bhuller R, Schlage WK, Hoeng J (2024) · DOI 10.1186/s42238-024-00250-y · revisao narrativa · Background Anxiety disorders (ADs) are a complex group of mental disorders and majorly contribute to the global health-related burden. Symptoms and clinical management differ widely depending on the specific diagnosis. There is a need for new, more effective pharmacological treat · en

Cannabidiol-Ion Channel Interactions Represent a Promising Preventive and Therapeutic Strategy in Hepatocellular Carcinoma. — Chávez-López MG, Avalos-Fuentes A, Cruz-Manzo EDC, Aguirre-Arriaga PA, Florán B, Pérez-Carreón JI et al. (2026) · DOI 10.3390/pathophysiology33010008 · revisao narrativa · cannabidiol-ion channel interactions represent a promising strategy in liver cancer therapy · en

Therapeutic Application of Modulators of Endogenous Cannabinoid System in Parkinson's Disease. — Khaspekov LG, Illarioshkin SN (2024) · DOI 10.3390/ijms25158520 · revisao narrativa · The endogenous cannabinoid system (ECS) of the brain plays an important role in the molecular pathogenesis of Parkinson's disease (PD). It is involved in the formation of numerous clinical manifestations of the disease by regulating the level of endogenous cannabinoids and changi · en

Cannabidiol in Neurology: Current Insights and Translational Perspectives — Białoń M, Kędziora M, Starowicz K (2025), Preprints.org · DOI 10.20944/preprints202512.1733.v1 · revisao narrativa · CBD exibe efeitos neuroprotetores e anti-inflamatórios · en

Cannabinoids: Therapeutic Use in Clinical Practice. — Pagano C, Navarra G, Coppola L, Avilia G, Bifulco M, Laezza C (2022) · DOI 10.3390/ijms23063344 · revisao narrativa · potencial terapêutico em várias condições · en

What Do We Know About Medical Cannabis in Neurological Disorders and What Are the Next Steps? — Lacroix C, Alleman-Brimault I, Zalta A, Rouby F, Cassé-Perrot C, Jouve E et al. (2022) · DOI 10.3389/fphar.2022.883987 · revisao narrativa · Medical use of cannabis has been receiving growing attention over the last few decades in modern medicine. As we know that the endocannabinoid system is largely involved in neurological disorders, we focused on the scientific rationale of medical cannabis in three neurological di · en

Medical Cannabis in the Treatment of Parkinson's Disease. — Aladeen TS, Mattle AG, Zelen K, Mesha M, Rainka MM, Geist T et al. (2023) · DOI 10.1097/wnf.0000000000000550 · outro · 87% dos pacientes apresentaram melhora em sintomas de PD após iniciar MC · en

Study on knowledge and perceptions on the uptake of non-medicinal cannabis-substances and preparations by Portuguese consumers: Borderline issues. — Elias A, Rosado C, Costa MDC (2024) · DOI 10.1016/j.heliyon.2024.e40827 · outro · alto grau de satisfação com produtos à base de cannabis · en

Cannabis sativa extracts reduce inclusion formation in a cell model of alpha-synuclein aggregation. — de Almeida Cruz T, de Paulo Osorio R, de Menezes Epifanio NM, Merghani M, Pereira MD, de Almeida Chaves DS et al. (2026) · DOI 10.1016/j.fitote.2025.106968 · ensaio clinico · reduz número de inclusões intracelulares · en

Cannabidiol and Parkinson's disease: Investigating receptor interactions and their therapeutic implications. — Okrah EA, Allan C, Doblin MS, Annesley SJ (2026) · DOI 10.1016/j.pharmthera.2025.108943 · pre clinico · Cannabidiol (CBD) is one of the major active constituents among the several hundreds of compounds found in the cannabis plant. It is a non-psychoactive compound known for its anti-inflammatory, neuroprotective, antidepressant and anxiolytic effects. In preclinical studies it has · en

Cannabidiol improves L-DOPA-induced dyskinesia and modulates neuroinflammation and the endocannabinoid, endovanilloid and nitrergic systems. — Nascimento GC, Bálico GG, de Mattos BA, Dos-Santos-Pereira M, Oliveira IGC, Queiroz MEC et al. (2025) · DOI 10.1016/j.pnpbp.2025.111456 · ensaio clinico · reduz movimentos involuntários anormais significativamente · en

Preventive beneficial effects of cannabidiol in a reserpine-induced progressive model of parkinsonism. — Lima AC, Bioni VS, Becegato MS, Meier Y, Cunha DMG, Aguiar NA et al. (2025) · DOI 10.3389/fphar.2025.1539783 · ensaio clinico · atenua catalepsia induzida por reserpina e previne diminuição na rotulagem de TH · en

Healthcare Providers' Acceptability of Cannabis And Cannabidiol to Manage Parkinson's Disease in France. — Barré T, Cazorla G, Di Beo V, Bianchi C, Baunez C, Carrieri P (2026) · DOI 10.1016/j.curtheres.2026.100830 · outro · aceitação menor para cannabis e maior para CBD entre profissionais de saúde · en

Advice to People with Parkinson's in My Clinic: Cannabis. — de Freitas MET, Fox SH (2024) · DOI 10.3233/jpd-230358 · outro · Cannabis (in all the varied methods of delivery) continues to garner significant attention as a potential therapeutic intervention for neurodegenerative disorders, including Parkinson's disease (PD). The recent legalization of personal use of cannabis products in some parts of th · en

Effects of cannabidiol to circadian period, sleep, life span, close-proximity rhythm, egg reproduction and motor function in Drosophila melanogaster. — Kawasaki H, Sato T, Ishida N (2025) · DOI 10.1007/s10522-025-10305-z · ensaio clinico · melhora qualidade do sono e aumenta a longevidade sob condições de fome · en

[Optimized chromatographic methods for the identification and quantification of terpenes in Cannabis sativa oil for medicinal use] — Bajda L, Amaro MM, Bongiovanni GA (2023) · DOI 10.31053/1853.0605.v80.n2.39593 · outro · Introduction Cannabis sativa is a plant species with numerous active principles, so the list of its therapeutic uses is expanding. In this sense, there are numerous evidences of the possible medicinal use of terpenes, as well as their synergism with cannabinoids (entourage effect · es

The Colombian Medical Cannabis Paradox: A Scoping Review of Structural Barriers and Health Inequity. — Marín Arroyave OP, León Cruz P (2025) · DOI 10.3390/ijerph22121792 · revisao sistematica · Background: Law 1787 of 2016 established Colombia's medical cannabis framework, intended as a public policy to improve health equity by guaranteeing access and promoting inclusive development. This scoping review analyzes this policy's implementation as a social determinant of he · en

Characteristics of trauma patients involved in motor vehicle collisions before and after legalization of medical marijuana in Pennsylvania. — Gimbel K, Marco CA (2026) · DOI 10.1016/j.ajem.2025.10.008 · caso controle · aumento de acidentes de trânsito envolvendo motoristas que testaram positivo para maconha · en

Home Cultivation of Cannabis in a Context of Prohibition: Results from Two Online Cross-Sectional Surveys of People Using Cannabis Daily in France. — Bastien M, Mezaache S, Donadille C, Madrid LB, Lebrun M, Martin V et al. (2025) · DOI 10.3390/ijerph22081167 · transversal · In recent decades, European countries have seen a substantial increase in home cultivation of cannabis. In France, the prevalence of cannabis use continues to increase despite its possession, sale, and cultivation being strictly illegal. The present study aimed to describe the pr · en

Patterns of cannabis cultivation, cannabis and other drug use and market participation among Georgian small-scale cannabis growers: Results of online cross-sectional survey. — Mgebrishvili T, Kirtadze I, Potter GR, Otiashvili D (2025) · DOI 10.1016/j.drugpo.2025.104842 · transversal · Background The study aims to assess the demographic characteristics, patterns of cannabis cultivation, use of cannabis and other drugs, and market participation of cannabis growers in Georgia. Methods We conducted an online survey of Georgian cannabis growers. The International C · en

Population-based cross-sectional analysis of cannabis use among Kentucky adults, 2020-21. — Shafer S, Kennedy G, Christian WJ (2024) · DOI 10.1186/s42238-024-00251-x · transversal · Purpose We conducted this study to assess cannabis use rates in the state of Kentucky relative to socioeconomic, demographic, and geographic factors, as well as reasons for use and modes of use, before the legal medical marijuana market commences in 2025. Methods We pooled Kentuc · en

A user-informed perspective of the toxicological data gap in India's cannabis landscape. — Riyaz M (2025) · DOI 10.3389/ftox.2025.1734313 · revisao narrativa · Clinical research on cannabinoids relies on purified compounds and controlled dosing, creating a data gap that ignores the realities of illicit markets. This perspective, informed by thirteen years of firsthand experience within India's prohibited cannabis ecosystem, argues that · en

[The Road towards the Responsible and Safe Legalization of Cannabis Use in Portugal]. — Baptista-Leite R, Ploeg L (2018) · DOI 10.20344/amp.10093 · revisao narrativa · Introduction Recently, the world has seen examples of the legalization of cannabis for recreational purposes. Due to the diversity of experiences in progress, it is urgent to analyze the impacts of this legalization, from a public health perspective. Therefore, this article aims  · pt

How have cannabis use and related indicators changed since legalization of cannabis for non-medical purposes? Results of the Canadian Cannabis Survey 2018-2022. — Goodman S, Dann MJ, Fataar F, Abramovici H (2024) · DOI 10.1016/j.drugpo.2024.104385 · revisao narrativa · aumento de consumo de cannabis de 22% em 2018 para 27% em 2022 · en

The regulatory and scientific context in the study of the medicinal use of cannabis in Peru. — Wong-Salgado P, Moya-Salazar J, Contreras-Pulache H, Pardo-Villarroel C (2025) · DOI 10.3389/fmed.2025.1598227 · revisao narrativa · Cannabis has been historically utilized for medicinal purposes worldwide. However, it was classified as a controlled substance under the United Nations' 1961 Single Convention on Narcotic Drugs, alongside coca and opium. This classification influenced many countries, including Pe · en

Post-legalization shifts in cannabis use among young adults in Georgia-A nationally representative study. — Nadareishvili I, Rao SR, Otiashvili D, Gnatienko N, Samet JH, Lunze K et al. (2025) · DOI 10.1111/add.16688 · ensaio clinico · mínima mudança no uso de cannabis entre jovens adultos após a legalização · en

Attitudes of Patients with Non-Psychotic Mental Disorders Towards Cannabis After Its Legalization-Comparison with Patients Before Legalization. — Specka M, Rabl J, Bonnet U, Rosner M, Schmitt A, Scherbaum N (2026) · DOI 10.3390/brainsci16070730 · ensaio clinico · reduz medo de investigação policial · en

Measuring commercial cannabis availability: findings from a multi-state surveillance study in the US. — Nargis N, Asare S, Westmaas JL (2025) · DOI 10.1093/haschl/qxaf209 · outro · Introduction Cannabis legalization enables greater access to commercial cannabis among adults. Little is known about the extent to which demand for cannabis is met by licit or illicit markets among states with medical-only or recreational cannabis laws, or no legalization. Method · en

Commercial cannabis product testing: Fidelity to labels and regulations. — Limbacher SA, Godbole S, Wrobel J, Mackie DI, Goldman S, Brooks-Russell A (2026) · DOI 10.1371/journal.pone.0321832 · observacional · label values foram mais altos que os valores observados em produtos de flor e comestíveis · en

Medicinal Cannabis and Consumer Vulnerability in Australia: A Nexus of Policy and Market Factors. — Gething K, Erku D, Scuffham P (2025) · DOI 10.1111/hex.70176 · outro · Introduction Following the 2016 legalization of medicinal cannabis (MC) in Australia, significant barriers have led patients to seek unregulated cannabis for therapeutic use. This study examines consumer (patient, carer and family) submissions to a senate inquiry on these barrier · en

Bridging the gap: Exploring consumer experiences and motivations for transitioning between illicit and regulated cannabis markets. — Donnan JR, Howells R, Farooq S, Maillet M, Harris-Lane LM (2024) · DOI 10.1016/j.drugpo.2024.104644 · outro · Background Canada pioneered the non-medical legalization of cannabis production and sales, witnessing substantial growth in the regulated market over the last five years, post-legalization. However, persistent barriers hinder many consumers from transitioning to the legal market, · en

Is cannabis legalization associated with treatment completion? A study of pregnant women admitted for cannabis use in substance use treatment facilities, 2020-2022. — Carandang RR, Rhee TG, Ha T, Cunningham SD (2026) · DOI 10.1016/j.drugalcdep.2026.113023 · ensaio clinico · reduz a conclusão do tratamento (AOR 0.33) em estados com cannabis legalizada · en

Revisiting the Gateway Drug Hypothesis for Cannabis: A Secondary Analysis of a Nationwide Survey Among Community Users in Japan. — Masataka Y, Katayama M, Umemura F, Sugiyama T, Miki N, Akahoshi Y et al. (2025) · DOI 10.1002/npr2.70033 · ensaio clinico · sugere baixa probabilidade de progressão para outras drogas após uso de cannabis · en

Marijuana use and its association with unhealthy weight control and muscle-enhancing behaviors among sexual minority men in the United States: a cross-sectional analysis. — Ibeh C, Zhao Y, Tran A (2026) · DOI 10.1186/s42238-026-00398-9 · ensaio clinico · maior probabilidade de comportamentos de controle de peso não saudáveis (AOR até 3.12) · en

Variations in Regulated Cannabis Sales Conditions and Their Effect on Purchase Behaviour: Findings from an Observational Study. — Heckel N, Buschner M, Engeli EJE, Dürler P, Havelka EM, Haas M et al. (2026) · DOI 10.1159/000551031 · observacional · impact on purchase frequency was negligible · en

Increasing cannabis use is associated with increased social discount rates and decreased self-reported social use in college students. — Romanowich P, Connor-Smith C, Eugenio K, Nelson P (2026) · DOI 10.1037/pha0000849 · ensaio clinico · uso de cannabis acima da mediana está associado a menor compartilhamento de cannabis · en

Estimating Price Elasticity of Cannabis Use Among U.S. Adolescents: Evidence From States With Recreational Cannabis Commercialization. — Han B, Park H, He Y, Shang C, Shi Y (2026) · DOI 10.1016/j.jadohealth.2025.08.021 · ensaio clinico · aumento de preços de cannabis associado a menor probabilidade de uso atual · en

Quantification of THC, heavy metals, pesticides, mycotoxins, and microbial contaminants in cannabis inflorescence reveals higher levels in illicit samples than in the licensed Canadian market — Fiering Q, MacKey J, Kim H, Risha Y, Denkert R, Iuogovaz M et al. (2025), Research Square · DOI 10.21203/rs.3.rs-8186487/v1 · outro · THC levels em 48% dos produtos licenciados desviaram mais de 20% das concentrações rotuladas · en

Influence of Socio-Ecological and Economic Correlates on Marijuana Legalization Policy Across the States of America. — Salehin M, Pillai VK (2025) · DOI 10.3390/ijerph22060823 · outro · Marijuana legalization has been at the center of debate in the social and political realm of the United States. So far, thirty nine states and the District of Columbia have legalized marijuana either for recreational or medical purposes. States are taking a cautious approach to l · en

Revealed reality of cultivation and licit/illicit use of Cannabis (Cannabis sativa L.) in the western mid-hills of Nepal: a list experiment. — Kloepfer TM, Kaneko S, Joshi NP (2025) · DOI 10.1186/s42238-025-00276-w · outro · Cannabis has a long history of utilization in various regions around the world for different purposes. In western Nepal, Cannabis is specifically used as a food crop, textile material, and lucrative cash crop, although the Nepali Narcotic Drug Control Act of 1976 ultimately prohi · en

Impact of legalization on cannabis exposure calls to the British Columbia Poison Control Centre. — Trieu J, Dobbin N, Henderson SB, McVea D (2026) · DOI 10.17269/s41997-025-01022-8 · outro · aumento de 17% nas chamadas de exposição a cannabis anualmente · en

Opinions of Illicit Cannabis Growers on the Industrial Legalization of Cannabis in Ghana: An Exploratory Qualitative Study. — Dovlo JM, Agyei ST, Dwomoh F, Manu E (2026) · DOI 10.1177/29768357261458735 · qualitativo · Background With the recent industrial cannabis legalization in Ghana, there is a need to ascertain the perspectives of illegal cannabis growers on the policy discourse to inform its implementation. Aim We explored the opinions of illicit cannabis growers in Hohoe Municipality reg · en

Transitions to legal cannabis markets: Legal market capture of cannabis expenditures in Canada following federal cannabis legalization. — Hammond D, Hong D, Rundle S, Iraniparast M, Kilmer B, Wadsworth E (2025) · DOI 10.1016/j.drugpo.2025.104828 · outro · captura de mercado legal de 78% · en

Association of recreational cannabis legalization with changes in medical, illegal, and total cannabis expenditures in Canada. — McDonald AJ, Cooper A, Doggett A, Halladay J, Belisario K, MacKillop J (2025) · DOI 10.1016/j.drugpo.2025.104793 · outro · medical cannabis decreased to 3.7% of the market post-RCL vs 11.8% antes · en

High stakes: how legal cannabis pricing impacts the illicit market. — Hebert R, Boehnke KF, Joshi S (2026) · DOI 10.1186/s42238-026-00455-3 · outro · preços ilícitos mais baixos em estados com dispensários recreativos · en

Modeling Strategic Interactions in Recreational Cannabis Legalization: An Evolutionary Game Approach to Market Dynamics — Wang M, Ding J, Liu Z, Deng G, Chen Y (2025), medRxiv · DOI 10.1101/2025.09.15.25335743 · outro · Background and Aims The global shift toward cannabis legalization raises urgent policy challenges regarding the transition from illicit to regulated markets. This study constructs an evolutionary game-theoretic model to investigate the strategic interactions between local govern · en

How Consumers Transition Between Illicit and Legal Cannabis Markets in Early Legalization Periods? Evidence from a National Panel with a Recent Policy Shock — Xu L, Zhang S, Su K, Shang C (2026), Research Square · DOI 10.21203/rs.3.rs-9381647/v1 · ensaio clinico · aumento de 31.6 pontos percentuais na obtenção de cannabis de fontes legais · en

[Cardiovascular safety of the recreational use of cannabis associated to sildenafil: Systematic review]. — Olcina Rodriguez J, López Briz E, Olcina Domínguez P (2020) · DOI 10.1016/j.androl.2018.12.003 · revisao sistematica · relaciona uso de cannabis e sildenafil a eventos cardiovasculares · es

How adolescent cannabis use reshapes the developing brain - a systematic review. — Ricci V, Sarni A, De Berardis D, Martinotti G, Maina G (2026) · DOI 10.3389/fpsyt.2026.1822300 · revisao sistematica · associa com alterações estruturais no cérebro e risco elevado de dependência (ORs 3.9-7.2) · en

Cannabis: Potenzial und Risiken. Eine wissenschaftliche Bestandsaufnahme — Hoch E, Friemel CM, Schneider M (Hrsg.) (2019), Springer / relatório BMG (Alemanha) · revisao sistematica · Potencial terapêutico com riscos gerenciáveis · de

Relationships between cannabis and cocaine use in a randomized trial of combined buprenorphine and naltrexone for DSM-IV cocaine dependence. — Smith CL, Pelagio A, Schmidt A, McPherson S, Rodin N, Stark BC et al. (2026) · DOI 10.1016/j.addbeh.2026.108817 · ensaio clinico rct · aumenta as chances de submeter um UDS de cocaína em 47% vs THC-negativo · en

Probability and Predictors of Transition from First Use to Dependence (NESARC) — Lopez-Quintero C et al. (2011), Drug and Alcohol Dependence · DOI 10.1016/j.drugalcdep.2010.11.004 · coorte · ~8,9% de transição para dependência · en

Prevalence, Associations and Comorbidity of Cannabis Use and Cannabis Use Disorders in the Australian National Mental Health Surveys From 2007 to 2020-22. — Wilson J, Sunderland M, O'Dean S, Slade T, Dawson D, Dobson O et al. (2026) · DOI 10.1111/dar.70134 · coorte · prevalência de uso e CUD estável ao longo do tempo · en

Persistent cannabis users show neuropsychological decline from childhood to midlife — Meier MH et al. (2012), PNAS · DOI 10.1073/pnas.1206820109 · coorte · Queda de ~8 pontos de QI (início adolescente) · en

Psychosocial Stressors as Risk Factors for Prenatal Cannabis Use: A Multilevel Analysis of U.S. PRAMS Data, 2016–2022 — Yu S, Park K, Oh SS, Song IH (2026), Research Square · DOI 10.21203/rs.3.rs-9605132/v1 · coorte · trauma-related stressors aumentam uso de cannabis na gravidez (OR = 2.16) · en

Association of cannabis use disorder with postoperative complications following panniculectomy: a multicenter propensity-matched analysis. — Mokhtar J, Ha JY, Almeida VFA, Lellouch AG, Vyas KS, Doh SJ et al. (2026) · DOI 10.1186/s44452-026-00013-z · coorte · aumenta complicações pós-operatórias, RR 1.82 para dor e RR 1.48 para complicações de pele · en

Factors associated with lower-risk cannabis use in adults in their mid-thirties. — Dubé G, O'Loughlin J, Fallu JS, Huỳnh C, Sylvestre MP (2025) · DOI 10.1186/s42238-025-00374-9 · coorte · null · en

The Health Effects of Cannabis and Cannabinoids (NASEM 2017) — direção veicular — NASEM (2017), National Academies Press · DOI 10.17226/24625 · documento de politica · Aumento substancial do risco de colisão · en

Medicinal use of non-prescribed cannabis: a cross-sectional survey on patterns of use, motives for use, and treatment access in the Netherlands. — Strada L, Korteling S, Vergeer M, Oomen P (2025) · DOI 10.1186/s42238-025-00355-y · transversal · percepção de eficácia alta na auto-medicação com cannabis · en

Cannabis use within the United States: Prevalence of cannabis use by state legal status and perceptions of benefit and harm. — Bontemps AP, Hawes ES, Pridgen BE, Wagner WP, Black D, Cropsey KL (2026) · DOI 10.1016/j.dadr.2026.100431 · transversal · Background Cannabis use has increased in the United States as legalization has spread. While Δ-9 THC remains the most-used federally illegal substance, use of other psychoactive hemp-derived products (Δ-8 THC, Δ-10 THC, HHC, THC-O) has grown. The current study investigated patter · en

Through the haze: a multinational cross-sectional comparison of cannabis risk knowledge gaps among young adults. — Maiwald A, Gomes de Matos E, Olderbak S, Schwarzkopf L, Koller G, Hanewinkel R et al. (2026) · DOI 10.1186/s42238-026-00439-3 · transversal · BACKGROUND: Young adults report heightened cannabis use yet show gaps in cannabis-related risk knowledge. Risk knowledge gaps in young adults with diverse cannabis use experience and across countries with varying cannabis policies, as well as associations with knowledge levels we · en

Evaluating the use and perceptions of cannabis and vaping post-cannabis legalisation in people with cystic fibrosis and CFTR-related disorder: survey results from a large Canadian adult cystic fibrosis clinic. — Dagenais R, Karlsen E, Lee K, Quon BS (2025) · DOI 10.1136/bmjresp-2024-002715 · transversal · 85% dos usuários atuais relataram uso médico, com eficácia percebida para gerenciar sintomas · en

[Neuroimaging and drug addiction: neuroanatomical correlates of cocaine, opiates, cannabis and ecstasy abuse]. — Verdejo-García A, Pérez-García M, Sánchez-Barrera M, Rodriguez-Fernández A, Gómez-Río M (2007) · DOI 10.33588/rn.4407.2006356 · revisao narrativa · Introduction Drug abuse is related to neurocognitive alterations linked to the functioning of several areas of the brain. The application of advanced neuroimaging techniques has allowed important advances to be made in research being conducted on why stable disorders are produced · es

Recent Trends in Cannabis Use in Adults Ages 60 Years and Older. — Thayer RE, Anquillare E, Coromac-Medrano J, Hardin EE, Hatcher K, Hermann GE (2026) · DOI 10.2147/sar.s560360 · revisao narrativa · This narrative review highlights the growing population of older adults (OA) who use cannabis and health considerations of cannabis use especially relevant to aging. The majority of OA who endorse using cannabis also report choosing it for medical purposes, most commonly to targe · en

Cannabis, psychosis, and violence: case reports and comprehensive evidence review. — Finn KP, Murray RM, Stuyt E, Randall K (2026) · DOI 10.3389/fpsyt.2026.1824748 · revisao narrativa · null · en

The impact of recreational cannabis legalization on pediatric emergency department visits in British Columbia, Canada. — Xiao M, Ibrahimova A, Zargaran A, Cheng P, Karbakhsh M, Rajabali F et al. (2026) · DOI 10.24095/hpcdp.46.4.04 · outro · aumento de 55.5% nas visitas ao ED por envenenamento de cannabis após a legalização · en

Perinatal Cannabis Use: Nurse Perceptions and Educational Opportunities. — Iobst SE, Fendish Y, Skelton KR (2026) · DOI 10.1097/nmc.0000000000001232 · outro · Purpose To explore nurse perceptions of perinatal cannabis use, current nurse and patient education on perinatal cannabis use, and educational needs for nurses and patients on perinatal cannabis use. Study design and methods We conducted a multiple-case qualitative case study. Us · en

[Why and how keep in mind cannabis in our smoking outpatients?] — Olano Espinosa E, Lozano Polo A, Grifell Guàrdia M, Pinet Ogué MC, Isorna Folgar M, Moreno Arnedillo JJ et al. (2020) · DOI 10.1016/j.aprim.2018.05.014 · outro · EVICT project has noted the increase in cannabis use in the Spanish youth population, and has studied its association with tobacco, concluding that: It has an influence in the learning to smoke process: The beginning can be combined and with bi-directional influence. It has an in · es

TAAT hemp cigarettes' unsubstantiated cessation and harm reduction claims. — Lempert LK, Bialous SA, Ling PM (2025) · DOI 10.1136/tc-2025-059573 · outro · Introduction The US Food and Drug Administration (FDA) has the authority to prohibit companies from making unauthorised harm reduction claims about tobacco products. The 2018 Farm Bill removed hemp products containing no more than 0.3% delta-9-tetrahydrocannabinol (THC) from regu · en

Identifying an initial set of core components for perinatal cannabis use harm reduction counseling: An application of the Consensus on Relevant Elements (CORE) process. — Albanese AM, Cramer ER, Frank HE, Rogers BG (2026) · DOI 10.3389/adar.2026.15935 · outro · Cannabis use during pregnancy or lactation is a key topic in healthcare today. It is recommended that patients abstain from perinatal use and healthcare providers are encouraged to discuss use with patients. However, some perinatal individuals continue to use even once educated a · en

Factors associated with youth opposition or support for cannabis legalization in Lebanon. — El-Khoury J, Slim A, Cherro M, Ghandour LA (2026) · DOI 10.1186/s42238-026-00426-8 · outro · BACKGROUND: In 2020, Lebanon initiated the legalization process for the cultivation of cannabis for medical and industrial purposes only. This paper aims to examine the factors associated with youth attitude towards the legalization of medicinal and recreational cannabis in Leban · en

Adolescent Cannabis Use After Cannabis Legalization and the COVID-19 Pandemic. — Young-Wolff KC, Slama NE, Pacula RL, Padon AA, Silver LD, Sterling SA et al. (2026) · DOI 10.1001/jamanetworkopen.2026.7720 · outro · Importance Understanding how cannabis legalization and large-scale societal disruptions influence adolescent cannabis use is important, as early use is associated with adverse health and educational outcomes. California has the largest regulated cannabis market in the US and prov · en

A quantitative projection of the net health effects of cannabis legalization in Germany. — Gandjour A (2025) · DOI 10.1371/journal.pone.0330879 · outro · QALY losses from CUD-related harms are approximately nineteen times greater than health gains from reduced contamination · en

Cortical Complexity Alterations in Methamphetamine, Cannabis, and Opioid Users: An EEG-Based Analysis. — Marvi N, Haddadnia J, Fayyazi Bordbar MR, Davarinia F (2026) · DOI 10.31661/jbpe.v0i0.2408-1805 · outro · aumento de complexidade em usuários de cannabis em comparação ao grupo controle saudável · en

A qualitative study on cannabis use for harm reduction and pain among veterans enrolled in an SUD treatment program. — Pleasant T, Ono S, Kansagara D, Lovejoy J, Lovejoy T, Wyse J (2026) · DOI 10.1186/s12954-026-01412-2 · qualitativo · null · en

Cannabis products and risk perceptions among people who consume and do not consume cannabis in the UK: findings from the International Cannabis Policy Study. — Wadsworth E, Hines LA, Hammond D, Freeman TP (2026) · DOI 10.1186/s12954-026-01456-4 · outro · Background Population data on cannabis use-beyond prevalence and frequency of use-in the UK is lacking, yet needed to inform harm reduction messaging about cannabis. This study examined (a) recreational and medical cannabis use; (b) cannabis product use; (c) cannabis risk percept · en

The Association Between Sociodemographic Factors and co-Use of Cigars or Cigarillos with Cannabis. — Xu L, Zhang S, Meng L, Shang C (2026) · DOI 10.1080/10826084.2026.2675987 · outro · Background : Cigar/cigarillo smoking and cannabis use frequently co-occur, reflecting overlapping patterns of substance use and shared risk factors. However, little is known about how co-use of cigars/cigarillos and cannabis is associated with sociodemographic factors, as well as · en

Genetic Pathways Point to the Biology Underlying the Association Between Cannabis Use Disorder and Psychosis. — Austin-Zimmerman I, Li Q, Johnson EC, Trotta G, Spinazzola E, Coleman JRI et al. (2026) · DOI 10.1016/j.bpsgos.2026.100711 · meta analise · apoia bidirecionalidade causal entre CUD e psicose (CUD para psicose β IVW = 0.31) · en

Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis — Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E (2016), Schizophrenia Bulletin · DOI 10.1093/schbul/sbw003 · meta analise · OR ~3,9 para uso mais intenso vs não-uso · en

Sex-specific vulnerabilities in cannabis-induced psychosis: A scoping review. — Ricci V, Berardis D, Martinotti G, Maina G (2026) · DOI 10.1016/j.ajp.2026.105086 · revisao sistematica · Background Cannabis-induced psychosis presents complex sex-based disparities that challenge traditional epidemiological patterns. While males demonstrate higher cannabis use rates, emerging evidence reveals paradoxical vulnerability patterns where females may show heightened susc · en

Relationships between cannabis use and mental disorders: assessing the coherence of evidence from studies with different methodologies. — Hall W, Yimer TM, Thorne RL, Hoch E, Burke C, Gridley A et al. (2026) · DOI 10.1016/s2215-0366(26)00086-6 · revisao sistematica · cannabis uso diário é uma causa contributiva de psicose · en

The risk of psychosis associated with cannabis use by people with attention-deficit hyperactivity disorder: A systematic review. — Suetani S, Honarparvar F, Muller P, Kesby JP, Parker S (2026) · DOI 10.1177/10398562261439662 · revisao sistematica · cannabis não aumenta risco de psicose em pessoas com ADHD · en

Correlates of Engagement and Associations With Outcomes in a Cannabis Harm-Reduction Mobile App for Youth With First-Episode Psychosis: Exploratory Analysis of the CHAMPS Pilot Randomized Controlled Trial. — Mahroug A, Lachance-Touchette P, Coronado-Montoya S, Abdel-Baki A, Côté J, Crocker C et al. (2026) · DOI 10.2196/84836 · ensaio clinico rct · Background Continued cannabis use among young people with first-episode psychosis (FEP) has been linked to poorer clinical and functional outcomes (eg, increased symptom severity and higher relapse rates). Digital harm-reduction interventions may represent a promising, person-cen · en